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Abstract 
 
  The fetal lung undergoes extensive physiological and biochemical maturation 
prior to birth in preparation for its postnatal function as an organ for gas exchange. 
Pulmonary surfactant, a substance that reduces surface tension and prevents alveolar 
collapse,  is  produced  by  type  II  pneumocytes  within  the  lung.  Reduced  ability  to 
produce  surfactant  leads  to neonatal respiratory distress syndrome.  Synthesis of the 
phospholipid  component  of  surfactant,  phosphatidylcholine  (PC),  is  stimulated  by 
fibroblast-pneumocyte factor (FPF), a protein expressed by fibroblast cells within the 
fetal lung. Although its function is well known, the identity of this important protein has 
remained  a  mystery.  Recent  research  has  suggested  that  FPF  may  be  neuregulin-1,  
a growth factor found in many tissues during development. 
 
  Enhanced synthesis of PC (and therefore detection of FPF) is measured using a 
tissue  culture-based  method.  Primary  cultures  of  lung  fibroblasts  and  type  II 
pneumocytes are prepared, and fibroblast-conditioned medium (FCM) is exposed to the 
type  II  cells.  Resultant  PC  synthesis  is  measured  using  radioisotope-labeled  
PC-precursor and a chloroform-based lipid extraction method. Initial results using this 
method were very inconsistent, so a study was undertaken to determine which parts of 
the method could be contributing to this inconsistency. Cell density of type II cultures 
(measured  in   g  DNA.plate
-1)  was  shown  to  have  a  significant  effect  on  results. 
Treatment of fibroblasts with 100 nM dexamethasone and exposure of type II cultures 
to the resultant FCM caused a mean 9.17% increase in PC synthesis, but when only type 
II  cultures  with  a  cell  density  below  25   g  DNA.plate
-1  were  analyzed,  this  value 
increased  to  17.56%.  Type  II  cultures  with  cell  density  above  this  threshold  value 
showed  a  mean  increase  in  synthesis  of  only  3.39%.  The  consistent  application  of    v 
[
3H]-choline  chloride  also  had  a  significant  effect  on  results.  Experiments  utilizing 
phorbol  12-myristate  13-acetate  to  stimulate fibroblasts were very inconsistent. The 
mean activity of the initial [
3H]-choline chloride solution prepared for these experiments 
was found to be 2.04  Ci.mL
-1, compared to a mean of 4.79  Ci.mL
-1 for all other 
experiments. Observations from this section of the study led to considerable revision of 
the method used to measure PC synthesis. 
 
  Generation  of  FPF  by  fetal  lung  fibroblasts  is  stimulated  by  a  number  of 
compounds, and several were investigated in order to determine the best way to produce 
FPF for further analysis. One of these compounds was neuromedin C, which had been 
shown to cause a significant increase in surfactant secretion. Exposure of fibroblasts to 
1 nM neuromedin C led to a mean 3.23% decrease in surfactant synthesis, but this was 
not  significantly  different  from  control.  The  lack  of  effect  is  most  likely  due  to 
insufficient specific receptors that bind neuromedin C being present. 
 
  Quadrupolar ion trap mass spectrometry (MS) was used to analyze FCM and 
determine if neuregulin-1 (NRG1) could be FPF. A mass spectrum was obtained for 
recombinant NRG1, with predominant ions of 1068, 1142 and 1246 m/z. All three of 
these  ions  were  also  detected  in  both  control  and  dexamethasone-treated  FCM.  
Partial fragmentation of 1068 m/z of NRG1 was achieved using MS
2, and generated a 
base peak of 1047 m/z. This fragmentation was also observed in 1068 m/z from FCM. 
LC/MS was utilized to quantify NRG1 in FCM, using a standard curve generated using 
recombinant NRG1. Control FCM had a NRG1 concentration of 19.85  g.mL
-1, while 
the concentration in dexamethasone-treated FCM was 41.59  g.mL
-1. FCM which had 
given no positive response to dexamethasone when tested using the indirect cultured 
cell system had a control NRG1 concentration of 20.85  g.mL
-1, and a dexamethasone-  vi 
treated concentration of 22.84  g.mL
-1. These values were not significantly different 
from the control value for FCM in those fibroblast cultures that had generated a positive 
response to dexamethasone. Results of this section of the study have provided strong 
evidence that NRG1 is a major component of FPF, and a review of the NRG1 signaling 
pathway further supports this conclusion. 
 
  Insulin-like growth factors (IGFs) are functionally related to neuregulins and are 
known  to  be  important  in  fetal  development.  The  effect  of  IGF-II  on  synthesis  of 
surfactant  PC  and  its  subsequent  secretion  from  type  II  pneumocytes  was  studied.  
In terms of PC synthesis, IGF-II was tested at concentrations of 0.4, 0.6 and 0.8  M. 
The mean increase in synthesis was found to be 6.00, 6.15 and 6.91%, respectively. 
These values were not significantly different from control values. Secretion of PC was 
tested over the concentration range of 0.1 to 1.6  M, with no significant effect observed. 
Possible inhibition by IGF-II was also studied, using the known stimulants of secretion, 
neuromedin  C  and  isoproterenol.  No  significant  effect  on  the  enhanced  level  of 
secretion was observed when IGF-II was added with either secretagogue. Lack of an 
appropriate receptor and/or the possibility that cultured cells may not exactly mimic the 
situation in vivo are probably the reasons IGF-II has no effect on either synthesis or 
secretion.    vii
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V    volt Chapter 1. General introduction 
 
The air sac, capable of gas exchange with the atmosphere, first evolved during 
the Devonian period, and allowed primitive fish to move onto land (Possmayer, 1982). 
In terrestrial vertebrates, including mammals, this air sac is known as the lung. The 
mammalian lung consists of two lobes and is connected to the upper airway by the 
trachea and bronchi. Inside the lung, the branching of the bronchi forms the bronchial 
tree,  with  each  branch  terminating  in  an  alveolus.  The  alveoli  are  the  site  of  gas 
exchange with the atmosphere. Human lungs contain approximately 300 million alveoli, 
which gives the lungs a far greater internal than external surface area (Snell, 2007). 
During development, human fetal lungs function within the fluid intrauterine 
environment, and must adapt to the extrauterine atmosphere at birth. There are many 
physiological events that must occur to allow this adaptation, and key among them is 
the induction of the pulmonary surfactant system. Pulmonary surfactant is a complex, 
surface-active material that is composed of phospholipids and four specific surfactant-
associated proteins. The surfactant lines the alveolar surface of the lung (Griese, 1999) 
(Figure 1.1).  
The  air-liquid  interface  within the alveoli is subject to great surface tension 
which,  if  unmodified,  would  lead  to  progressive  atelectasis  and  respiratory  failure.  
The primary function of pulmonary surfactant is to reduce this surface tension to very 
low values, and dynamically alter the tension as surface area changes with inspiration 
and expiration (Johannson and Curstedt, 1997). Surfactant also functions to protect the 
lung from injury and infection that may be caused by the inhalation of particles and 
microorganisms (Griese, 1999). 
The induction of the surfactant system does not occur until late in gestation, as 
the  lungs  are  not  involved  in  gas  exchange  until  after  birth.  Infants  that  are  born Chapter 1                                                                                                                                      Introduction 
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prematurely have immature lungs containing little surfactant, which leads to neonatal 
respiratory distress syndrome (NRDS) (Griese, 1999). This condition causes extremely 
high surface tension in the alveoli during expiration, and they tend to collapse, greatly 
reducing the ability of the lung to obtain sufficient oxygen for bodily needs (Levine and 
Gordon, 1942). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Micrograph of alveolar space with a magnified diagram of the air-
liquid  interface  illustrating  the  surfactant  system  (Whitsett  and 
Weaver, 2002). Chapter 1                                                                                                                                      Introduction 
  3
1.1 History of the surfactant system 
  The discovery of the surfactant system began in 1805 with the publication of 
Young’s paper ‘An essay on the collision of fluids’, which was followed a year later by 
Laplace’s paper on the same topic. The relationship between force, surface tension and 
radii of curvature defined by these papers became known as the Young-Laplace law 
(Comroe,  1977).  Over  100  years  later,  Langmuir  developed  a  method  to  determine 
molecular dimensions using surface physics and chemistry (Langmuir, 1917), and this 
led  to  the  development  of  equipment  for  measuring  surface  tension  under  dynamic 
conditions.  
  In 1929, von Neergaard theorized that a relationship might exist between the 
specialized material lining the lung and the Young-Laplace law. In spite of its potential 
importance, this work was not recognized until much later. In his 1954 paper, Radford 
found  a  ten-fold  discrepancy  in  calculating  lung  surface  area  using  physical 
measurement and histological methods. He argued that a surface active substance was 
unlikely to exist, so the lung must be in a semi-solid state (Radford, 1954). In the same 
year, Macklin published a paper describing the mucoid film that coats the alveoli.  In his 
description  he  postulated  that  this  film  would  maintain  a  constant  surface  tension 
(Macklin, 1954). The following year, Pattle proposed that, in order to prevent alveolar 
transudation and resulting pulmonary oedema, the surface tension in the lung must be 
maintained at a low level (Pattle, 1955). 
  The work of Radford and Pattle prompted Clements to derive a quantitative 
measurement  of  alveolar  surface  tension,  under  dynamic  conditions.  These 
measurements  definitively  showed  the  presence  of  a  surface  active  material  that 
maintained  a  constant  surface  tension  (Clements,  1957).  Clements’  surface  tension 
values were confirmed in 1959 by Avery and Mead, who studied ‘hyaline membrane 
disease’. They found a three-fold increase in mean surface tension in infants who had Chapter 1                                                                                                                                      Introduction 
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died from this condition (Avery and Mead, 1959). These results led to further studies of 
the development and induction of the surfactant system in mammals (Buckingham et 
al., 1968; Comroe, 1977). 
 
1.2 Lung cell types 
The induction of the surfactant system is regulated by the interaction between 
two  cell  types  within  the  lung:  epithelial  (type  II  pneumocyte)  and  mesenchymal 
(fibroblast) cells (Smith and Fletcher, 1979).  
Type II cells are cuboid in shape and are located in the corners of the alveoli. 
They have a high number of lamellar bodies, as well as mitochondria, Golgi apparatus 
and rough endoplasmic reticulum (Ballard, 1986). The primary function of the type II 
cell is the synthesis and secretion of pulmonary surfactant. Surfactant is stored in the 
bell-shaped  lamellar  bodies  until  its  secretion  by  exocytosis  (Bangham  and  Horne, 
1964).  Each  type  II  cell  contains  approximately  150  (±  30)  lamellar  bodies,  with 
exocytosis  occurring  at  a  rate  of  15  bodies  per  hour  (Young  et  al.,  1981).  
The differentiation of the type II cell is a key step in lung maturation and surfactant 
production. 
The  ‘timer’  for  this  differentiation  is  within  the  tissue,  and  involves  an 
interaction between the epithelial (pneumocyte) and mesenchymal (fibroblast) tissues 
(Smith and Post, 1989). This interaction appears to occur prior to day 13 in fetal rats, 
and commits the type II cells to their phenotype. A key indicator of this differentiative 
event  is  glycogen  depletion,  which  provides  an  energy  source  for  the  formation  of 
lamellar bodies (Smith and Post, 1989).  
  There  are  two  types  of  cellular  change  –  proliferation  and  development. 
Fibroblasts from the pseudo-glandular stage of lung development stimulate epithelial 
cell proliferation, while those from the saccular stage stimulate differentiation (Caniggia Chapter 1                                                                                                                                      Introduction 
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et al., 1991). Also, fibroblasts in close proximity to the epithelial cells produce mainly 
differentiation factors while those further away produce mainly proliferation factors. 
Pneumocyte cells do not respond to proliferation factors once they have developed past 
the saccular stage (Caniggia et al., 1991). 
Differentiation of epithelial cells (type II pneumocytes) is triggered by the subjacent 
mesenchyme (fibroblasts). The fibroblasts respond to glucocorticoids and secrete the 
differentiation  factor  (Caniggia  et  al.,  1991).  Glucocorticoids  bind  more  readily  to 
fibroblasts  adjacent  to  pneumocytes  than  those  located  peripherally,  because  these 
adjacent fibroblasts are enriched with glucocorticoid receptors.  
 
1.2.1 Tissue culture 
The use of whole lungs in studies of cellular differentiation does not consider the 
cellular diversity found within those lungs (Post et al., 1983), requiring individual cell 
types to be cultured separately. It has been found that isolated and cultured fetal alveolar 
type II cells retain characteristics of in vivo type II cells, in particular the ability to 
synthesize and secrete phosphatidylcholine (PC). These cultured cells also retain the 
ability to proliferate and respond to fibroblast-pneumocyte factor (FPF) (Post et al., 
1983).  
Culture studies found several factors which will enhance the quality of cell culture. 
A higher purity of cells is obtained if collagenase is used to disperse cells, and fetal calf 
serum is essential for optimal growth (Post et al., 1983). The optimal conditions for  
in vitro generation of FPF by fibroblasts were the use of primary cultures, maintenance 
of cultures in a medium that does not cause rapid cellular proliferation, and induction of 
pyridoxal deficiency to enhance responsiveness to glucocorticoids (Smith, 1981a). Chapter 1                                                                                                                                      Introduction 
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1.3 The pulmonary surfactant system 
1.3.1 Composition of surfactant 
In the lungs surfactant exists in two pools – the intracellular and extracellular 
pools. Intracellular surfactant is stored in the type II cells in lamellar bodies (Wright and 
Clements, 1987). The extracellular pool of surfactant is the layer that lines the alveoli 
(Schurch et al., 1995). Alveolar material, and that obtained through bronchoalveolar 
lavage, contains several different morphological and biochemical forms of surfactant.  
These forms include (Wright and Clements, 1987): 
 
a)  densely-packed  multilamellar  structures  that  resemble  secreted  lamellar 
contents; 
b)  unique lattice-like structures called tubular myelin; 
c)  the surface film; 
d)  multilamellar and unilamellar vesicles; and 
e)  distinct structures that resemble open-ended bilayers. 
 
Of  these  forms,  it  is  thought  that  the  lamellar  body  contents  expand  and  form  the 
complex structure of tubular myelin upon contact with the alveolar space. This process 
is triggered by calcium, as well as the environmental conditions within the space (King 
et al., 1983). The process by which the bilayer structures form a monolayer film is not 
understood. 
While the properties of surfactant are well known, and can be readily identified, 
its  exact  in  vivo  chemical  composition  is  not  known.  This  is  most  likely  because 
surfactant is heterogeneous in both chemical composition and morphology (Robertson, 
1984). In addition, surfactant isolated for testing is likely to comprise active surfactant, Chapter 1                                                                                                                                      Introduction 
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newly secreted surfactant and surfactant that is ready for recycling and removal from 
the alveolar lining. 
  Pulmonary surfactant contains several types of lipid, including phospholipids, 
triglycerides,  cholesterol  and  fatty  acids  (Johannson  and  Curstedt,  1997).  Of  these, 
phospholipids  are  present  in  the  greatest  quantities.  Phosphatidylcholine  comprises  
70-80% of surfactant lipids, and phosphatidylglycerol a further 5-10% (King, 1982). 
Approximately 60% of surfactant phosphatidylcholine is present in the disaturated form, 
with  both  fatty  acids  being  palmitic  acid.  This  lipid  is  known  as 
dipalmitoylphosphatidylcholine (DPPC) (Hildebran et al., 1979). The polar end of the 
DPPC molecule contains the choline residue, while the other, non-polar end contains the 
two  palmitic  acid  residues.  It  is  currently  thought  that  DPPC  is  the  component  of 
surfactant responsible for reducing surface tension (Holm et al., 1996).  
  The role of phosphatidylglycerol (PG) is less well understood. The level of PG 
is generally low during gestation and increases either prior to, or shortly after, birth 
(Hallman  et  al.,  1977;  Egberts  and  Noort,  1986).  Phosphatidylglycerol  is  the  most 
variable surfactant component in different mammalian species. It is greatly reduced in 
species such as cats (Shelley et al., 1984), and replaced with phosphatidylinositol (PI) in 
adult rhesus monkeys (Egberts et al., 1987). Studies on PG-deficient adult rabbits have 
shown no obvious changes to surfactant properties or function, although these studies 
did use PI to substitute for PG (Beppu et al., 1983; Hallman et al., 1985). Human 
infants who are born prior to the pre-natal increase in PG levels are more likely to suffer 
from NRDS than those born after (Hallman et al., 1977), suggesting a definite role for 
PG  in  the  function  of  surfactant.  It  is  possible  that  the  presence  of  PG  helps  with 
alveolar stability (Hallman and Gluck, 1976), or in the association of proteins with 
phospholipids (King and Martin, 1980). Chapter 1                                                                                                                                      Introduction 
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Surfactant  generally  contains  5-10%  protein,  and  these  surfactant-associated 
proteins (SP) interact extensively with the phospholipids. These interactions include 
changing  the  structure and properties  of lipid layers and  films  (Yu  and Possmayer, 
1988; Dhand et al., 1998). There are four surfactant proteins that have been identified: 
SP-A,  SP-B,  SP-C  and  SP-D.  The  general  characteristics  of  each  protein  are 
summarized below (Table 1.1). 
 
Table 1.1:   Characteristics  of  the  four  surfactant-associated  proteins,  SP-A,  
SP-B, SP-C and SP-D (Yu and Possmayer, 1988). 
 
 
 
 
 
 
Due to differences in the methods used to isolate surfactant, a precise quantitation of the 
surfactant proteins has not been obtained. Recent research has shown that the formation 
and  stability  of  surfactant  are  critically  dependent  on SP-B and SP-C (Weaver and 
Conkright, 2001), while SP-A is important for immune and inflammatory responses 
(Crouch  and  Wright, 2001). Other  proteins have also been isolated with surfactant, 
including albumin, immunoglobulins A and G (King et al., 1973; Paciga et al., 1980) 
and uteroglobin (Guy et al., 1992). The function of these additional proteins is not fully 
understood, although it is possible that they have roles in immunity and extending the 
functional life of surfactant (Guy et al., 1992). 
  Several factors have been shown to affect the composition of surfactant, most 
notably diet. A deficiency of vitamin A can delay the maturation of lungs in newborn 
Protein
Molecular 
weight 
range
Structure
MW of 
polypeptide 
chains (kDa)
Polarity
SP-A high octadecamer 26.0 hydrophilic
SP-B low dimer 8.7 hydrophobic
SP-C low monomer 4.0 hydrophobic
SP-D high dodecamer 39.0 hydrophilicChapter 1                                                                                                                                      Introduction 
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rats (Chailley-Heu et al., 1999) and reduce the surfactant phospholipid levels by more 
than 20%. This is probably due to the relationship between plasma retinol levels and 
expression of key enzymes in the lipid synthesis pathway. It has also been found that 
vitamin A deficiency can reduce the amounts of SP-A, SP-B and SP-C (Chailley-Heu et 
al., 1999). Choline-deficient diets can lead to surfactant phosphatidylcholine levels that 
are nearly 50% lower than those in control rats (Yost et al., 1985). 
 
1.3.2 Biophysical function of surfactant 
  The surface tension that exists at the alveolar air-water interface opposes lung 
inflation.  The  action  of  pulmonary  surfactant  is  to  reduce  this  surface  tension  to 
effectively  zero,  meaning  that  the  whole  of  the  alveolar  space  remains  open,  even 
during expiration (Griese, 1999). If this did not occur, blood oxygenation would be 
reduced  and  the  physical  work  required  for  adequate  breathing  would  increase.  
One study has shown that the presence of surfactant may be required to maintain proper 
function of not only the alveoli, but also the bronchioles leading to them (Enhorning and 
Holm, 1993). Reduced surface tension is also important for ensuring that the alveoli do 
not become filled with fluid, as high surface tension can lead to a thick film developing 
and inundating the sites of gas exchange (Guyton et al., 1984). Surfactant is involved in 
the removal of foreign material and discarded cells from the alveolar space, as well as 
possible immune cell functions (Jarstrand, 1984). 
The monolayer film is the active form of surfactant. It is enriched with DPPC, 
indicating that DPPC is the component of surfactant responsible for surface tension-
reducing properties (Hildebran et al., 1979). Other lipids and proteins in surfactant are 
thought to facilitate lipid transport through the aqueous environment of the air-water 
interface at the alveolar surface. In particular, the hydrophobic proteins SP-B and SP-C 
play a role in this transport (Gil et al., 1995). It has also been observed that calcium ions Chapter 1                                                                                                                                      Introduction 
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are essential for transport processes in the alveoli (King et al., 1983). The function of 
SP-A  differs  from  the  other  proteins, and  it is  thought  to alter the  distribution and 
movement  of  surfactant  within  the  alveoli,  especially  through  acceleration  of  lipid 
movement. SP-A also has a protective function, by minimizing the inhibitory effect of 
blood proteins (Cockshutt et al., 1990).  
 
1.4 Synthesis of surfactant 
1.4.1 Site and timing of synthesis 
  The two main surfactant phospholipids, dipalmitoylphosphatidylcholine (DPPC) 
and phosphatidylglycerol (PG), are found only in trace amounts in tissues outside of the 
lungs (Clements and King, 1976). There is a large body of evidence to suggest that 
surfactant synthesis takes place in type II pneumocyte cells within the alveoli. Type II 
cells comprise approximately 15% of all cells within the lung, and are characterized by 
the presence of  a large number of lamellar bodies, which are the site of surfactant 
storage  and  the  mechanism  of  secretion  (via  fusion  with  the  cellular  membrane) 
(Haagsman and van Golde, 1991). Analysis of the phospholipid content of lamellar 
bodies within type II cells shows that the lipids are almost identical to those found in 
pulmonary surfactant (Hallman et al., 1981). Culturing of isolated type II cells, and 
treatment of these cultures with labeled phospholipid precursors produces phospholipids 
very similar in composition to surfactant (Dobbs et al., 1982; Mason, 1987). It has been 
shown that immature type II cells have a greatly reduced ability to synthesize lipids, 
implying a relationship between the development of the lungs and the ability to produce 
surfactant.  
  Evidence does exist to suggest that lamellar bodies are not the sole organelle 
involved  in  surfactant  synthesis.  Only  some  of  the  enzymes  required  for  surfactant 
phospholipid  synthesis  are  found  within  these  bodies,  and  certain  key  enzymes  for Chapter 1                                                                                                                                      Introduction 
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phosphatidylcholine  production  are  absent  (Baranska  and  van  Golde,  1977).  
The  autoradiographic  study  of  Chevalier  and  Collet  (1972)  provided  a  wealth  of 
information on the production and storage of pulmonary surfactant. The majority of 
surfactant lipids are synthesized in the endoplasmic reticulum and transferred to the 
Golgi apparatus. From here, small lamellar bodies transport the lipids to larger bodies, 
which are the site of storage and secretion (Chevalier and Collett, 1972). Surfactant 
proteins are also synthesized in the endoplasmic reticulum and transferred to the Golgi 
apparatus (Sorokin, 1967). The transfer from the Golgi apparatus to the lamellar bodies 
probably involves multivesicular bodies, which are found in high concentrations in type 
II cells. The lamellar bodies are the site where surfactant lipids and proteins are first 
associated and assembled into the final storage form of surfactant (Williams, 1977).  
The exact site of production of SP-D is not known (Voorhout et al., 1992; Zhang et al., 
2006), implying that other organelles or even cell types may be involved. 
In  humans,  type  II  cells  are  identifiable  after  20-22  weeks of gestation, but 
secretion of surfactant is only detected after 30-32 weeks. These results are mirrored in 
all mammalian species studied to date, where surfactant synthesis seems to begin after 
the completion of 80-90% of gestational development. Fetal type II cells are actually 
capable  of  synthesis  of  surfactant  from  early  in  gestation,  but  only  at  low  levels.  
This rises dramatically to that required late in gestation (Fraslon-Vanhulle et al., 1994). 
Pulmonary fatty acid synthesis peaks during this period, and certain enzymes involved 
in lipid synthesis, such as fatty acid synthase and acetyl-CoA carboxylase, also show a 
marked  rise  in  activity  (Fraslon-Vanhulle  et  al.,  1994).  The  surfactant-associated 
proteins SP-A, SP-B and SP-C, as well as their respective mRNAs, appear during this 
period and increase in concentration until birth (Smith, 1984), stimulated by hormones 
such  as  leptin  (Kirwin  et  al.,  2006).  The  level  of  mRNA  for  choline  phosphate 
cytidylyltransferase  also  increases  (Fraslon  and  Batenburg,  1993).  Chapter 1                                                                                                                                      Introduction 
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It has been observed that special pretranslational regulation of several key enzymes 
involved in increasing the rate of fatty acid synthesis occurs in the pulmonary system 
during  development  (Batenburg  and  Whitsett,  1989;  Fraslon  and  Batenburg,  1993). 
However hormones, which are vitally important in controlling surfactant synthesis prior 
to birth, do not seem to initiate the commencement of this synthesis. 
 
1.4.2 Synthesis of phospholipids 
The production of surfactant phospholipids begins with a glycerol backbone that 
is produced from glucose obtained from the bloodstream. The most likely starting point 
for  synthesis  of  the  diacyl  glycerolipids  is  the  formation  of  glycerol-3-phosphate 
(Kennedy, 1986). Fetal type II cells contain large intracellular glycogen stores, which 
are the major source of this glycerol-3-phosphate. Fatty acids are obtained from the 
blood, as well as being synthesized de novo from lactate. In particular, lipogenesis is 
required for the production of palmitate. The enzymes involved in lipogenesis increase 
in activity towards birth. 
Production  of  phospholipids  can  be  accelerated  by  several  factors. 
Glucocorticoids act on lung fibroblast cells to produce fibroblast-pneumocyte factor 
(FPF) (Smith, 1978). Epidermal growth factor (EGF) enhances the rate of production of 
PC by type II cells (Sen and Cake, 1991) apparently via enhanced release of FPF from 
lung fibroblasts. FPF is discussed in more detail in 1.5. 
 
1.4.2.1 Production of phosphatidylcholine 
  In  mammals,  phosphatidylcholine  (PC)  is  produced  by  the  CDP-choline 
pathway. Choline is endocytosed and phosphorylated to choline phosphate by choline 
kinase. A CDP residue is added, and the phosphate removed by the enzyme choline 
phosphate  cytidylyltransferase.  The  phosphorylcholine  moiety  is  then  transferred  to Chapter 1                                                                                                                                      Introduction 
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diacylglycerol  to  produce  phosphatidylcholine  catalyzed  by  the  enzyme 
cholinephosphotransferase. The key regulatory step in this pathway is believed to be 
choline  phosphate  cytidylyltransferase,  which  has  a  high  binding affinity for  lipids, 
implying a negative feedback mechanism (Dunne et al., 1996). This pathway produces 
approximately 90% of the PC synthesized in a given cell (Epstein and Farrell, 1975). 
The  alternative  pathway  for  PC  synthesis  involves  methylation  of 
phosphatidylethanolamine  (Batenburg,  1992).  Synthesized  PC  is  then  converted  to 
DPPC within type II cells. 1-saturated-2-unsaturated-PC is deacylated to lyso-PC and 
then  reacylated  with  palmitoyl-CoA  to  produce  DPPC  (Haagsman  and  van  Golde, 
1991).  
 
1.4.2.2 Regulation of PC synthesis 
  The  study  of  regulation  of  PC  synthesis  began  with  the  observation  that 
administration of glucocorticoids to fetal lambs accelerated lung maturation (Liggins, 
1969).  Treatment  of  fetal  rabbits  with  the  same  steroids  enhanced  the  activity  of 
surfactant and the appearance of type II cells (Whitsett et al., 1985). In humans, the 
administration of glucocorticoids prior to normal maturation leads to increased use of 
glucose, acceleration of glycogenolysis, increased phospholipid synthesis and enhanced 
lung maturation (Smith, 1984). It has become clear that mesenchyme-derived factors 
have a major role in the differentiation and development of type II cells (Smith, 1979). 
The factor involved in lung development is called fibroblast-pneumocyte factor (FPF), 
and  it  acts  to  stimulate  PC  synthesis  via  increased  intracellular  cyclic  AMP  levels 
(Smith, 1979).  
  There are many different chemicals that can regulate synthesis of PC. Gross and 
Wilson  (1982)  found  that  dexamethasone,  a  synthetic  glucocorticoid,  causes  a  
2.5-fold increase in PC synthesis. This effect has been observed in rats (Gross and Chapter 1                                                                                                                                      Introduction 
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Wilson,  1982),  rabbits  (Ballard  et  al.,  1984)  and  humans  (Gonzales  et  al.,  1986).  
In addition, it has been found that the response to this hormone can be enhanced through 
an additive or synergistic effect with triiodothyronine (T3) (Schellenburg et al., 1988). 
The use of corticosteroids together with insulin and/or prolactin leads to a two-fold 
increase in lamellar body phospholipid concentration compared to controls (Mendelson 
et al., 1981). Glucocorticoids also enhance expression of mRNA for SP-B (Ahmad et 
al., 1996), as well as promoting stability of SP-A mRNA (Seidner et al., 1996). 
Dexamethasone  has  also  been  shown  to  block  production  of  transforming 
growth factor β (TGFβ), which blocks the maturation of type II pneumocytes (Torday 
and  Kourembanas,  1990;  McDevitt  et  al.,  2007).    It  is  therefore  possible  that 
dexamethasone simultaneously exerts both stimulatory and inhibitory effects on fetal 
lung fibroblasts. 
 
1.4.3 Inhibition of the surfactant system 
  The ratio of male: female deaths is 4:1 in the first trimester, 2:1 in the second 
and nearly 1:1 in late pregnancy. However, after birth it rises again to 2:1, due to the 
incidence of neonatal respiratory distress syndrome (Torday and Nielsen, 1987). Male 
infants are at a greater risk of developing NRDS than female infants of the same age 
(Miller and Futrakul, 1968). This trend is found in most animal models, except avians, 
where the sex-determination system, and thus the trend in NRDS are reversed (Smith 
and Post, 1989).  
The lecithin/sphingomyelin ratio, as well as the levels of PC and PG in the 
amniotic fluid of male fetuses is 1.5 to 2 weeks behind female fetuses (Torday et al., 
1981; Fleisher et al., 1985). Male fetuses are less responsive to glucocorticoids (Ballard 
et al., 1980) and fibroblasts derived from male fetuses produce less FPF than those from 
female fetuses (Torday, 1984). The lungs from female fetuses have greater stability Chapter 1                                                                                                                                      Introduction 
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(Kotas  and  Avery,  1980),  epithelial  cells  differentiate  sooner  to  form  type  II  cells 
(Adamson and King, 1984), and rates of surfactant synthesis are higher than in lungs 
from males (Nielsen et al., 1982). The most likely cause of these differences are male 
androgens,  which  may  inhibit  lung  development  in  some  way.  Administration  of 
dihydrotestosterone  (DHT)  to  fetal  rabbits  decreased  the  production  of  surfactant  
(Nielsen et al., 1982). DHT exerts its effect at a pre-translational level and inhibits 
production of FPF by fibroblasts (Floros et al., 1987), or reduces the response of type II 
cells to FPF (Torday and Nielsen, 1987). The fact that sex-based differences in response 
to steroids and surfactant production also occur in isolated cell cultures suggests that 
there is also a possible genetic basis for this difference. 
  Infants of diabetic women born at full-term have a higher incidence of NRDS 
than infants of non-diabetic women (Robert et al., 1976). It has been found that in these 
infants, PG is greatly reduced or even entirely absent from the surfactant (Cunningham 
et al., 1978). It has been proposed that fetal hyperinsulinemia associated with maternal 
diabetes can antagonize lung development (Obenshain et al., 1970). Insulin has been 
shown to reduce the stimulatory effect of corticosteroids on PC synthesis (Smith, 1978), 
although  this  has  not  been  supported  by  other  work  (Mendelson  et  al.,  1981). 
Mendelson and colleagues (1981) also could not show inhibition of PG synthesis by 
insulin. Insulin appears to affect the levels of surfactant-associated proteins, as SP-A 
concentration is significantly lower in the amniotic fluid of diabetic mothers (Katyal et 
al., 1984). Snyder and Mendelson (1987) showed that inhibition of SP-A synthesis in 
human lungs by insulin is dose-dependent. In some species fetal hyperglycemia in the 
absence of hyperinsulinemia has also been seen to block lung maturation (Carlson et al., 
1984). 
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1.5 Fibroblast-pneumocyte factor 
1.5.1 Characteristics of fibroblast-pneumocyte factor 
Fibroblast-pneumo(no)cyte factor (FPF) is a polypeptide differentiation factor 
that is present in the culture medium of glucocorticoid-treated lung fibroblasts (Smith 
and  Post,  1989).  It  is  a  heat-stable,  dialyzable  oligopeptide  (Smith,  1979)  that  is  
inactivated by trypsin (Smith and Post, 1989). It has only one known activity, although 
there may be more. FPF has an apparent molecular mass in the range of 5 to 15 kDa 
(Smith and Post, 1989), although it is unknown whether this represents a form of the 
protein that differs from the active form (Scott and Das, 1993). Studies suggest that both 
the FPF peptide and its mRNA precursor occur in very low abundance in vivo (Floros et 
al., 1985).  
Epithelial-mesenchyme interactions, such as that facilitated by FPF, are highly 
organ-specific, but not species-specific, and occur widely (Smith and Fletcher, 1979). 
FPF has been isolated from human lung fibroblast cultures (Scott and Das, 1993) and 
similar  activity  has  been  found  in  cats,  rabbits,  rats,  two  species  of  monkey  and 
chickens (Smith and Fletcher, 1979). This activity was not found in newborn rabbits or 
rats,  where  the  lungs  are  already  developed  and  the  function  of  FPF  is  no  longer 
required (Smith and Fletcher, 1979).  
FPF activity has been detected in human amniotic fluid from 27 to 40 weeks 
gestation, although the activity declined with advancing gestation and was inversely 
related  to  cell  number  (Seybold  and  Smith,  1980).  The  actual  presence  of  FPF  in 
amniotic fluid is not related to lung maturation in the fetus, and its decrease follows the 
decrease in total protein content in late gestation (Seybold and Smith, 1980). There is 
also an inverse relationship between cortisol and FPF levels in human amniotic fluid 
(Seybold and Smith, 1980), indicating that as the level of cortisol decreases (implying 
usage within the fetus), the amount of FPF produced increases. Chapter 1                                                                                                                                      Introduction 
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A similar differentiation factor has been found to be responsible for epithelial-
mesenchyme interactions in the liver and has been termed fibroblast-hepatocyte factor. 
It is a heat-stable, low molecular weight protein that is antigenically different from FPF 
(Dow et al., 1983). Stretch-stimulated surfactant synthesis is known to occur through 
another epithelial-mesenchyme interaction, mediated by parathyroid hormone-related 
protein (Torday and Rehan, 2002). 
  Recent  research  (Dammann  et  al.,  2003)  has  suggested  that  neuregulin-1β  
(NRG-1), a growth factor involved in many different stages of human development, 
may be FPF. They found that both fibroblast-conditioned medium (FCM) and NRG-1 
had the same stimulatory effect on surfactant synthesis in type II cells, and that the 
activity  of  both  was  blocked  by  an  antibody  to  NRG-1.  Histological  observation 
revealed that lung fibroblast cells secrete NRG-1, and that this secretion increased as 
surfactant synthesis increased prior to parturition (Dammann et al., 2003). The receptors 
for  neuregulins,  ErbB  receptors,  were  up-regulated  in  type  II  pneumocyte  cells  by 
exposure to dexamethasone (Dammann et al., 2006). This research has provided the 
strongest evidence yet for the identity of FPF. 
 
1.5.2 Induction of FPF 
Surfactant synthesis is under multi-hormonal control and local cell and tissue 
interactions modulate the endocrine signals (Smith and Post, 1989). The central role is 
played  by  endogenous  fetal  glucocorticoids.  In  the  fetal  lung,  inactive  cortisone  is 
metabolised to the active form  cortisol  (Smith and Post, 1989). This glucocorticoid 
activity acts on the fibroblast to produce FPF, which acts on the type II pneumocyte cell 
(Smith and Post, 1989). The glucocorticoid hormone binds to cytosolic receptors (GR) 
which are then translocated to the nucleus of the fibroblast (Smith and Post, 1993). 
There,  they  bind  to  glucocorticoid  response  elements,  leading  to  the  induction  or Chapter 1                                                                                                                                      Introduction 
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repression  of  gene  transcription  ((Smith  and  Post,  1993).  In  the  rat,  glucocorticoid 
receptor mRNA levels in the whole lung rapidly increase between days 18 and 19 of 
gestation and decrease again by days 20-22, and following day 19 there is a gradual rise 
in GR-binding activity (Smith and Post, 1993). 
The effect of glucocorticoids on fibroblast cells is inhibited by the presence of 
actinomycin D during the first, but not the second, 24 hours of incubation, implying that 
the  response  involves  transcriptional  events  (Floros  et  al.,  1985).  Fractionation  of 
mRNA  and  subsequent  translation  produces  a  peptide  that  possesses  FPF  activity 
(Floros  et  al.,  1985).  The  glucocorticoid  effect  is  also  blocked  by  the  presence  of 
cycloheximide during the first and second 24 hours of incubation, indicating that protein 
synthesis is required (Floros et al., 1985).  The mRNA and protein products are both 
stable, existing in the cell for some time (Smith and Post, 1989). These results suggest 
that glucocorticoids act at a pre-translational level to induce production of FPF and that 
the primary translation products are biologically active (Floros et al., 1985). However, 
monoclonal antibody to FPF will not recognize the protein unless it has undergone post-
translational modification, implying significant changes to the in vivo peptide (Smith 
and Post, 1989). The low detected activity of translation products indicates that both the 
mRNA and FPF protein are present in very low abundance (Floros et al., 1985). 
Dexamethasone has no overall impact on the activity of fetal lung choline kinase 
or  choline  phosphotransferase.  Direct  exposure  of  mixed  fetal  lung  cell  cultures  to 
cortisol results in a 1.6-fold increase in the incorporation of labelled choline into PC 
(Post et al., 1986). The effect of glucocorticoids can still be seen in pure type II cell 
cultures, but a 10-fold increase in hormone concentration is required. Thus, FPF acts not 
only as a signal transducer, but also as an amplifier (Smith and Post, 1991). The action 
of glucocorticoids on the fibroblasts is slow, which limits their use as therapy for NRDS 
through the stimulation of surfactant production and secretion (Smith and Post, 1989). Chapter 1                                                                                                                                      Introduction 
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Epidermal growth factor (EGF) also enhances choline incorporation into PC in 
type II cells by an indirect mechanism (Sen and Cake, 1991). When glucocorticoids and 
EGF are added together the effect is not additive and maximal stimulation is the same as 
with the steroid alone (Sen and Cake, 1991). Both act via a similar mechanism – they 
produce  a  stimulatory  factor  that  has  a  similar  chromatographic  elution  profile. 
However,  EGF  does  not  appear  to  increase  choline  phosphate  cytidylyltransferase 
activity so it is possible that it does not act via FPF (Gross et al., 1986).  
Thyroid  hormones  (e.g.  triiodothyronine  (T3))  appear  to  enhance  the 
responsiveness of type II cells to FPF (Smith and Post, 1989). Glucocorticoids acting on 
the mesenchyme and T3 acting on epithelia have a synergistic effect (Smith and Sabry, 
1983).  T3  has  no  effect  on  FPF  production,  but  potentiates  the  effects  of  both 
glucocorticoids and FPF (Smith and Sabry, 1983). 
In  an  analogous  situation  liver  cells  from  chick  embryos  grown  in  mixed 
cultures, tyrosine aminotransferase (TAT) activity is induced by cortisol stimulation 
(Dow et al., 1983). However, pure hepatocyte cultures do not respond to cortisol. If 
cortisol is incubated with mixed cultures and the conditioned medium transferred to 
pure hepatocytes, TAT activity is detected (Dow et al., 1983). A substance produced by 
the fibroblasts when exposed to cortisol is capable of inducing TAT activity in the 
hepatocytes (Dow et al., 1983) and this is known as the fibroblast-hepatocyte factor.  
 
1.5.3 Action of FPF 
FPF-enhanced  maturation  does  not  lead  to  changes  in  lung  weight  (Smith, 
1979). Rather, it is a physiological ‘on switch’ that prepares the type II cells for their 
postnatal function (Smith and Post, 1989). As little as 1  g of partially-purified FPF can 
accelerate lung maturation in fetal rats (Smith, 1979). Exposure of fetal type II cells to 
FPF enhances the incorporation of radioactively-labelled choline, glycerol and palmitate Chapter 1                                                                                                                                      Introduction 
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into phosphatidylcholine (Post and Smith, 1984a). It also stimulates the formation of 
phosphatidylglycerol from labelled glycerol and palmitate. However, it does not affect 
the synthesis  of  other phospholipids, specifically stimulating only the production of 
surfactant phospholipids (Post and Smith, 1984a). The activities of enzymes in this 
pathway are not significantly altered except for a two-fold increase in the activity of 
choline phosphate cytidylyltransferase (Post et al., 1986), the rate-limiting enzyme in 
surfactant phospholipid synthesis (Post and Smith, 1984b). Exposure of fetal type II 
cultures  to  cortisol-conditioned  fibroblast  medium  results  in  a  1.5-fold  increase  in 
choline incorporation into PC (Post et al., 1986). This correlates well with the doubling 
of the choline phosphate cytidylyltransferase activity. Thus, the action of FPF can be 
measured by increased conversion of choline phosphate to CDP-choline, and decreased 
cellular levels of choline phosphate (Post et al., 1986).  
The  effect  of  FPF  is  rapid  (60  minutes)  suggesting  that  choline  phosphate 
cytidylyltransferase  is  controlled  by  enzyme-modulator  interactions  rather  than  by 
changes in the number of enzyme molecules (Post et al., 1986). It is most likely a post-
translational effect such as the translocation of inactive enzyme from the cytosol to the 
endoplasmic reticulum, where it is activated. This is probably controlled by reversible 
phosphorylation or the effects of long-chain fatty acids or their CoA derivatives on the 
enzyme (Post et al., 1986). Thus, the general timeline is: glucocorticoid induction of 
FPF  in fibroblasts ￿  FPF induction  of cyclic AMP in epithelial cells ￿ enhanced 
production of saturated phosphatidylcholine (Smith and Sabry, 1983).  
 
1.5.4 Inhibition of FPF 
As discussed above, male infants are at a far greater risk of developing NRDS 
than female infants. Significantly higher 11-oxidoreductase activity and FPF activity are 
found in cultures derived from female fetuses (Torday, 1984). Mixed cultures from Chapter 1                                                                                                                                      Introduction 
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female lungs synthesized twice as much PC as male cultures, while there were no sex-
specific differences in PC synthesis in pure type II cultures (Torday, 1984). Thus, the 
effect of testosterone is on the fibroblast cells, and their indirect interaction with the  
type  II  cells.  FPF  production  is  delayed  in  fibroblasts  derived  from  male  fetuses, 
because of the presence of dihydrotestosterone. This effect cannot be reversed, even if 
cells  are  subsequently  stimulated  with  cortisol  (Floros  et  al.,  1987).  
DHT  completely  blocks  cortisol  stimulation  of  PC  synthesis  (Torday,  1985). 
Dihydrotestosterone  appears  to  affect  events  in  FPF  production  that  occur  at  a  
pre-translational level (Floros et al., 1987).  
Insulin also inhibits production of FPF, leading to an increased incidence of 
NRDS in children of diabetic mothers (Smith and Post, 1989). The stimulatory effect of 
cortisol on FPF production is abolished in the presence of insulin (Carlson et al., 1984). 
It  was  initially  thought  that  insulin  blocked  activity  of  choline  phosphate 
cytidylyltransferase, but this is the enzyme that FPF acts on, and it is the production of 
FPF that is blocked by insulin (Carlson et al., 1984). Fetal hyperglycemia results in 
pancreatic islet cell hyperplasia and fetal hyperinsulinemia. The hyperinsulinemic fetal 
state and the associated antagonism of glucocorticoid action leads to a greater incidence 
of NRDS (Carlson et al., 1984).  
There are several other compounds that can inhibit the production or action of 
FPF. Cortisol stimulation of PC synthesis was reduced by the presence of monoclonal 
antibodies to FPF. The presence of these antibodies also delays lung maturation in vivo 
(Post et al., 1984). In late gestation, cortisol inhibits the production of FPF instead of 
stimulating it (Floros et al., 1987). It has also been suggested that FPF is produced by 
adult lung fibroblasts, however in adults it appears to inhibit PC synthesis by type II 
cells (Floros et al., 1987). The anti-glucocorticoid RU486 delays fetal lung maturation, Chapter 1                                                                                                                                      Introduction 
  22
confirming the vital role of these hormones in natural development (Smith and Post, 
1989). 
 
1.6 Secretion of surfactant 
Secretion from cells can occur via both constitutive and regulated pathways. 
Regulated  secretion  is  where  a  stimulus  causes  material  that  has  been  previously 
synthesized and stored to be released from a cell. This process is known as classical 
exocytosis  (Michael  et  al.,  2006).  The  general  sequence  of  events  that  occurs  for 
secretion of surfactant from the lamellar bodies of type II cells is as follows (Dietl and 
Haller, 2005): 
 
1.  Extracellular stimuli modulate intracellular chemical events; 
2.  These events cause movement of lamellar bodies towards the apical surface of 
the cell; 
3.  The  lamellar  bodies  position  themselves  adjacent  to  the  apical  plasma 
membrane; and 
4.  Upon fusion with the apical membrane, the contents of the lamellar bodies are 
extruded into the alveoli. 
 
The steps linking the initial stimulus to final secretion are not well understood. 
  Many different models have been used to study secretion. Chemical methods are 
the most common, and they generally focus on only one component of surfactant, even 
though  surfactant  is  a  heterogeneous  mixture.  Most  studies  have  used  the  lipid 
components to monitor secretion, using whole animals, isolated lung slices and cultured 
type II cells (e.g. Dobbs et al., 1982; Whitsett et al., 1985). The main drawback to using 
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indirect effects via other cells. However, when using cultured type II cells, artifacts can 
be introduced and effects observed in vitro may be more or less important than in vivo.  
 
1.6.1 Factors affecting secretion of surfactant 
The mechanism of surfactant secretion is less well understood than that of surfactant 
synthesis. Several different types of stimuli are known to enhance secretion, including: 
 
1.  hyperventilation (Klass, 1979) 
2.  cholinergic agents (Corbet et al., 1976) 
3.  prostaglandins (Oyarzun and Clements, 1978) 
4.  thyroxine (Redding et al., 1972) 
5.  leukotrienes (Gilfillan and Rooney, 1986) 
6.  agents  known  to  elevate  cyclic-AMP  levels  in  type  II  cells,  such  as  
β-adrenergic agonists (Brown and Longmore, 1981; Mescher et al., 1983) 
7.  agents that elevate protein kinase C activity (Sano et al., 1985) 
8.  agents that increase the intracellular Ca
2+ concentration (Dobbs et al., 1986) 
9.  agents that activate purinoceptors (Gilfillan and Rooney, 1987). 
 
  Images of lamellar bodies engaged in exocytosis have been shown in secretion 
studies involving microscopy (Plate 1.1). The membrane that surrounds the lamellar 
body fuses with the plasma membrane of the cell (Kliewer et al., 1985). Evidence exists 
to suggest that most components of surfactant are secreted simultaneously. Specific 
activity-time curves for PC, DPPC, PG and cholesterol are all very similar (Wright and 
Clements, 1987), and proteins SP-B and SP-C are secreted with phospholipids (Henry et 
al., 1996).  SP-A and SP-D are secreted independently of the lamellar bodies (Rooney, Chapter 1                                                                                                                                      Introduction 
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2001). Synthesis and secretion are coupled, with high levels of surfactant components 
leading to inhibition of secretion (Dobbs et al., 1987). 
 
 
 
Plate 1.1:  Transmission  electron  micrograph  of  a  cultured  fetal  type  II 
pneumocyte  engaged  in  secretion  of  surfactant.  A  represents  a 
lamellar body that has fused with the cell membrane and is secreting 
its contents into the alveolar space. B represents an intact lamellar 
body within the cytosol. Total magnification including photographic 
enlargement = 46,500x. 
 
  Although the mechanism of secretion is not completely known, interaction with 
several different chemicals gives some information that may be used to build a partial 
picture of the process. The β-adrenergic agonist terbutaline increases secretion, and it is 
known  to  activate  cyclic  AMP-dependent  protein  kinase,  meaning  that  a Chapter 1                                                                                                                                      Introduction 
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phosphorylation reaction is likely to be involved (Griese et al., 1992). Cell actin, which 
has been shown to be closely associated with lamellar bodies, can be phosphorylated via 
a cyclic AMP-dependent protein kinase. Treatment of type II cells with cyclic AMP 
alters the intracellular distribution of cytoskeletal β-actin. This evidence suggests that 
the  pathway  of  secretion  involves  cyclic  AMP-dependent  protein  kinase-mediated 
phosphorylation of actin as a key step (Wright and Clements, 1987). Use of A23187 on 
cells  increases  cyclic  AMP  as  well  as  Ca
2+,  indicating  that  the  intracellular  Ca
2+ 
concentration may also affect surfactant secretion (Dobbs et al., 1986). Treatment of 
cells with ATP causes generation of inositol-1,4,5-trisphosphate and diacylglycerol and 
these compounds lead to the activation of Ca
2+/calmodulin-dependent protein kinase 
and protein kinase C (PKC) (Griese et al., 1991; Chander et al., 1995), although down-
regulation of PKC has also been observed (Chander et al., 1998). Several regulatory 
peptides, known to activate these two protein kinases, have also been shown to have an 
effect  on  surfactant  secretion  (Asokananthan  and  Cake,  1996).  Certain  compounds, 
including compound 40/80 and substance P, have been shown to inhibit secretion from 
type II cells (Rice and Whitsett, 1984; Rice and Singleton, 1986a). 
  Administration of β-adrenergic agonists  prior to delivery  has been  shown to 
lower the risk of NRDS (Bergman et al., 1982), which is consistent with the observation 
that they stimulate secretion of PC. These include isoproterenol, terbutaline, salbutamol 
and isoxsuprine (Abdel-Latif and Hollingsworth, 1980; Brown and Longmore, 1981; 
Chander,  1989).  Activation  of  cell-surface  receptors  by  these  agonists  is  likely  to 
activate the Gs protein, which stimulates adenylate cyclase and therefore elevates the 
level of cyclic AMP (Brown and Longmore, 1981). A further indication that cyclic 
AMP can elevate secretion is that a permeable analogue, 8-bromoadenosine-3’5’-cyclic 
monophosphate, can also increase secretion (Brown and Longmore, 1981). Chapter 1                                                                                                                                      Introduction 
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  Purinoceptor agonists are classified as either P1 or P2, depending on the potency 
of  response  to  ATP,  ADP,  AMP  and  adenosine  (Brown  et  al.,  1977).  Secretion 
increases in response to P1 agonists, namely AMP, adenosine and non-metabolizable 
adenosine analogues, as well as P2 agonists, namely ATP and ADP (Chander, 1989). P1 
agonists act to increase cyclic AMP levels within type II cells, whereas the action of P2 
agonists is less clear. One proposed mechanism is that P2 agonists increase hydrolysis 
of phosphatidylinositol-4,5-bisphosphate (PIP2), which produces diacylglycerol leading 
to activation of protein kinase C (Fisher et al., 1984). P2 agonists are more potent than 
P1, causing a five-fold increase in secretion (Rice and Singleton, 1986b).  
  Phorbol 12-myristate 13-acetate (PMA) is a tetracyclic diterpene isolated from 
croton oil (Hecker, 1968), and it is a potent tumor promoter. PMA induces secretion of 
PC,  in  both  a  time-dependent  and  dose-dependent  fashion  (Dobbs  et  al.,  1982).  
The molecular structure of PMA is similar to diacylglycerol, which is known to activate 
protein  kinase  C,  leading  to  cell-specific  phosphorylation  (Nishizuka,  1984).  
These compounds increase the affinity of the enzyme for Ca
2+, which is required for its 
activation. 
  The  calcium  ion  (Ca
2+)  may  be  a  secondary  messenger  in  the  regulation  of 
secretion.  Calcium  ionophores  increase  the  cytosolic  Ca
2+  in  type  II  cells  (Page-
Robberts, 1972), and this increases the rate of secretion (Marino and Rooney, 1980; 
Dobbs et al., 1986). Stimulation of type II cells with ATP also increases intracellular 
Ca
2+ and PC secretion (Rice and Singleton, 1987). 
  Treatment of fetal rabbits in vivo with epidermal growth factor (EGF) on day 24 
of gestation led to greater lung distensibility and increased deflation stability by day 27. 
Morphological maturation of the alveoli was enhanced, and the number of type II cells 
and the number of lamellar bodies per cell were also increased (Catterton et al., 1979). 
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choline (Gross and Dynia, 1984), as well as increasing secretion from fetal rat type II 
cells (Sen and Cake, 1991). The mechanism by which EGF enhances secretion is not 
well  understood,  although  it  has  been  observed  that  treatment  with  EGF  increases 
intracellular Ca
2+ concentration and protein kinase C activity (Berridge, 1987).  
 
1.7 Clearance and recycling of surfactant 
  Secreted surfactant is removed from the alveoli via three different mechanisms 
(Bourbon, 1991): 
 
a)  Degradation  –  components  are  broken  down  and  used  to  synthesize  new 
surfactant lipids and proteins; 
b)  Recycling (or Resorption) – components are not degraded, but are taken up by 
type II cells, incorporated into new lamellar bodies and re-secreted; and 
c)  Removal  –  surfactant  is  removed  from  the  alveolar  region  either  as  intact 
molecules or partially-degraded compounds. 
 
It is possible that if material is not removed from the alveolar region then it could build 
up to dangerous levels. Removal of surfactant does not occur via the lymphatic system 
(Tarpey et al., 1983), although macrophages can digest surfactant compounds (King and 
Martin, 1980). Resorption of surfactant by type II cells is responsible for the majority of 
the clearance from the alveolar region (Hallman et al., 1981), and isolated type II cells 
in culture can ingest PC (Chander et al., 1983). It is possible that uptake involves it 
specifically  binding  to  receptors,  followed  by  endocytosis  (Williams  et  al.,  1984).  
A portion of surfactant is taken up into type II cells, degraded by lysosomes and the 
resulting degradation products transported to the endoplasmic reticulum for re-synthesis 
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  The majority of surfactant is reused without being degraded. In rabbits, it has 
been estimated that as much as 85% of surfactant is reutilized (Magoon et al., 1983). 
Phosphatidylcholine turnover in the alveoli occurs every 10.1 hours, but the biological 
half-life of the compound is 41 hours (Jacobs et al., 1983). This difference clearly 
indicates that PC is reused within the type II cells. PC is thought to be deposited as 
intact molecules back into lamellar bodies once it has been resorbed (Hallman et al., 
1981). Multivesicular bodies are formed as precursor compartments in this recycling 
process (Jacobs et al., 1985; Fisher et al., 1987).  
  It is likely to be more energy efficient to recycle surfactant material that has 
already been produced, rather than to degrade and re-synthesize it. It has been estimated 
that approximately 10% of the alveolar pool of surfactant is recycled per hour (Jacobs et 
al., 1985), although the efficiency of reuse varies greatly with age (Jobe et al., 1989). 
Radiolabelled lipids remain in the alveolar space for several days. The specific activity 
of lavage and lamellar body lipids gradually becomes equal, and does not fall to zero 
until over 100 hours post-injection (Hallman et al., 1981). It is possible that recycling is 
stimulated by β-adrenergic agonists and cyclic AMP (Fisher et al., 1987).  
 
1.8 Respiratory Distress Syndrome 
  Premature birth is the primary cause of morbidity and mortality in infants less 
than one month old (Griese and Westerburg, 1998). The major factor contributing to 
these deaths is neonatal respiratory distress syndrome (NRDS), which is caused by the 
immaturity  of  the  lungs  and  a  deficiency  of  pulmonary  surfactant  (Griese  and 
Westerburg,  1998).  Other  health  effects  of  NRDS  include  pulmonary  oedema  and 
leakage of plasma contents into the airway (Cott et al., 1987; Liu et al., 1997; Wang and 
Notter, 1998). There is also a risk of bronchiolar over-distension during inspiration, 
which  can  cause  epithelial  disruption  in  the  airways  (Robertson,  1984).  Levels  of Chapter 1                                                                                                                                      Introduction 
  29
oedema  and  unresorbed  pulmonary  fluid  are  greater  during  the  early  stages  of  the 
disease (DeSa, 1969).  Most  cases of NRDS  are  caused by a functionally immature 
respiratory system, which produces far less surfactant than is required (Griese, 1999). 
  Infants with NRDS exhibit a classic histopathological pattern, with liquid- and 
fibrin-filled  and/or  collapsed  alveoli  and  over-distended,  aerated  terminal  airways 
(Robertson, 1984). This pattern is known as atelectasis and is caused as the air-liquid 
interface rises to the bronchiolar level at end-expiration, as well as increased resistance 
to aeration due to capillarity in the conducting airways. NRDS is also known as hyaline 
membrane disease, as hyaline membranes are found lining the terminal airways (Griese, 
1999). 
 
1.8.1 Biochemistry of NRDS 
  Avery and Mead (1959) were the first to observe a deficiency of surfactant in the 
watery lung extract of infants with what was, at the time, known as hyaline membrane 
disease. Infants with NRDS have a complete lack, or greatly reduced amount, of both 
PC and PG as well as decreased levels of surfactant phospholipids and SP-A. These 
result in an increased alveolar surface tension (Griese, 1999). Infants with NRDS who 
die within the first 48 hours of life have been shown to have a specific lack of SP-A 
(Markgraf  et  al.,  1990).  Other  surfactant-associated  proteins  are  not  as  reduced  in 
concentration as the lipids, which can modify the activity of surfactant and cause further 
problems (Ikegami et al., 1984; Seeger et al., 1985). These problems possibly arise due 
to competition or chemical interactions between the proteins and other components of 
surfactant.  
  A hereditary deficiency of SP-B can also cause NRDS, due to changes in the 
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the gene coding for SP-B is sufficient to cause NRDS symptoms. Deficiency of SP-C 
can also reduce the stability of surfactant (Glasser et al., 2001). 
 
1.9 Proposed study 
  The purpose of the present study was to attempt to identify and better understand 
the nature of fibroblast-pneumocyte factor. The direct use of FPF to treat NRDS would 
present a viable alternative to current treatments, and avoid problems associated with 
inhibition of FPF production by compounds such as insulin and dihydrotestosterone. 
The study required the optimization of existing protocols for production and detection 
of the protein via tissue culture. From this, a refined method was established which will 
improve reproducibility of future results. Several possible stimulants of FPF production 
were tested to determine which would have the greatest indirect effect on surfactant 
synthesis. Conditioned medium produced by exposure of cultured fetal lung fibroblasts 
to these stimulants was then analyzed in an attempt to identify FPF. 
  Recent literature had indicated that neuregulin-1β is the most likely candidate 
for FPF (Dammann et al., 2003). Other studies had identified a probable role for NRG1 
in lung  development (Patel et al., 2000; Liu et al., 2004), and further study of the 
neuregulin system showed that it could fulfill the functions of FPF. This protein was 
analyzed using HPLC and quadrupolar ion trap mass spectrometry, and the resultant 
spectra used to search for FPF in the fibroblast-conditioned media (FCM) produced 
using the tissue culture system. This method was also used to quantify the amount of 
neuregulin-1β  present  in FCM, and  to detect any  change in  its concentration  when 
fibroblasts were exposed to dexamethasone. 
  The observation that NRG1 could indeed be FPF prompted the examination of 
similar proteins for possible roles in the surfactant system. The effect of insulin on the 
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Mendelson, 1987), and due to similarities to both insulin and the neuregulins (Zorzano 
et al., 2003) and a demonstrated role in lung development (Maitre et al., 1995), it is 
possible that insulin-like growth factors (IGFs) may also exert an influence on both 
synthesis and secretion of surfactant. Tissue culture-based experiments involving the 
addition of IGF-II, as well as other known agonists and antagonists, were conducted.  Chapter 2. Materials and methods 
 
2.1 Animals 
  Nineteen-day pregnant rats of the Wistar strain of Rattus norvegicus were used 
for all experiments. The full gestation period of these animals is 22 days, so fetuses 
were  delivered  approximately  three  days  premature.  Animals  were  supplied  by  the 
Animal Resource Centre (Murdoch, Western Australia). Their mating protocol involves 
caging male and female rats overnight, followed by vaginal smearing the next morning. 
If sperm is detected, then conception is considered to have occurred. This is accurate to 
within  eight  hours  of  actual  conception  and  is  considered  to  be  day  zero.  
All  experiments  complied  with  National  Health  and  Medical  Research  Council 
guidelines  and  were  approved  by  the  Murdoch  University  Animal  Experimentation 
Ethics Committee. 
 
2.2 Preparation of materials for cell culture 
2.2.1 Materials 
Eagle’s  minimal  essential  medium  (MEM)  and  newborn  bovine  serum  were 
obtained  from  Thermo  Fisher  Scientific,  Waltham,  MA,  USA.  Penicillin  G, 
streptomycin sulfate, solubilised β-amphotericin (Fungizone) and 3,5-diaminobenzoic 
acid were supplied by Sigma-Aldrich, St. Louis, MO, USA. L-glutamine was purchased 
from  Invitrogen  Corp.,  Carlsbad,  CA,  USA.  Chloramphenicol  was  obtained  from  
NBL  Gene  Sciences  Ltd.,  Northumberland,  UK.  Collagenase  A  (Clostridium 
histolyticum)  was  a  product  of  F.  Hoffman-La  Roche  Ltd.,  Basel,  Switzerland.  
FSA  Laboratories,  Leicester,  UK  supplied  ‘Hi-Safe  II’  scintillant.  Filters  were 
purchased  from  Millipore  Pty.  Ltd.,  Billerica,  MA,  USA.  All  radioisotope-labelled Chapter 2                                                                                                                                            Methods 
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compounds were supplied by GE Healthcare, Little Chalfont, UK. All other reagents 
were of analytical grade. 
 
2.2.2 Charcoal treatment of newborn calf serum 
  Newborn calf serum (NBCS) was incubated with sterile, acid-washed charcoal  
(50  mg.mL
-1  serum)  for  30  minutes  in  a  37°C  shaking  water  bath,  to  remove 
endogenous steroids. Charcoal was then removed by two successive centrifugations at 
27000 g for 45 minutes at 4°C in a Beckman J2-21M/E centrifuge using a JA-20 rotor 
(Beckman  Instruments,  Palo  Alto,  CA,  USA).  Serum  was  filtered  through  a  
0.44   m  Millipore  filter  to  remove  remaining  charcoal,  and  then  through  a  
0.22  m Millipore filter to sterilize. Charcoal-treated newborn calf serum was stored in 
11.5 mL aliquots at -20°C.  
 
2.2.3 Preparation of rat immunoglobulin G 
  Rat immunoglobulin G (IgG) was purified using the method of Hudson and Hay 
(1976). Serum was obtained from whole blood via centrifugation, and stored at -20°C 
until  purification.  The  serum  was  diluted  1:2  with 0.145 M NaCl, followed  by the 
addition of  100% (w/v) (NH4)2SO4 (buffered to pH 7.2) to a final concentration of 
45%. This mixture was stirred for 30 minutes at room temperature and the precipitate 
collected via centrifugation (at 1000 g for 15 minutes). The precipitate was washed with  
45% (NH4)2SO4 and re-dissolved to the original volume in phosphate-buffered saline 
(PBS) (pH 7.2). PBS contains 136.9 mM NaCl, 8.1 mM Na2HPO4, 2.68 mM KCl and 
1.47  mM K2HPO4.  This new  mixture was centrifuged at 1000 g  for 15 minutes to 
remove  any  remaining  insoluble  material.  The  supernatant  was  adjusted  to  
40%  (NH4)2SO4  and  the  precipitate  washed  with  a  40%  (NH4)2SO4  solution.  This 
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two changes of PBS (at least 12 hours per change). Any precipitate was removed via 
centrifugation and the purified material was lyophilized and stored at 4°C. 
 
2.2.4 Preparation of balanced salts solution 
  Balanced salts solution (BSS) was prepared by mixing 900 mL MilliQ water,  
50 mL 20x saline solution and 50 mL of 20x buffer solution. The solution was adjusted 
to pH 7.4 and filtered through a 0.22  m Millipore filter to sterilize. 20x saline solution 
contains 2.74 M NaCl, 54 mM KCl, 20 mM CaCl2 and 20 mM MgCl2. 20x buffer 
solution  contains  119  mM  NaHCO3,  111  mM  D-glucose,  27  mM  Na2HPO4  and  
3 mM NaH2PO4. 
 
2.2.5 Preparation of culture media 
  Eagle’s  minimal  essential  medium  was  reconstituted  as  specified  by  the 
manufacturer, and supplemented with 0.2% NaHCO3. This mixture was then adjusted to 
pH  7.4.  L-glutamine,  penicillin  G  and  streptomycin  sulphate  were  added  to  final 
concentrations of 2.6 mM, 100 IU.mL
-1 and 100  g.mL
-1, respectively. Medium was 
sterilized by filtration through a 0.22  m Millipore filter and 3.23  g.mL
-1 of Fungizone 
was then added. This solution is termed MEM
+. To produce MEM-complete (MEM
c), 
newborn  calf  serum  was  added  to  a  concentration  of  10%.  Due  to  a  persistent 
contamination by a chloramphenicol-sensitive bacterium in late 2005, 50  g.mL
-1 of this 
antibiotic was added to the medium from November 2005. 
 
2.3 Isolation of fibroblasts and type II pneumocytes 
  Sterile techniques were used during all cell isolation procedures, all of which 
were performed at room temperature unless otherwise stated. Nineteen-day pregnant 
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100% CO2. Fetuses were delivered by Caesarean section. Fetal lungs were removed and 
placed in a Petri dish of warm BSS. Any other tissues, such as the heart and thymus, 
were removed and discarded. Lungs were subsequently minced using a McIlwain tissue 
chopper (The Mickle Laboratory Engineering Co., Surrey, UK) set at 0.1 mm with two 
traverses,  one  perpendicular  to  the  other.  Tissue  was  then  placed  in  a  sterile  flask 
containing 0.75 mL warm BSS per lung and collagenase (approximately 0.26 U.mg
-1, 
slight variation between batches) was added to a final concentration of 0.2 mg.mL
-1. 
The  flask  was  gassed  with  carbogen  (95:5  O2:CO2)  for  90  seconds  to  ensure  cell 
survival, and incubated for 20 minutes in a 37°C shaking water bath. 
  Following incubation the tissue was filtered through two layers of sterile French 
voile gauze into centrifuge tubes. Additional warm BSS was added to ensure that all 
tissue was transferred from the culture flask to the tube. The mixture was centrifuged at 
20 g for two minutes, supernatant was removed and replaced with warm BSS, and the 
washing  procedure  repeated.  Cells  were  resuspended  in  warm  serum-free  MEM
+  
(10 mL per 20 lungs) and plated onto 6 cm (diameter) Corning tissue culture plates  
(3 mL per plate). These plates were incubated for 30 minutes at 37°C in a humidified 
CO2  incubator  (5%  CO2,  95%  air)  to  allow  adhesion  of  fibroblasts.  Following 
incubation, non-adhering cells were suspended by gentle swirling and removed from the 
plates. To each plate, 3 mL of MEM-complete was added. 
  The non-adhering cells were used to isolate type II pneumocytes, according to 
the method of Dobbs et al. (1986). Type II cells lack Fc receptors, whereas most other 
lung  cells  possess  these  receptors  and  so  adhere  to  plates  coated  with  IgG. 
Bacteriological plates (Falcon 1001, Falcon Labware, Becton Dickinson, Lincoln Park, 
NJ, USA) were coated with 3 mL of rat IgG solution (0.5 mg.mL
-1) at least 24 hours 
prior to use, and dried at room temperature under ultraviolet light to maintain sterility. 
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cultures were transferred onto these plates. IgG plates were incubated in the humidified 
CO2 incubator for 60 minutes. Following incubation, plates were removed from the 
incubator and type II cells were resuspended by gentle panning (so as not to detach 
other cell types). Type II cells were transferred to a sterile flask and diluted with MEM
+ 
to a concentration of 0.185 lungs.mL
-1. NBCS was then added to a final concentration 
of 10%. 3 mL of this cellular suspension (equivalent to 0.5 lungs) was plated onto 6 cm 
(diameter) Primaria tissue culture plates. After 2-3 days these plates are considered to be 
confluent cultures consisting of at least 90% type II cells (Plates 2.1, 2.2). This method 
was validated previously using Papanicolaou staining (Sen, 1991). 
 
2.4 Conditions of cell culture 
  Cultures  were  maintained  in  a  water-saturated  atmosphere  of  5%  CO2  and  
95% air and at a temperature of 37°C. The incubator was a Forma Scientific 3157 
water-jacketed CO2 incubator (now supplied by Thermo Fisher Scientific, Waltham, 
MA, USA). The carbon dioxide level was monitored using a Bacharach Fyrite test kit 
(Bacarach  Instruments  Co.,  Pittsburg,  PA,  USA).  To  help  maintain  a  sterile 
environment, 500 mL of Microshield 5 antiseptic solution (Johnson & Johnson, East 
London, UK) was added to the water pan, which was changed every month.  
  Type  II  cultures  were  given  a  media  change  at  24  hours  post-plating.  
This involved removing media from the plates, washing with 2 mL of BSS and adding  
3  mL  of MEM
c to each plate. Fibroblast cultures were given a media change after  
48 hours of culture, and every 48 hours (72 hours over weekends) after that, for 14 days. 
BSS and MEM
c were pipetted into the corner of the plate, so as not to detach cells. 
  Since the conclusion of tissue culture experiments for this project, it has come to 
light that there was an error in the laboratory techniques that had been provided at the 
beginning of the project. Both type II and fibroblast cultures should receive a media  Chapter 2                                                                                                                                            Methods 
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Plate 2.1:  Phase  contrast  photomicrograph  of  a  typical  19-day  fetal  type  II 
pneumocyte culture. 
 
Type II pneumocytes were isolated and cultured from 19-day fetal rats. A phase contrast 
photomicrograph  of  cells  was  taken  after  four  days  in  culture  using  a  Kodak 
Ektachrome  160  tungsten  film  on  an  Olympus  IMT-2  inverted  phase  microscope.  
The overall magnification (including photographic enlargement) was 880x. Chapter 2                                                                                                                                            Methods 
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Plate 2.2:  Transmission electron micrograph of a typical 19-day fetal type II 
pneumocyte culture. 
 
Type II pneumocytes were isolated and cultured from 19-day fetal rats. A transmission 
electron micrograph of cells was taken after four days in culture using a Philips CM100 
electron microscope. The overall magnification (including photographic enlargement) 
was 4680x. Chapter 2                                                                                                                                            Methods 
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change 24 hours after plating, and then every 48 hours, regardless of weekends. Failure 
to follow this regimen can greatly affect the yield of cells on fibroblast plates. 
 
2.5 Preparation of fibroblast-conditioned medium 
  After 15 days in culture, fibroblast plates were considered confluent, and free of 
any type II cell contamination (Plate 2.3), as judged by microscopy. At this time, media 
was removed from the plates and they were washed twice with 2 mL of BSS. 1.7 mL of 
MEM
+ was added to each plate as well as 17  L of additive + vehicle (test) or vehicle 
only (control). Plates were returned to the incubator for a further 24 hours, after which 
fibroblast-conditioned medium was collected, transferred to sterile bottles and stored at 
-80°C.  Cells  were then harvested from the plates for DNA assay using the method 
described for synthesis experiments (2.6). 
 
2.6 Initial synthesis experimental method 
  Fibroblast-conditioned medium (FCM) produced by the above method should 
contain fibroblast-pneumocyte  factor (FPF) (Smith and Post, 1989). To confirm the 
presence and activity of the protein, it was necessary to test its ability to stimulate 
synthesis of phosphatidylcholine (PC) by type II cells. The following method has been 
used in this laboratory for over a decade, and is based on the lipid extraction method of 
Bligh and Dyer (1959). 
FCM was removed from the -80°C freezer and thawed at room temperature. 
This was demonstrated by Smith (1981a) to have no effect on activity of FPF. FCM was 
then  heat-treated  in  a  65°C  water  bath  for  60 minutes to remove known inhibitory 
factors. After cooling to room temperature, it was filtered through a 0.22  m Millipore 
syringe filter and diluted 1:4 with MEM
+ (0.8 mL FCM: 2.4 mL MEM
+). To this diluted  
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Plate 2.3:  Phase contrast photomicrograph of a typical 19-day fetal fibroblast 
culture. 
 
Pulmonary  fibroblasts  were  isolated  and  cultured  from  19-day  fetal  rats.  A  phase 
contrast photomicrograph of the cells was taken after 15 days culture using a Kodak 
Ektachrome  160  tungsten  film  on  an  Olympus  IMT-2  inverted  phase  microscope.  
The overall magnification (including photographic enlargement) was 1240x. Chapter 2                                                                                                                                            Methods 
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media, 24  L of either additive + vehicle or vehicle only was added, depending on the 
FCM required. Bottles were thoroughly vortexed to ensure adequate mixing. 
Type II plates were removed from the incubator after approximately 72 hours of 
culture and the media removed. Plates were washed twice with 2 mL of BSS and 3 mL 
of  diluted,  supplemented  fibroblast-conditioned  media  was  added  to  each  plate.  
In addition, control plates were produced by adding 3 mL of MEM
+ plus 30  L of either 
additive + vehicle or vehicle only. Plates were returned to the incubator for a further  
21 hours incubation. 
  A solution of 7  Ci.mL
-1 [methyl-
3H]-choline chloride in MEM
+ was prepared. 
The labeled choline, supplied as an ethanol solution, was dried under nitrogen prior to 
the addition of MEM
+. Type II plates were removed from the incubator and 500  L of 
this [
3H]-choline chloride solution was added to each. Plates were swirled to mix and 
returned to the incubator for a further 6 hours. This incubation time was used as it 
represents the middle of the linear phase of choline incorporation. 
At the conclusion of incubation, plates were removed from the incubator and 
placed on ice to prevent further lipid synthesis. Media was removed from the plates and 
discarded. Plates were washed twice with 1 mL of BSS, with cells being scraped from 
the plate with a spatula at each step. The wash buffer was collected, along with the cells, 
into a pre-weighed conical centrifuge tube, which was kept on ice until all plates had 
been harvested. Weighing of tubes provides a preliminary indication of cultures with a 
poor  yield.  Tubes  were  centrifuged  at  1000  g  and  4°C  for  two  minutes  and  the 
supernatant  was  removed  by  aspiration  and  discarded.  Centrifuge  tubes  were  again 
weighed, to allow calculation of the weight of cells harvested from each plate. 400  L 
of BSS was added to each tube and the tubes were sonicated using a Braunsonic 1510 
sonicator  with  a  microprobe  (B.  Braun,  Melsungen,  Germany)  at  10  watts  for  10 
seconds to disrupt the cells.  Chapter 2                                                                                                                                            Methods 
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From this sonicate, two 50  L aliquots were taken and dried in a 50°C oven to 
determine DNA content. Lipids were extracted from cells using the method of Bligh and 
Dyer (1959) as follows: A further 200  L aliquot of the sonicate was taken and added to 
a  tube  containing  2  mL  methanol,  1  mL  chloroform,  600   L  of  MilliQ-H2O,  
50  L of L-3-phosphatidylcholine-1,2-di[1-
14C]palmitoyl (approximately 10000 dpm) 
as  a recovery  standard and 20   L of 2.5 mg.mL
-1 phosphatidylcholine as a carrier.  
A further 1 mL of chloroform and 1 mL of MilliQ-H2O were added, the tubes vortexed 
for 10 seconds and placed in a 4°C refrigerator for at least 48 hours. 
The amount of DNA was determined using a method adapted from Hinegardner 
(1971).  DNA  assay  tubes  were  removed  from  the  oven  after  at least 24 hours and  
100  L of a 0.3 g.mL
-1 3,5-diaminobenzoic acid solution was added to each. Tubes were 
placed back in the 50°C oven for a further 45 minutes to allow product development. 
After this, 1.5 mL of 1.0 M HCl was added to each tube. Tubes were read in a Perkin-
Elmer  LS-50  luminescence  spectrofluorometer  (Perkin-Elmer,  Waltham,  MA,  USA) 
with excitation wavelength at 415 nm and emission wavelength at 505 nm. 
During  the  48  hours  in  the  refrigerator,  the  chloroform:methanol  extract 
separated  into  two  layers,  with  the  lower  layer  containing  lipid.  The  upper 
water/methanol layer was removed via aspiration and a 400  L aliquot of the lower 
layer was taken and placed into a scintillation vial. The contents of the vial were dried 
by evaporation for two hours and 3 mL of scintillant was added to each vial. Vials were 
vortexed  and left to stand  at  room temperature  for 24 hours prior to counting  in a 
Beckman LS3801 scintillation counter (Beckman Instruments, Palo Alto, CA, USA). 
Three 50  L samples from the [
14C]-labelled phosphatidylcholine standard were also 
counted.  Tubes  were  counted  for  both 
3H  and 
14C.  To  determine  synthesis  of 
phospholipids, several  calculations were performed using data from the experiment.  
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The first calculation was: 
 
 
 
This determined the recovery of 
14C, which was used to obtain the full count for 
3H at 
100% recovery. DNA, which was calculated from 50  L of sonicate, was multiplied by 
four  to  give  the  total  from  200   L  of  sonicate,  the  same  volume  used  for  lipid 
extraction. The 
3H value, which had been corrected for recovery, was then divided by 
the DNA in 200  L to give dpm incorporated.ng DNA
-1. Duplicates were performed for 
all  experiments,  and  these  were  averaged  to  give  a  mean  value.  By comparing the 
control and test values for both direct and indirect treatments, the percentage increase 
due to FPF was determined. The choline-labelled material produced using this method 
was  previously  characterised  by  TLC  (Sen,  1991)  and  shown  to  consist  almost 
exclusively (>85%) of phosphatidylcholine. 
 
2.7 Early synthesis results 
2.7.1 Dexamethasone 
  Dexamethasone  has  been  demonstrated  to  cause  a  2.5-fold  increase  in  PC 
synthesis in rat lung cultures (Gross and Wilson, 1982), but direct exposure of type II 
cells to dexamethasone has no effect. However, when fibroblasts cells are exposed to 
dexamethasone  and  the  resultant  conditioned  medium  exposed  to  type  II  cultures,  
PC synthesis is augmented (Smith and Post, 1989). Dexamethasone (Sigma-Aldrich,  
St.  Louis,  MO,  USA)  was  stored  at  4°C  as  a  10   M  solution  in  propylene  glycol  
(Ajax Chemicals, Auburn, NSW, Australia). Following the method described in 2.5, 
dexamethasone  was  added  to  confluent  fibroblast  plates  to  a  final  concentration  of  
100 nM, as this concentration had previously been shown to give maximal stimulation 
14C input (dpm)
14C recovered (dpm)
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(Sen, 1991). Control plates substituted propylene glycol. The resultant FCM was tested 
for its ability to increase PC synthesis according to the method described in 2.6. 
  Thirteen pairs of control and test FCM were tested and the results obtained were 
very inconsistent (Table 2.1). Rather than the expected increase in synthesis, both the 
direct and indirect treatments showed a mean decrease (14.91 and 26.07% respectively).  
 
Table 2.1:   The direct and indirect effect of dexamethasone on the augmentation 
of PC synthesis by type II pneumocytes. 
 
 
 
 
 
 
 
Primary cultures of lung fibroblasts were grown to near confluence, followed by 24 
hours incubation in the presence or absence of 100 nM dexamethasone in MEM
+. The 
fibroblast-conditioned media (FCM) were collected and stored at -80°C. Prior to use, 
the media were thawed and incubated at 65°C for one hour, cooled to room temperature 
and filter-sterilized to remove detached cells and cellular debris. The media were then 
diluted  1:4  with  MEM
+.  The  effect  on  PC  synthesis  by  type  II  pneumocytes  was 
investigated by exposing the cells either to the FCM (indirect) or to MEM
+, with and 
without  dexamethasone  (direct).  The  data  represent  the mean  ± SE. The number  of 
replicates examined for each condition is indicated in parentheses, and each replicate 
comprised four cultures. Data were compared using single-factor ANOVA. 
 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference P-value
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
Direct (13)
Control 40.05 ± 7.61
Dexamethasone 34.08 ± 6.56 ↓  14.91% 22.64
Indirect (13) 0.18
Control 36.29 ± 7.16 
Dexamethasone 26.83 ± 5.84  ↓  26.07% 24.21 15.37Chapter 2                                                                                                                                            Methods 
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PC synthesis values (expressed in dpm.ng DNA
-1) were very high for these experiments,  
being almost double the magnitude previously observed (Sen and Cake, 1991). Standard 
error  values  were  also  very  high,  as  much  as  21.8%  in  the  case  of  indirect 
dexamethasone treatments. Single-factor ANOVA (p = 0.18) indicated no significant 
difference between the direct and indirect treatments. 
  The  manufacturer  of  the  dexamethasone  was  contacted  and  confirmed  that, 
while the product has no specific ‘expiry date’, its activity could not be guaranteed more 
than six months after purchase. As the dexamethasone used was far older than this, it is 
likely that poor quality reagents were the cause of the inconsistent results obtained in 
this set of experiments. 
 
2.7.2 PMA 
  The inconsistent results obtained with dexamethasone led to consideration of 
possible  alternative  stimulants  of  FPF  production.  12-O-Tetradecanoylphorbol-13-
acetate,  more  commonly  known  as  phorbol  12-myristate  13-acetate  (PMA),  is  a 
tetracyclic diterpene isolated from croton oil (Hecker, 1968) that has previously been 
shown  to  have  a  significant  effect  on  PC  synthesis  via  fibroblasts  (Sen,  1991).  
PMA acts via protein kinase C, meaning that it is likely to stimulate FPF production via 
a different mechanism than glucocorticoids. These factors made it an ideal choice for a 
second series of experiments. PMA was stored at 4°C as a 0.5 mg.mL
-1 solution in 
dimethylsulphoxide  (DMSO)  (both  from  Sigma-Aldrich,  St  Louis,  MO,  USA).  
This solution was diluted with 1% DMSO in BSS to give a working concentration of  
2  g PMA.mL
-1. The vehicle added to the plates was 1% DMSO in BSS. FCM was 
generated as described in 2.5 and tested as in 2.6. 
  Fourteen pairs of control and test FCM were tested, and again the results were 
very inconsistent (Table 2.2). Both the direct and indirect tests showed a mean decrease Chapter 2                                                                                                                                            Methods 
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Table 2.2:  The direct and indirect effect of phorbol 12-myristate 13-acetate on 
the augmentation of PC synthesis by type II pneumocytes. 
 
 
 
 
 
 
 
 
Primary cultures of lung fibroblasts were grown to near confluence, followed by 24 
hours  incubation  in  the  presence  or  absence  of  2   g.mL
-1  phorbol  12-myristate  
13-acetate (PMA) in MEM
+. The fibroblast-conditioned media (FCM) were collected 
and stored at -80°C. Prior to use, the media were thawed and incubated at 65°C for one 
hour, cooled to room  temperature and  filter-sterilized to remove detached cells and 
cellular debris. The media were then diluted 1:4 with MEM
+. The effect on PC synthesis 
by  type  II  pneumocytes  was  investigated  by  exposing  the  cells  either  to  the  FCM 
(indirect)  or  to  MEM
+,  with  and  without  PMA  (direct).  The  data  represent  the  
mean  ± SE.  The  number  of  replicates  examined  for  each  condition  is  indicated  in 
parentheses, and  each  replicate comprised four  cultures. Data were compared using 
single-factor ANOVA. 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference P-value
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
Direct (14)
Control 21.07 ± 6.57
PMA 15.94 ± 3.31 ↓  24.35% 35.59
Indirect (14) 0.93
Control 21.97 ± 5.54
PMA 18.75 ± 4.07 ↓  14.66% 37.25 16.08Chapter 2                                                                                                                                            Methods 
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in PC synthesis (24.35 and 14.66% respectively). Standard error values were again very 
high, with direct control treatments having an error of 31.8%. Single-factor ANOVA  
(p  =  0.93)  showed  no  significant  difference  between  direct  and  indirect  response  
to PMA. 
 
2.8 Final synthesis experimental method 
  The erratic results obtained from the first 29 experiments indicated a possible 
problem with the experimental methodology. To improve accuracy, several steps were 
added to the method, mostly to monitor the addition of [
3H]-choline chloride to the 
plates. The entire method for synthesis experiments is presented again, with alterations 
and additions noted in bold. 
FCM was removed from the -80°C freezer and thawed at room temperature. 
This was demonstrated by Smith (1981a) to have no effect on activity of FPF. FCM was 
then  heat-treated  in  a  65°C  water  bath  for  60 minutes to remove known inhibitory 
factors.After cooling to room temperature, it was filtered through a 0.22  m Millipore 
syringe filter and diluted 1:4 with MEM
+ (0.8 mL FCM: 2.4 mL MEM
+). To this diluted 
media, 24  L of either additive + vehicle or vehicle only was added, depending on the 
FCM. Bottles were thoroughly vortexed to ensure adequate mixing. 
  Type II plates were removed from the incubator after approximately 72 hours of 
culture and the media removed. Plates were washed twice with 2 mL of BSS and 3 mL 
of  diluted,  supplemented  fibroblast-conditioned  media  was  added  to  each  plate.  
In addition, control plates were produced by adding 3 mL of MEM
+ plus 30  L of either 
additive + vehicle or vehicle only. Plates were returned to the incubator for a further  
21 hours incubation. 
  A solution of 7  Ci.mL
-1 [methyl-
3H] choline chloride in MEM
+ was prepared. 
The labeled choline, supplied as an ethanol solution, was dried under nitrogen prior to Chapter 2                                                                                                                                            Methods 
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the addition of MEM
+. The flask was incubated in a 37°C shaking water bath for  
10 minutes to ensure all of the choline chloride had gone into solution. Media was 
removed  from  type  II  plates  to  sterile  tubes,  and  500         L  of  
[
3H]-choline chloride solution added to each. Tubes were vortexed and a 50         L 
sample of each taken for determination of initial 
3H content. In addition, three  
50        L samples of the [
3H]-choline chloride solution were taken to be counted as 
well. Media was returned to the plates, which were placed in the incubator for a 
further 6 hours. Samples for counting were placed in scintillation vials, 3 mL of 
scintillant was added to each, vials were vortexed and they were left in the dark for 
at least 24 hours prior to counting. 
At the conclusion of incubation, plates were removed from the incubator and 
placed on ice to prevent further lipid synthesis. Media was removed from the plates and 
discarded. Plates were washed twice with 1 mL of BSS, with cells being scraped from 
the plate with a spatula at each step. The wash buffer was collected, along with the cells, 
into a pre-weighed conical centrifuge tube, which was kept on ice until all plates had 
been harvested. Weighing of tubes provides a preliminary indication of cultures with a 
poor  yield.  Tubes  were  centrifuged  at  1000  g  and  4°C  for  two  minutes  and  the 
supernatant  was  removed  by  aspiration  and  discarded.  Centrifuge  tubes  were  again 
weighed,  to  allow  calculation  of  the  weight  of  cells  harvested  from  each  plate.  
400  L of BSS was added to each tube and the tubes were sonicated using a Braunsonic 
1510 with a microprobe at 10 watts for 10 seconds to disrupt the cells. 
From this sonicate, two 50  L aliquots were taken and dried in a 50°C oven to 
determine DNA content. Lipids were extracted from cells using the method of Bligh and 
Dyer (1959) as follows: A further 200  L aliquot of the sonicate was taken and added to 
a tube containing 2 mL methanol, 1 mL chloroform, 600  L of MilliQ-H2O, 50  L of  
L-3-phosphatidylcholine-1,2-di[1-
14C]palmitoyl  (approximately  10000  dpm)  as  a Chapter 2                                                                                                                                            Methods 
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recovery  standard  and  20   L  of  2.5  mg.mL
-1  phosphatidylcholine  as  a  carrier.  
This mixture was vortexed for 10 seconds and left to stand at room temperature 
for 10 minutes. A further 1 mL of chloroform and 1 mL of MilliQ-H2O were added, the 
tubes vortexed for 10 seconds and placed in a 4°C refrigerator for at least 48 hours. The 
total volume of the organic layer was 2.05 mL. 
The amount of DNA was determined using a method adapted from Hinegardner 
(1971).  DNA  assay  tubes  were  removed  from  the  oven  after  at least 24 hours and  
100  L of a 0.3 g.mL
-1 3,5-diaminobenzoic acid solution was added to each. Tubes were 
placed back in the 50°C oven for a further 45 minutes to allow product development. 
After  this,  1.5  mL  of  1.0  M  HCl  was  added  to  each  tube.  Tubes  were  read  in  a  
Perkin-Elmer LS-50 luminescence spectrofluorometer (Perkin-Elmer, Waltham, MA, 
USA) with excitation wavelength at 415 nm and emission wavelength at 505 nm. 
During  the  48  hours  in  the  refrigerator,  the  chloroform:methanol  extract 
separated  into  two  layers,  with  the  lower  layer  containing  lipid.  The  upper 
water/methanol layer was removed via aspiration and a 400  L aliquot of the lower 
layer was taken and placed into a scintillation vial. The contents of the vial were dried 
by evaporation for two hours and 3 mL of scintillant was added to each vial. Vials were 
vortexed and left in the dark at room temperature for 24 hours prior to counting in a 
Beckman LS3801 scintillation counter (Beckman Instruments, Palo Alto, CA, USA). 
Three  50   L  samples  from  the 
14C-labelled  phosphatidylcholine  standard  were also 
counted. Tubes were counted for both 
3H and 
14C, and in most cases were counted 
either two or three times to confirm values. 
To determine synthesis of phospholipids, several calculations were performed 
using data from the experiment. The first calculation was: 
 
14C input (dpm)
14C recovered (dpm)
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This determined the recovery of 
14C, which was used to obtain the full count for 
3H at 
100% recovery. DNA, which was calculated from 50  L of sonicate, was multiplied by 
four  to  give  the  total  from  200   L  of  sonicate,  the  same  volume  used  for  lipid 
extraction. The 
3H value, which had been corrected for recovery, was then divided by 
the DNA in 200  L to give dpm incorporated.ng DNA
-1. Duplicates were performed for 
all  experiments  and  these  were  averaged  to  give  a  mean  value.  By  comparing  the 
control and test values for both direct and indirect treatments, the percentage increase 
due to FPF was determined. The choline-labelled material produced using this method 
was  previously  characterised  by  TLC  (Sen,  1991)  and  shown  to  consist  almost 
exclusively (>85%) of phosphatidylcholine. 
Results were tabulated and graphed using Microsoft Excel 2003 (v11.8117) and 
statistics calculated using SPSS for Windows 14.0.1. 
 
2.9 Results from modified method 
2.9.1 Dexamethasone 
  A new batch of dexamethasone (also from Sigma-Aldrich) was purchased and 
used as described in 2.7.1. Sixteen pairs of control and test FCM were tested using the 
modified method (2.8) and the results obtained were much more consistent (Table 2.3). 
Direct treatment with dexamethasone showed a mean increase of 1.77%, while indirect 
treatment yielded a 9.17% mean increase. Standard error values were much lower than 
in  the  earlier  experiments,  with  the  highest  being  9.9%  over  16  experiments.  
PC synthesis values (expressed in dpm.ng DNA
-1) for these experiments were of similar 
magnitude as those observed previously (Sen and Cake, 1991). Single-factor ANOVA 
(p  =  0.02)  showed  a  significant  difference  between  the  stimulatory  effect  of 
dexamethasone exposure in direct and indirect treatments, indicating that the synthesis Chapter 2                                                                                                                                            Methods 
  51
experiments were now a reliable method for detecting the presence of FPF. FCM from 
these experiments was stored at -80°C for future use in isolating FPF (3.2.1). 
 
Table 2.3:  The direct and indirect effect of dexamethasone on the augmentation 
of  PC  synthesis  by  type  II  pneumocytes,  utilizing  the  modified 
experimental method. 
 
 
 
 
 
 
 
 
Primary cultures of lung fibroblasts were grown to near confluence, followed by 24 
hours incubation in the presence or absence of 100 nM dexamethasone in MEM
+. The 
fibroblast-conditioned media (FCM) were collected and stored at -80°C. Prior to use, 
the media were thawed and incubated at 65°C for one hour, cooled to room temperature 
and filter-sterilized to remove detached cells and cellular debris. The media were then 
diluted  1:4  with  MEM
+.  The  effect  on  PC  synthesis  by  type  II  pneumocytes  was 
investigated by exposing the cells either to the FCM (indirect) or to MEM
+, with and 
without  dexamethasone  (direct).  The  data  represent  the mean  ± SE. The number  of 
replicates examined for each condition is indicated in parentheses, and each replicate 
comprised four cultures. Data were compared using single-factor ANOVA. 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference P-value
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
Direct (16)
Control 28.34 ± 2.77
Dexamethasone 28.84 ± 2.84 ↑  1.77% 31.04
Indirect (16) 0.02
Control 26.82 ± 2.54
Dexamethasone 29.28 ± 2.65 ↑  9.17% 26.88 12.84Chapter 2                                                                                                                                            Methods 
  52
2.10 Experimental reliability 
Several  values  were calculated to monitor  the  reliability  of the  experiments.  
Type II DNA values were converted to the total DNA per plate, to monitor cell yield 
from week to week. The mean amount of DNA per plate was also calculated for the 
fibroblast plates used in a given experiment. By taking a mean of 
14C recovered and 
dividing  it  by  the  mean 
14C  input,  the  percentage  recovery  was  calculated.  
This indicated what percentage of total lipids was being extracted and counted for each 
experiment. The three samples of the [
3H]-choline chloride solution were also averaged 
to monitor the actual amount of 
3H being added to the plates for each experiment.  
The samples taken from each plate immediately after the addition of 
3H showed how 
much 
3H  was  present  on  each  plate  at  the  beginning  of  incubation.  Both  of  these  
3H  values  were  multiplied  by  20  and  divided  by  2.22x10
6  to  convert  to   Ci.mL
-1.  
The ratio of total and plate 
3H radioactivity was also monitored to ensure an accurate 
1:7 dilution onto the plate.  
  It should be noted that although these changes were not implemented until the 
final five experiments using PMA, data for plate DNA and percentage recovery of lipids 
were being collected from the first dexamethasone experiment. This allowed these three 
values to be calculated for all experiments. Values relating to 
3H radioactivity could 
only  be  calculated  for  the  final  five  PMA  experiments  and  the  second  batch  of 
dexamethasone experiments. 
  To determine if any of the monitored parameters were influencing the results of 
the synthesis experiments, values for those experiments which gave a positive indirect 
effect  (of FCM  on PC secretion by type II cells) were compared with those which 
showed  no  indirect  effect.  Values  were  also  compared  between  data  sets  
(e.g.  dexamethasone,  PMA)  to  determine  if  the  erratic  results  were  due  to  these Chapter 2                                                                                                                                            Methods 
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parameters. All statistical comparisons were achieved using single-factor ANOVA, with 
a confidence level of 95%.  
 
2.10.1 Type II pneumocyte cell density 
Comparison of experiments that gave a positive indirect effect in response to the 
added  agent  with  those  that  were  unresponsive  showed  that  overall  there  was  no 
significant difference in type II cell density (p= 0.42) (Table 2.4). Standard error values 
were  small,  with  a  mean  of  15.3%,  indicating  that  density  was  consistent  within 
experimental  sets.  However,  there  was  a  clear  difference  for  the  second  batch  of 
dexamethasone experiments, where the cultures which did not respond to the FCM had 
a significantly higher cell density of 36.20  g.plate
-1, compared to 24.06  g.plate
-1 for 
those plates which had a positive response (p = 0.04).  
 
Table 2.4:  Mean  DNA  level  of  type  II  cultures  (       g.plate
-1)  for  experiments 
which  gave  a  positive  indirect  response  and  those  which  did  not.  
P-values were obtained using a single-factor ANOVA. 
 
 
 
 
   
 
Type  II  pneumocytes  do  not  culture  well  from  single  cells,  requiring  large 
groups of cells to be plated. These clumps then spread out across the plate as culture 
time progresses (Tajbakhsh and Cake, unpublished observations). If the large clumps 
have  not  spread  out  by  the  time  the  plates  are  considered  confluent  and  used  for 
Positive response No response
Dexamethasone 17.93 ± 2.31 26.16 ± 6.19 0.50
PMA 32.53 ± 5.48 39.14 ± 5.39 0.42
Dexamethasone (new) 24.06 ± 3.16 36.20 ± 4.36 0.04
Additive P-value
DNA level (       g.plate
-1)Chapter 2                                                                                                                                            Methods 
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experiments (i.e. after four days), results will be affected. Cells located on the exterior 
of the clumps will behave as expected, but those on the interior will not have the same 
exposure to stimulants (e.g. dexamethasone, FPF) and radiolabelled choline precursor. 
This means that both synthesis of PC and incorporation of 
3H into that PC would be 
reduced. These interior cells would however contribute to the DNA extracted from the 
plate, and would therefore decrease the apparent synthesis of PC, which is calculated as 
dpm.ng DNA
-1. Visual observation of cultures has shown that for plates with very high  
cell density (often in excess of 40  g.plate
-1) the cells are not distributed evenly across 
the plate, with many of these cellular clumps still present. 
  Purification of type II cells prior to plating is achieved through binding of other 
cells types to IgG, leaving only type II cells in suspension. Large clumps of cells are 
likely to contain other cells types, such as fibroblasts, and these will be transferred to 
the type II plate, as they are not exposed to IgG. This means that the type II plates will 
also contain contaminating fibroblasts which will be exposed as culture time progresses 
and the clumps spread out. This will have an effect on apparent PC synthesis for two 
reasons.  Firstly,  as  with  clumped  type  II  cells,  fibroblasts  will  not  contribute  to 
synthesis but will add to cell density, thereby reducing the calculated level of synthesis. 
Secondly, when exposed to dexamethasone any fibroblasts cells will produce FPF and 
thereby increase synthesis of PC in neighbouring type II cells. This latter effect should 
be  cancelled  out  because  of  the  addition  of  dexamethasone  to  all  cultures 
(supplementation), but it is possible that response to dexamethasone may be reduced 
when fibroblast contamination is high. Confluent cell cultures have also been observed 
to down-regulate expression of receptors for growth factors (e.g. Csordas et al., 2000). 
  Following this investigation, the results from the second batch of dexamethasone 
experiments were analyzed again, this time separating them into those cultures where 
the  cell  density  was  less  than  25   g.plate
-1  and those  where it exceeded this  value  Chapter 2                                                                                                                                            Methods 
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(Table  2.5). This  threshold  value was determined by analysis based on response to 
dexamethasone  and  cell  density.  The  indirect  cultures  with  high  cell  density  
(mean = 35.05  g.plate
-1) showed a 3.39% increase in synthesis from exposure to FCM, 
compared to those with cell density below the threshold value (mean = 17.80  g.plate
-1) 
which  showed  a  17.56%  increase.  This  result  is  highly  significant (p  =  0.003) and 
indicates that cell density had a considerable impact on the sensitivity of the cultures. 
Further investigation using the FCM generated and tested via this method focused only 
on those samples that had been tested on type II cultures with a cell density below  
25  g.plate
-1. 
The density of cells on the type II plate may also have influenced the response of 
experiments using  PMA, as  the mean  cell density for these experiments was 35.84 
 g.plate
-1. Comparison of cell density between experimental sets indicated that the mean 
concentration for PMA was significantly higher than for either of the dexamethasone 
sets  (p  =  0.01).  In  the  case  of  the  PMA  experiments,  where  results  were  very 
inconsistent,  it  is  possible  that  cell  density  was  a  major  factor  that  was  not  being 
considered  prior to the  introduction of the revised method. Analysis of cell density 
indicates that this value should definitely be monitored in all future experiments to 
ensure  consistency  of  results.  Unfortunately,  attempts  to  produce  primary  type  II 
cultures  with  a  consistent  cell  density  have  not  been  successful.  Primary  fibroblast 
cultures are required, as line cells do not show the same response (Smith, 1981a). It is 
possible that a cell line could be used to generate type II cultures, and this may improve 
reliability.  Given  that  this  would  require  a  major  alteration  to  the  tissue  culture 
procedures in use, this alternative was not explored in this study. Chapter 2                                                                                                                                            Methods 
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Table 2.5:   The effect of dexamethasone on PC synthesis in type II pneumocytes 
taking  the  density  of  the  type  II  pneumocyte  cultures  into 
consideration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary cultures of lung fibroblasts were grown to near confluence, followed by 24 
hours incubation in the presence or absence of 100 nM dexamethasone in MEM
+. The 
fibroblast-conditioned media (FCM) were collected and stored at -80°C. Prior to use, 
the media were thawed and incubated at 65°C for one hour, cooled to room temperature 
and filter-sterilized to remove detached cells and cellular debris. The media were then 
diluted  1:4  with  MEM
+.  The  effect  on  PC  synthesis  by  type  II  pneumocytes  was 
investigated by exposing the cells either to the FCM (indirect) or to MEM
+, with and 
without  dexamethasone  (direct).  The  data  represent the mean  ± SE. The number  of 
replicates examined for each condition is indicated in parentheses, and each replicate 
comprised four cultures. Data were compared using single-factor ANOVA. 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference P-value
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
< 25        g DNA.plate
-1
Direct (8)
Control 27.99 ± 5.82
Dexamethasone 29.21 ± 6.08 ↑  4.36% 16.29
Indirect (8) 0.003
Control 22.95 ± 3.55
Dexamethasone 26.98 ± 4.14 ↑  17.56% 17.80 15.43
> 25        g DNA.plate
-1
Direct (8)
Control 29.20 ± 3.31
Dexamethasone 28.79 ± 3.37 ↓  1.4% 42.51
Indirect (8) 0.24
Control 30.31 ± 4.07
Dexamethasone 31.34 ± 4.15 ↑  3.39% 35.05 17.46Chapter 2                                                                                                                                            Methods 
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2.10.2 Fibroblast plate cell density 
  Comparison of those cultures that gave a positive indirect effect with those that 
were  unresponsive  showed  that  overall  there  was  no  significant  difference  in  cell 
density of the fibroblast cultures (p = 0.90) (Table 2.6). Standard error values were 
small, with  a mean value  of 15.1%, indicating that  density  was  consistent between 
experiments  using  a  given  additive.  A  difference  was  found  for  the  initial 
dexamethasone  experiments,  where positive  experiments had a  fibroblast  density  of 
10.33   g.plate
-1  compared  to  16.88   g.plate
-1  for  those  that  did  not  respond  
(p = 0.03). These experiments were very inconsistent, and it is possible that the density 
of the fibroblasts was one of many factors adversely influencing the results. It is not 
clear how fibroblast cell density might affect the results, but it is likely to be due to 
similar issues as those discussed in 2.10.1. The basal level of FPF may be much higher 
in  dense  fibroblast  cultures,  potentially  diminishing  the  observed  response  to 
dexamethasone. Conversely, insufficient numbers of cells on a given plate will mean 
that not enough FPF is produced to stimulate PC synthesis, while too many may limit 
exposure to stimulants. 
  A  study  currently  being  conducted  by  an  Honours  student  under  my  
co-supervision has indicated that the level of DNA per plate of fibroblast cultures may 
not  be  a  reliable  indicator  of  the  quality  of  fibroblasts  (in  terms  of  their ability to 
proliferate). It has been observed that if media changes are not performed every 48 
hours, the health of the fibroblast cells can be greatly affected (Ellison, unpublished 
data). These poor quality cells would still contribute to cell density as calculated using 
the amount of DNA, but are unlikely to contribute to FPF production. Given that the 
initial method used for these experiments did not stipulate media changes exactly 48 
hours apart, it is possible that some of the fibroblast cultures were in poor health by the 
time FCM was being generated.  Chapter 2                                                                                                                                            Methods 
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Table 2.6:  Mean DNA level of fibroblast cultures (       g.plate
-1) for experiments 
which  gave  a  positive  indirect  response  and  those  which  did  not.  
P-values were obtained using a single-factor ANOVA. 
 
 
 
 
 
2.10.3 Percentage recovery using [
14C]-DPPC 
  Comparison of tests that gave a positive indirect effect with those that did not 
respond  showed  that  overall  there  was  no  significant  difference  in  the  percentage 
recovery of the [
14C]-DPPC internal standard (p = 0.90) (Table 2.7). Standard error 
values were very small with a mean of 4.4%, indicating that percentage recovery was 
extremely  consistent  throughout  the  entire  study.  Assuming  complete  recovery  of  
[
14C]-labelled standard and taking into account that only 400  L of the chloroform layer 
was counted, the expected recovery is 100%. The mean value for recovery was 91.78%, 
showing that  the  method  used is a very reliable way to assess surfactant synthesis.  
None of the individual experimental sets showed any significant variation in recovery, 
and comparison between data sets also showed no significant difference (p = 0.55). 
Percentage recovery did not influence the results obtained in any of the experiments 
conducted. This further indicates the reliability of the lipid extraction method, as the 
amount extracted from one experiment to another was consistent. 
 
Positive response No response
Dexamethasone 10.33 ± 1.80 16.88 ± 1.34 0.03
PMA 17.48 ± 1.91 15.02 ± 1.73 0.36
Dexamethasone (new) 14.02 ± 3.34 10.81 ± 2.66 0.52
Additive P-value
DNA level (       g.plate
-1)Chapter 2                                                                                                                                            Methods 
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Table 2.7:  Mean percentage recovery of the [
14C]-DPPC internal standard for 
experiments which gave a positive indirect response and those which 
did not. P-values were obtained using a single-factor ANOVA. 
 
 
 
 
 
2.10.4 Initial [
3H]-choline chloride radioactivity 
Comparison of tests that gave a positive indirect effect with those that did not 
respond showed that overall there was no significant difference in the radioactivity of 
the  [
3H]-choline  chloride  solution  that  was  prepared  for  synthesis  experiments  
(p = 0.15) (Table 2.8). Standard error values were low, with a mean of 6.4%, indicating 
consistency  between  experiments  using  a  given  additive.  A  contributor  to  the 
inconsistency  in  the  results  for  these  experiments  may  be  due  to  variability  in  the 
amount of 
3H added to plates during each experiment. 
The radioactivity of this stock 
3H solution was significantly lower for the PMA 
experiments than for dexamethasone (p = 0.000002). The mean activity for the PMA 
experiments was 2.04  Ci.mL
-1 compared with 5.09  Ci.mL
-1 for dexamethasone. If 
insufficient [
3H]-choline chloride was supplied at the beginning of an experiment, it 
would  mean  that  synthesis  of  labelled  PC  would  be greatly limited,  indicating  that  
3H activity may have been a major factor in the inconsistent results obtained during 
these experiments. The random nature of scintillation counting also means that lower 
values are more difficult to count accurately.  
 
Positive mean
No response 
mean
Dexamethasone 95.55 ± 5.95 89.05 ± 7.80 0.63
PMA 87.05 ± 1.60 89.75 ± 1.25 0.21
Dexamethasone (new) 94.30 ± 2.40 95.00 ± 5.00 0.89
Additive P-value
[
14C]-DPPC recovery (%)Chapter 2                                                                                                                                            Methods 
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Table 2.8:  Mean  radioactivity  of  stock  [
3H]-choline  chloride  solution  
(       Ci.mL
-1 ) for experiments which gave a positive indirect response 
and those which did not. P-values were obtained using a single-factor 
ANOVA. 
 
 
 
 
 
 
The process of drying under nitrogen means that the [
3H]-choline will be dried 
onto the interior surface of the bottle and early results indicated that it does not go back 
into solution as quickly as previously thought. A study was undertaken to determine the 
optimum  solubilization  time  for  the  [
3H]-choline  solution.  Triplicate  [
3H]-choline 
solutions were prepared exactly as described in 2.8, and these solutions were placed in a 
shaking water bath at 37°C. Samples were taken for counting at 0, 5, 10, 15, 20, 30, 45 
and  60  minutes.  Scintillant  was  added  and  the  samples  were  kept  in  the  dark  for  
24  hours  prior  to  counting.  The  study  showed  that  the  solution  reached  its  highest 
activity (13.5% increase) after 10 minutes incubation (Figure 2.1), so it was decided in 
all future experiments to incubate the solution for 10 minutes prior to use. The addition 
of  this  step  to  the  method  meant  that  the  activity  could  be  monitored  and  kept 
consistent. 
 
Positive mean
No response 
mean
PMA 1.90 ± 0.09 2.17 ± 0.34 0.58
Dexamethasone (new) 4.80 ± 0.32 5.38 ± 0.16 0.20
[
3H]-choline chloride 
radioactivity (       Ci.mL
-1) Additive P-valueChapter 2                                                                                                                                            Methods 
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Figure 2.1  Radioactivity of [
3H]-choline chloride in MEM
+ solution at different 
times of incubation in a 37°C shaking water bath. 
 
 
It  should  be  noted  that  the  intended  activity  of  [
3H]-choline  chloride  in  this  stock 
solution  was  7.0   Ci.mL
-1,  which  is  much  greater  than  the  mean  value  of  
4.55  Ci.mL
-1 obtained for these experiments. While the values obtained were very 
consistent, a value closer to the intended activity was not reliably obtained. This is 
possibly due to insufficient time being allowed for the [
3H]-choline to go back into 
solution following drying, or possibly due to a pipetting error. Pipettes were calibrated 
regularly, but [
3H]-choline chloride is provided in ethanol, and volatile solvents are 
often  difficult  to  pipette  accurately.  It  is  also  possible  that  the  activity  of  the  
[
3H]-choline chloride solution changed over time. However, given that it is supplied as 
an  ethanol  solution,  activity  would  be  expected  to  increase  over  time  as  ethanol 
evaporated. For these experiments, it was decided that a consistent value was more 
important than the desired radioactivity, so the issue was not explored further. 
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2.10.5 Plate [
3H]-choline chloride radioactivity 
Comparison of tests that gave a positive indirect effect with those that did not 
respond showed that overall there was no significant difference in the radioactivity of 
the [
3H]-choline chloride on each plate at the beginning of an experiment (p = 0.35) 
(Table 2.9). Standard error  values  were very low,  with a mean of 4.7%, indicating 
consistency between experiments using a given additive. This indicates that the amount 
of [
3H]-choline added to each plate was not likely to have been affecting the results 
obtained  in  any  given  experimental  set.  As  with  the  activity  of  the  stock  
3H solution, values for this parameter were less than the expected value of 1.0  Ci.mL
-1. 
The activity of 
3H solution in the cultures was significantly lower for the PMA 
experiments  than  for  dexamethasone  (p  =  0.001).  The  mean  activity  for  the  PMA 
experiments was 0.47  Ci.mL
-1 compared with 0.69  Ci.mL
-1 for dexamethasone. This 
is clearly related to the lower activity of the initial [
3H]-choline chloride solution, and 
will be discussed further in 2.10.6.  
 
Table 2.9:  Mean  radioactivity  of  [
3H]-choline  chloride  solution  on  individual 
plates  (       Ci.mL
-1  )  for  experiments  which  gave  a  positive  indirect 
response and those which did not. P-values were obtained using a 
single-factor ANOVA. 
 
 
 
 
Positive mean
No response 
mean
PMA 0.51 ± 0.01 0.44 ± 0.04 0.31
Dexamethasone (new) 0.65 ± 0.04 0.73 ± 0.02 0.18
[
3H]-choline chloride 
radioactivity (       Ci.mL
-1) Additive P-valueChapter 2                                                                                                                                            Methods 
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2.10.6 
3H Ratio 
From analysis of the plate 
3H radioactivity, it is clear that none of the values 
were close to the desired value of 1.0  Ci.mL
-1. However, because the initial activity 
was much lower than expected, this value cannot be taken alone as an indication of 
consistency. Instead, the ratio of the two values must be considered to determine if the 
appropriate dilution is being made onto the plate. This value is expressed as:  
 
 
 
 
The desired value is a ratio of 0.143, with values higher than this representing a higher 
plate concentration than expected and lower values indicating a low radioactivity. 
Comparison of tests that gave a positive indirect effect with those that did not 
respond  showed  that  overall  there  was  no  significant  difference  in  the  ratio  of  the 
activity  on  the  individual  plates  and  activity  of  the  initial 
3H  solution  
(p  =  0.16)  (Table  2.10).  Standard  error  values  were  low,  with  a  mean  of  8.9%, 
indicating consistency between experimentals using a given additive. The mean value is 
close to 0.143, being 0.183 ± 0.016, indicating that even though the initial activity is 
lower than expected, the dilution onto the plate is consistent and close to 1:7. This 
confirms that the radioactivity of the initial 
3H solution is likely to have been more 
important to the consistency of results than transfer to plates. 
The ratio of plate to initial 
3H activity was significantly higher for the PMA 
experiments  than  for  dexamethasone.  This  shows  that,  in  spite  of  the  fact  that  the 
activity of the initial 
3H solution was lower, the amount being transferred to plates was 
on average greater than the 1:7 dilution expected. This is most likely due to pipetting 
errors. Analysis of the results in 2.10.5 indicates that while the ratio was higher, the 
actual radioactivity added to each plate was still significantly lower than for the other 
plate radioactivity
stock radioactivityChapter 2                                                                                                                                            Methods 
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experimental set monitored, and so was still likely to have been a major factor in the 
inconsistency of these results. 
 
Table 2.10:  Mean  ratio  of  plate 
3H  and  stock  [
3H]-choline  chloride  solution 
radioactivity for experiments which gave a positive indirect response 
and  those  which  did  not.  Expected  ratio  is  0.143.  P-values  were 
obtained using a single-factor ANOVA. 
 
 
 
 
 
2.11 Discussion 
Refinement of the methodology used in tissue culture experiments meant that a 
consistent  indirect  response  to  dexamethasone  could  be  obtained.  The  response 
observed was also consistent with previous results (Smith, 1978; Gross and Wilson, 
1982).  Dexamethasone  is  considered  to  interact  with  cytoplasmic  glucocorticoid 
receptors  within  the  fibroblast  cell,  inducing  the  steroid-receptor  complexes  to 
translocate to the nucleus where  they bind to  glucocorticoid response  elements and 
enhance transcription of the gene for FPF and other glucocorticoid-regulated proteins 
(Smith  and  Post,  1993).  Consistency  of  results  for  these  experiments  was  very 
important, as FCM produced by this method has been shown to contain FPF (Smith and 
Post, 1989), and samples that reliably contained FPF were essential for further attempts 
at identification. 
The indirect response observed with PMA was very inconsistent, and did not 
reflect previous results (Sen, 1991). The most likely reasons for this have already been 
Positive mean
No response 
mean
PMA 0.266 ± 0.010 0.190 ± 0.051 0.48
Dexamethasone 0.136 ± 0.002 0.137 ± 0.002 0.97
Additive P-value
Plate:stock [
3H]-choline chloride 
radioactivity ratioChapter 2                                                                                                                                            Methods 
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discussed, and it is likely that the lack of response in this study was due to variations in 
cell density and inconsistencies in the  addition of  radioisotope-labelled compounds, 
rather than in the actual biochemical interaction of PMA with fibroblast cells. 
The  early  experiments  conducted  during  this  study  indicated  that  the  tissue 
culture system  used  to test for  the  presence  and activity  of FPF was affected by a 
number of factors. The amount of DNA per plate, used as an indication of the number of 
cells on a given culture plate, can have a significant effect, and it has become apparent 
that there is an upper limit to this value for type II cultures. Too many cells on a plate 
can greatly reduce synthesis of PC, and non-contributing cells will reduce apparent 
synthesis due to the way this value is calculated. Feedback mechanisms that exist to 
regulate the surfactant system are also likely to have an impact at high cell density. High 
density  type  II  pneumocytes  would  mean  increased  secretion  of  surfactant  during 
incubation, and a high level of secreted surfactant has been shown to inhibit further 
synthesis (Dobbs et al., 1987). The effect of fibroblast cell density is less clear, but is 
likely to be similar to that for type II cells. The health of fibroblast cells may also be an 
important factor. 
Type II cell density contributed to the lack of response from the cultures with a 
density above 25  g DNA.plate
-1 in the second batch of dexamethasone experiments, 
which used the refined method. Indirect experiments with type II cultures with a cell 
density  below  the  threshold  (mean  density  =  17.8   g  DNA.plate
-1)  showed  a 
dexamethasone-induced increase of 17.56% in PC synthesis. Those with cell density 
above  25   g  DNA.plate
-1  (mean  density  =  35.05   g  DNA.plate
-1)  showed  a  3.39% 
increase. The threshold value was used to analyze the results of similar experiments 
conducted by an Honours student under my co-supervision (Peh, 2006), and a similar 
trend was revealed (Table 2.11). Indirect experiments with type II culture cell density 
below 25  g DNA.plate
-1 (mean density = 14.8  g DNA.plate
-1) showed an increase of Chapter 2                                                                                                                                            Methods 
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18.1% in PC synthesis, while those with cell density above the threshold (mean density 
= 40.5  g DNA.plate
-1) showed a 13.3% decrease. These results are consistent with 
those of this study, further highlighting the effect of type II pneumocyte cell density on 
PC synthesis as discussed in 2.10.1. 
  The  consistent  application  of  radioisotope-labelled  compounds  is  also  very 
important.  Percentage  recovery, as  measured  by the use of  a [
14C]-labelled internal 
standard, was very consistent, and so is unlikely to have influenced the results. Accurate 
delivery of [
3H]-choline chloride is also important, and is likely to have caused the 
erratic results observed when using PMA as a stimulant. The amount of 
3H applied to 
each plate in these experiments very inconsistent, meaning that even if synthesis was 
stimulated, it would not have been detected at accurate levels. 
  The modification of the synthesis method has greatly improved reproducibility 
of results, and has allowed the accurate monitoring of several parameters that had not 
previously been considered as having a significant effect on the results. It has also 
meant that the indirect response on type II pneumocytes by FCM produced by exposing 
fibroblasts to dexamethasone is consistent. The revised method has now been adopted 
within the laboratory, reducing the likelihood of miscommunication of methodology in 
future. Any further experiments should utilize the method as described, and should also 
attempt to further improve the reliability of the monitored values.  
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Table 2.11:   The effect of dexamethasone on PC synthesis in type II pneumocytes  
taking  the  density  of  the  type  II  pneumocyte  cultures  into 
consideration (Peh, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Primary cultures of lung fibroblasts were grown to near confluence, followed by 24 
hours  incubation  in  the  presence  or  absence  of  100  nM  dexamethasone  in  MEM
+.  
The fibroblast-conditioned media (FCM) were collected and stored at -80°C. Prior to 
use,  the  media  were  thawed  and  incubated  at  65°C  for  one  hour,  cooled  to  room 
temperature and filter-sterilized to remove detached cells and cellular debris. The media 
were then diluted 1:4 with MEM
+. The effect on PC synthesis by type II pneumocytes 
was investigated by exposing the cells either to the diluted FCM or to MEM
+, with and 
without dexamethasone. The data represent the mean ± SE. The number of replicates 
examined for each condition is indicated in parentheses, and each replicate comprised 
four cultures. 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
< 25        g DNA.plate
-1
Direct (9)
Control 29.0 ± 5.8
Dexamethasone 26.6 ± 4.7 ↓  8.2% 13.3
Indirect (9)
Control 26.8 ± 5.2
Dexamethasone 31.6 ± 5.5 ↑  18.1% 14.8 3.6
> 25        g DNA.plate
-1
Direct (5)
Control 22.2 ± 4.5
Dexamethasone 22.1 ± 4.3 ↓  0.4% 41.2
Indirect (5)
Control 18.7 ± 3.6
Dexamethasone 16.2 ± 4.8 ↓  13.3% 40.5 7.5Chapter 3. Identification of the fibroblast-pneumocyte 
factor 
 
3.1 Introduction 
  The  function  of  fibroblast-pneumocyte  factor  (FPF)  is  well  known,  but  its 
identity has remained a mystery. Smith (1979) described a heat-stable oligopeptide with 
only one known activity. It has an apparent molecular mass in the range of 5 to 15 kDa 
(Smith and Post, 1989) and antibodies have been raised against it (Post et al., 1984).  
In spite of this information, there was little evidence (or even speculation) as to the 
actual identity of FPF. It was not known whether it represented a novel protein or one 
that had been previously described in another system. In order to attempt to identify it, 
information would need to be gathered to provide a starting point for the investigation. 
 
3.1.1 Glucocorticoid response elements 
  The  effect  of  glucocorticoid  hormones  such  as  dexamethasone  on  surfactant 
synthesis is well known, and it is thought that this process is mediated by FPF. Steroid 
hormones, including glucocorticoids as well as estrogens, progestins and androgens, all 
mediate their effects by regulating the initiation of transcription of target genes. These 
hormones  cross  the  cell  membrane  via  diffusion  and  encounter  specific  receptors 
(sequence-specific DNA-binding transcription factors) within the cell (Bentley, 1998). 
The receptors for steroid hormones are members of a superfamily of large proteins that 
contain specific functional domains: the ligand- or hormone-binding domain, the DNA-
binding  domain  and  the  transcription  activation  domain.  The  DNA-binding  domain 
mediates the interaction of the receptor with its specific binding site upstream of the 
promoter region of the target gene. These specific binding sites are known as hormone 
response elements (HREs) (Bentley, 1998). Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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The original work in characterizing the response element of glucocorticoids was 
done by Scheidereit and Beato (1984)  on mouse mammary tumour virus (MMTV).  
The hormone receptor binds to four sites within the glucocorticoid response element 
(GRE) -72 to -192 bases upstream of the primary transcription initiation site. The GRE 
is defined as an inverted (or palindromic) repeat of a hexamer sequence separated by 
three nucleotides and under the standard system this is classified as IR3. These GRE 
sequences have been found in the promoters of many glucocorticoid-responsive genes, 
including MMTV and tyrosine aminotransferase (Cooney and Tsai, 1994). A consensus 
sequence has been generated from the combination of a large number of glucocorticoid-
responsive genes (Beato, 1989) and has been found to be: 
5’-G-G-T-A-C-A-N-N-N-T-G-T-T-C-T-3’ 
3’-C-C-A-T-G-T-N-N-N-A-C-A-A-G-A-5’ 
 
  Expression  of  the  gene  encoding  FPF  is  enhanced  by  dexamethasone,  most 
likely through the GRE. In order to identify potential candidate proteins for FPF, both 
human  and  rat  genomes  were  Blast  searched  for  this  consensus  sequence. 
Unfortunately, this yielded far too many results to sufficiently narrow the search, so this 
line of investigation was not pursued any further. 
 
3.1.2 The smoking gun 
  Work by Dammann et al. (2003) found that neuregulin-1β had the same effect 
on  surfactant synthesis by  type  II pneumocytes  as FCM  containing FPF. They also 
found that the addition of a neuregulin-1β antibody to FCM inhibited its effect. This 
research presented the most compelling evidence yet as to the identity of FPF. The 
focus of the current study was shifted to focus on determining if neuregulin-1β was in 
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3.1.3 Neuregulins 
  The neuregulins are a family of growth factors that continue to be discovered in 
an increasing number of systems and organisms. The first neuregulin was purified from 
brain  tissue  and  named  the  glial  growth  factor  (Brockes  et  al.,  1980).  It  was  also 
discovered  in  other  mammalian  tissues  and  named  acetylcholine  receptor  inducing 
activity (Falls et al., 1990), neu differentiation factor (Peles et al., 1992) and heregulin 
(Holmes et al., 1992). It was not until the early 1990s (Marchionni et al., 1993) that all 
of these different compounds were determined to be the same protein, which was given 
the  consensus  name  neuregulin  (and  is  now  known  as  neuregulin-1).  The  multiple 
isoforms of neuregulin, many of which differ significantly in molecular weight and have 
great  diversity  of  activity  (Lemke,  1996),  elicit  cellular  responses  ranging  from 
proliferation and differentiation to migration and apoptosis (Falls, 2003). 
  The neuregulins are part of the epidermal growth factor (EGF) family (Prigent 
and Lemoine, 1992), which consists of a large number of ligands. The isoforms of 
neuregulin-1 are all generated from a single gene (nrg1) (Lemke, 1996), however three 
other  genes  encoding  neuregulins  have  also  been  discovered:  nrg2,  nrg3  and  nrg4 
(Busfield et al., 1997; Zhang et al., 1997; Harari et al., 1999). Little is known about the 
function of the proteins encoded by these three genes (termed neuregulin-2, 3 and 4, 
respectively), although they are known to bind to the same receptors as neuregulin-1 
(Falls,  2003).  NRG2  has  been  shown  to  elicit  different  responses  to  NRG1  when 
binding to the same receptor (Crovello et al., 1998). Unless otherwise stated, this review 
will focus solely on neuregulin-1 (NRG1). 
 
3.1.3.1 Functions of neuregulin-1 
  Neuregulin-1  was  first  identified  in  the  neuromuscular  system,  where  it 
functions  as  a  potent  mitogen  (Brockes  et  al.,  1980).  It  is  produced  by  embryonic Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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neurons shortly after birth (Marchionni et al., 1993; Chen et al., 1994) and is thought to 
be  involved  in  nerve  cell  proliferation,  differentiation  and  survival  (Lemke,  1996).  
In skeletal muscle cells, it can increase expression of specific genes (Harris et al., 1988) 
and also contributes to neuronal control of muscle cell gene expression (Fischbach et 
al., 1994).  Much of the work on NRG1 has used mammary epithelial cells, where they 
perform mitogenic, differentiation  and transformation functions (Lupu  et al., 1995). 
NRG1 is also important in the development of the cardiac (Meyer and Birchmeier, 
1995)  and  pulmonary  systems  (Patel  et  al.,  2000).  The  role  of  NRG1  in  lung 
development is discussed further in 3.1.3.5. Over-expression of NRG1 is important in a 
number  of  cancers,  including  breast  cancer  (Lemke,  1996).  Problems  with  NRG1 
signaling  are  also  thought  to  be  involved  in  a  number  of  disease  states,  including 
schizophrenia (Stefansson et al., 2002). 
 
3.1.3.2 Structure of neuregulin-1 
  The gene for neuregulin-1 is located on the short arm of human chromosome 8  
(Orr-Urtreger et al., 1993). It is 1.4 megabases long and less than 0.3% of this length 
actually  encodes  the  functional  protein  (Stefansson  et  al.,  2002).  At  least  sixteen 
different isoforms of NRG1 are formed from this single gene through a combination of 
alternative splicing and multiple promoter usage (Steinthorsdottir et al., 2004). Four 
splicing  hotspots  have  been  identified  which  seem  to  produce  most  of  the  known 
variants (Lemke, 1996), although six exons have recently been identified as likely to 
generate further isoforms (Steinthorsdottir et al., 2004). The biological reason for such a 
large  number  of  variants  is  not  currently  known,  although  some  display  different 
binding affinity for certain receptors (Kita et al., 1995) and some cell types express only 
specific isoforms (Lemke, 1996), implying cell- or tissue-specific functions. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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The three main distinguishing characteristics of the NRG1 isoforms are the type 
of EGF-like domain (α or β), the N-terminal sequence (I, II or III) and whether the 
protein is transmembrane or soluble (Falls, 2003). The EGF-like domain is the only part 
of NRG1 that is well characterized and it is very similar to the bioactive domain of 
epidermal-growth factor (EGF) (Carraway and Burden, 1995). All isoforms of NRG1 
contain this domain, meaning that they are all able to interact with the receptors of the 
EGF  family,  known  as  ErbB  receptors  (Lemke,  1996).  This  domain  has  been 
demonstrated as being essential for activity in all neuregulins (Carraway et al., 1994; 
1995).  NRG1  isoforms  are  divided  into  three  types  based  on  differences  in  the  N-
terminus. Type I NRG1s have an extracellular heparin-binding, immunoglobulin-like 
domain. Type II NRG1s share this domain and also possess a kringle domain, while 
type III NRG1s have a cysteine-rich domain (Esper et al., 2006). All NRG1 isoforms 
are generated as transmembrane forms, and proteolysis of these generates the soluble 
forms (Burgess et al., 1995).   
 
3.1.3.3 Neuregulin receptors 
  Neuregulins  interact  with  receptors  in  the  ErbB  family,  which  contains  four 
distinct  receptors  (ErbB1-4)  that  are  glycosylated  transmembrane  proteins  and  are 
regarded as the stereotype for receptor tyrosine kinase activity (Citri and Yarden, 2006). 
The ErbB receptors have been described as a signaling network, with interactions within 
and between individual receptors (Falls, 2003). The generalized structure of an ErbB 
receptor is an extracellular domain with two cysteine-rich regions, a transmembrane 
domain,  an  intracellular  juxtamembrane  domain  and  a  cytoplasmic  domain  with 
tyrosine  kinase  activity  (Lemke,  1996).  This  activity  catalyzes  phosphorylation  of 
tyrosine residues in  polypeptide sequences.  Proteins then bind to the newly created 
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1994).  Ligands  for  ErbB  receptors  contain  an  EGF-like  sequence  with  six  cysteine 
residues which is recognized by the receptor (Citri and Yarden, 2006). Binding of a 
ligand leads to a conformational change in receptor subunits and formation of dimers 
(Moriki et al., 2001). For example, in the case of ErbB1, this dimer consists of two 
ErbB1 receptors to which two ligand molecules bind (Lemmon et al., 1997). No NRG1 
isoforms have been found that interact with ErbB1, so the focus here will be on the 
remaining ErbB receptors. 
  ErbB2 is the best-characterized receptor in the ErbB family, and is also known 
as c-neu or HER2 (Lemke, 1996). The extracellular structure of ErbB2 is very similar to 
the ligand-bound form of ErbB1, preventing it from binding any ligands (Garrett et al., 
2002). This unusual structure means that it is primed for interaction with other ligand-
bound receptors, making it the preferred partner for heterodimerization (Tzahar et al., 
1996).  It  is  also  incapable  of  forming  homodimers  (Plowman  et  al.,  1990).  
ErbB2  appears  to  function  as  an  amplifier  for  the NRG1 signal (Citri and Yarden, 
2006), as it is able to interact with a greater number of phosphotyrosine-binding proteins 
than any of the other receptors (Jones et al., 2006).  
Two other ErbB receptors have been identified: ErbB3 (Kraus et al., 1989) and 
ErbB4 (Plowman et al., 1990). ErbB3 and 4 are very similar to ErbB2 and participate 
with this receptor in NRG1 signaling. ErbB3 has a defective tyrosine kinase activity due 
to substitutions in its cytoplasmic domain (Guy et al., 1994), meaning that it cannot 
transduce a signal on its own. ErbB4 binds a large number of ligands (Citri and Yarden, 
2006) and also exists in a number of different isoforms (Rio et al., 2000), making it a 
very versatile receptor. Heterodimers of ErbB2/ErbB3 and ErbB2/ErbB4 are capable of 
binding NRG1, as are homodimers of ErbB4 (Sliwkowksi et al., 1994; Tzahar et al., 
1994; Chan et al., 1995; Horan et al., 1995; Wallasch et al., 1995). The complexity of 
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other,  leading  to  transphosphorylation  (Carraway  and  Cantley,  1994).  Studies  with 
knockout mice have indicated that genes for these three receptors and NRG1 itself are 
essential for embryonic development to proceed past day 10 (Lemke, 1996). 
Regulation of these receptors is also complex, with both positive and negative 
feedback systems. Positive feedback loops exist and prolong the activity of signaling 
pathways, as well as enhancing the amplitude of the signal (Freeman, 2000). Positive 
feedback also occurs at a transcriptional level, where genes for other ErbB ligands are 
up-regulated following receptor-ligand binding (Schulze et al., 2001). Multiple negative 
feedback systems also exist, and are up-regulated after ligand binding to receptors. Most 
of these act more slowly than the positive feedback systems (Citri and Yarden, 2006). 
 
3.1.3.4 ErbB2/ErbB3 heterodimers 
In terms of cell growth and transformation, ErbB2/ErbB3 heterodimers are the 
most potent in the ErbB family (Pinkas-Kramarski et al., 1996). ErbB2 cannot bind any 
known  ligands,  while  ErbB3  cannot  transduce  a  signal,  but  together  they  form  a 
functional and powerful receptor (Figure 3.1). Both ErbB2 and 3 are expressed in most 
epithelial  cell  layers,  while  mesenchymal  tissues  are  a  source  of  ligands  such  as 
neuregulin (Citri et al., 2003). The potency of these heterodimers is explained by four 
main factors: the slow rate of ligand dissociation (Karunagaran et al., 1996); relaxed 
specificity  of  ligands  (Pinkas-Kramarski  et  al.,  1998);  ability  to  limit  endocytosis 
(Worthylake et al., 1999); and coupling to a number of signaling pathways. 
Heterodimers  of  ErbB2/ErbB3  activate  several  signaling  pathways:  mitogen-
activated protein kinase (MAPK) (Ben-Levy et al., 1994), phosphatidylinositol-3-kinase 
(PI3K)  (Prigent  and  Gullick,  1994),  phospholipase-Cγ  (PLCγ)  (Peles  et  al.,  1991), 
protein kinase C and the Janus kinase (Jak-STAT) (Liu and Kern, 2002). The most 
significant of these are MAPK, which is involved in cell proliferation, and PI3K, which  Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.1:  The  proposed  mechanism  of  neuregulin  induced  ErbB2/ErbB3 
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is  a  cell  survival  pathway  (Citri  et  al.,  2003).  Unlike  ErbB1  homodimers,  these 
heterodimers do not interact with pathways that down-regulate mitogenesis, such as 
Ras-specific GTPase-activating protein (Ras-GAP) (Bar-Sagi and Hall, 2000). 
 
3.1.3.5 Role of neuregulin in lung development 
Neuregulin-1 has been discovered in many systems, where it plays a crucial role 
in development. Its role in the early stages of development in the fetal lung has been 
partially characterized, such as the triggering of branching morphogenesis (Liu et al., 
2004).  Functions  for  NRG1  in  the  later  stages  of  development,  such  as  in  the 
stimulation of surfactant production, are less well understood. It is only recently that the 
importance of this signaling has begun to be uncovered.  
Research has shown that factors that regulate other facets of lung development, 
including retinoic acid (RA) and dihydrotestosterone (DHT), have been shown to affect 
expression of ErbB receptors (Dammann and Nielsen, 1998). Dexamethasone treatment 
leads to an increase in expression of these receptors and modification of dimerization 
(Dammann et al., 2006). In the second trimester of gestation, both ErbB2 and ErbB3 
can be detected in fetal lung, but not ErbB4 (Patel et al., 2000). Recent observations 
(Liu  et  al.,  2004)  have  confirmed  that  only  ErbB2  and  ErbB3  are  present  in  the 
developing lung. Both of these receptors are localized to the epithelial cells, such as 
type II pneumocytes (Patel et al., 2000). Exposure to recombinant NRG1 caused a four-
fold  increase  in  receptor  phosphotyrosine  content,  indicating  receptor  activation. 
Increases were also observed in epithelial cell density and proliferation, as well as a 
decrease in SP-A levels (Patel et al., 2000). These observations are consistent with 
NRG1 activation of the ErbB2/ErbB3 heterodimer. Activation of both PI3K (Liu et al., 
2004)  and  Jak-STAT  (Liu  and  Kern,  2002)  through  ErbB2/ErbB3  has  been 
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  As indicated in 3.1.2, it was the work of Dammann et al. (2003) that redirected 
this study towards neuregulin-1. In their work, Dammann et al. used immunostaining to 
detect NRG1β, and confirmed that it increased in concentration in fetal lung fibroblast 
cells  at  the  same  time  as  surfactant  synthesis  commenced  in  type  II  cells.  
These fibroblasts secreted the NRG1β and this stimulated synthesis of surfactant in 
these type II cells. Fibroblast-conditioned medium and recombinant NRG1β were both 
observed to increase synthesis and ErbB2 receptor phosphorylation, and this activity 
was blocked in both cases by an antibody to NRG1β. Immunoprecipitation was used to 
confirm the presence of NRG1β in FCM (Dammann et al., 2003).  This work, combined 
with the presence of the necessary receptors, presented a compelling case for NRG1β to 
be FPF, and led to this study’s attempts to confirm this using HPLC and LC/MS. 
 
3.1.4 HPLC and LC/MS 
  A general introduction to the two techniques used in this chapter is required to 
indicate  why  these  particular  instruments  were  chosen  for  this  investigation.  
High-performance  liquid  chromatography  (HPLC)  is  a  widely-used  separation 
technique,  while  liquid  chromatography/mass  spectrometry  (LC/MS)  is  a  similarly 
powerful  technique  for  separation  and  mass  analysis  of  compounds.  Both  of  these 
techniques are now used in many types of protein and proteomic research. 
 
3.1.4.1 High-performance liquid chromatography 
  The  principles  and  applications  of  high-performance  liquid  chromatography 
(HPLC) have been widely reviewed, and so only a general overview will be presented 
here. For further reading, useful books on the topic include Snyder et al. (1997) and 
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  The  modern  form  of  HPLC  is  reversed-phase  HPLC  (RP-HPLC),  which 
involves  the  use  of  two  phases:  a  mobile  phase  (polar)  and  a  stationary  phase  
(non-polar) (Meyer, 2004). The mobile phase is comprised of solvents which are moved 
through the stationary phase, contained in a packed column, to effect the separation.  
The mobile phase then moves through a detector, usually utilizing ultraviolet/visible 
(UV/Vis) spectroscopy, to enable the separated compounds to be visualized (Meyer, 
2004). Most mobile phases use a combination of water and a non-polar organic solvent 
such as acetonitrile or methanol, although many variations have been used for different 
analyses.  There is a similarly  large range of stationary phases available, varying in 
parameters such as composition, hydrophobicity and pore size. The most commonly 
used stationary phase is silica, which is treated to generate R-groups of a defined length 
(often 8 (C8) or 18 (C18) carbons) (Snyder et al., 1997).  
  The basis of the RP-HPLC separation is hydrophobic interaction (Snyder et al., 
1997). The relatively non-polar analytes interact with the non-polar stationary phase, 
with more hydrophobic compounds interacting more strongly. As the concentration of 
organic  solvent  in the mobile  phase is increased, compounds will elute in order  of 
increasing hydrophobicity. Variation of mobile phase parameters such as composition, 
pH buffering, and gradient, as well as column chemistry, will affect the retention time 
of analytes. The properties of the analytes, as well as sample preparation techniques, 
also have a large impact on separation (Snyder et al., 1997). 
  HPLC has been widely used in protein and proteomic research, both for analysis 
of samples and as a cleanup method for other analytical techniques. An excellent review 
of current progress and advances in the use of HPLC in proteomics was written by 
Mitulovic and Mechtler (2006).  
 Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
  79
3.1.4.2 Mass spectrometry 
  Mass  spectrometry  is  a  general  term  used  for  a  number  of  instruments  that 
analyze samples based on their mass to charge ratio. In the context of this study, it refers 
to  electrospray  ionization-quadrupole  ion  trap  mass  spectrometry  (ESI-MS).  
This system is often coupled with an HPLC instrument, and is then termed LC/MS.  
As with HPLC, only a general overview of the technique will be given. For further 
reading, Cole (1997) offers a thorough introduction to both electrospray ionization and 
associated mass spectrometry. Pramanik et al.. (2002) also covers a number of advances 
and applications of this technology. 
  Prior to mass analysis in a mass analyzer, the sample must be ionized. A range 
of methods exist for the ionization of compounds, including electron, chemical and 
photo-ionization. One of the most widely used, and generally considered to be the best 
for use with proteins, is electrospray ionization (ESI) (Kebarle and Ho, 1997). ESI was 
developed for ionization of large biological molecules (Fenn et al., 1989), and John 
Fenn was awarded the 2002 Nobel Prize in Chemistry for its development. The sample, 
consisting of analytes in solvent (often from an HPLC system), is forced through a 
small capillary (Figure 3.2). This capillary has a high electric field applied, and this 
causes the sample to nebulize. Nitrogen gas is also added to assist in the nebulization 
process. Solvent is evaporated through the use of a heated drying gas (usually nitrogen) 
and  eventually  analyte  ions  free  of  solvent  are  obtained.  The  exact  mechanism  of 
ionization is not completely understood, but involves the transfer of charge from the 
solvent droplets to analyte molecules as droplets become smaller and smaller (Kebarle, 
2000). The analyte ions are quasimolecular ions, usually due to the addition ([M+H]
+) 
or  loss  ([M-H]
-)  of  proton.  Other  adducts  can  form,  such  as  addition  of  sodium 
([M+Na]
+), due to the chemical composition of the sample (Kebarle and Ho, 1997). 
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Due  to  this  ionization,  the  mass  spectrometer  analyses  mass-to-charge  ratios  (m/z), 
rather than molecular masses. 
 
 
 
Figure 3.2:  Schematic of an electrospray ion source, indicating flow of solvent 
and drying gas (adapted from Agilent, 2003). 
 
 
  The ESI source is interfaced with the trap itself via a capillary (Figure 3.3). 
Following this are two skimmer lenses, an octopole and a series of lenses, which serve 
to focus the ions and remove any contaminants and neutral species. 
Quadrupole ion trap mass spectrometry (herein referred to as ion trap MS) is a 
modification of the quadrupole mass spectrometer (QMS). The QMS sets up a radio 
frequency (RF) quadrupolar field and uses an electrical field to stabilize ions passing 
through this field (McEwen and Larsen, 1997). In an ion trap MS, the linear quadrupole 
has been made circular, allowing ions to be selectively trapped and/or ejected from the 
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Figure 3.3:  Schematic indicating the general structure of a quadrupole ion trap 
mass spectrometer (Agilent, 2003).  
 
 
ring electrode halfway between them, forming a spherical space (Figure 3.4). Ions are 
trapped within this space using electrical fields, and resonance excitation (using the end-
cap  electrodes)  is  used  to  selectively  eject  ions  from  the  trap  (March,  2000).  
This functionality allows the instrument to be used for MS
n. In classical MS
n, a single 
mass is isolated and collision-induced dissociation is performed (usually using helium). 
The resulting fragments are analyzed and this process can be repeated a number of times 
(with the number defining the n value) to provide information on the structure and 
identity of the isolated compound (Robert, 1994). 
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Figure 3.4:  Schematic cross-section through an ion trap, showing the two end 
caps and the central ring electrode (adapted from Agilent, 2003). 
 
 
  Ion trap MS is a popular technique in proteomic research, for several reasons. 
Electrospray ionization allows the generation of ions directly from solution and is able 
to impart sufficient energy to ionize intact proteins (Kebarle and Ho, 1997). The ion trap 
can be used to determine the molecular weight of unknown proteins, and fragmentation 
can be used in  peptide sequencing (Aebersold and Goodlett, 2001). Comprehensive 
reviews of the many uses of mass spectrometry in proteomics include Aebersold and 
Goodlett (2001), Griffiths et al. (2001) and Aebersold and Mann (2003). 
 
3.2 Methods 
3.2.1 Pretreatment of FCM 
  Fibroblast-conditioned media from dexamethasone exposed cell cultures, with a 
mean cell density below 25  g.DNA plate
-1, were used for all analyses using LC/MS. It 
is likely that FCM from other experiments also contained FPF, but as this was not Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
  83
demonstrable by the indirect method (where fibroblasts were exposed to an agonist and 
the resulting FCM harvested and exposed to type II pneumocytes to observe any effect 
on surfactant phospholipid synthesis), they were excluded. Prior to use in this analysis, 
FCM had been stored at -80°C immediately after collection from cultures. Treatment of 
FCM  for  LC/MS  was  almost  identical  to  the  treatment  used  prior  to  tissue  culture 
experiments. FCM was thawed at room temperature, before being heat-treated in a 65°C 
water bath for 60 minutes. After cooling to room temperature, it was filtered through a 
0.22  m Millipore syringe filter and diluted 1:4 with MilliQ-H2O.  
 
3.2.2 HPLC 
Initial attempts to identify FPF were undertaken using HPLC only, in an attempt 
to separate the multitude of compounds present in FCM prior to LC/MS. Snyder et al. 
(1997) have indicated the parameters that should be investigated in initial HPLC method 
development. These are illustrated in Table 3.1. 
 
Table 3.1:  Variables  that  should  be  investigated  in  initial  HPLC  method 
development (Snyder et al., 1997). 
 
 
 
 
 
 
Most  of  these  parameters  were  tested  using  FCM  which  had  been  pretreated  as 
described  in 3.2.1. Work was conducted on an Agilent 1100 Series HPLC (Agilent 
Technologies Ltd., Alpharetta, GA, USA) with a quaternary pump, column thermostat 
Component Variable
column dimensions, particle size, stationary phase
mobile phase solvents, percentage of organic solvent, buffers
flow rate -
temperature controlled, not controlled
sample size injection volume
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and diode array detector. The software employed was Agilent Chemstation for LC 3D, 
Rev.  B.09.03.  The  range  of  variables  which  were  tested  is  shown  in  Table  3.2.  
All solvents and buffers were HPLC grade. 
 
Table 3.2:  Variables tested during HPLC method development, indicating the  
range tested for each. 
 
 
 
 
 
 
 
 
 
 
Particle size and stationary phase composition of the columns were the only 
parameters for which a range was not tested. Due to the high cost of HPLC columns, all 
of  the  above  tests  were  run  using  two  Vydac  ‘Protein  and  Peptide’  C18  columns:  
a  218TP5415  (5   m  particle  size,  4.6  mm  i.d.,  150  mm  length)  and  a  218TP52  
(5  m particle size, 2.1 mm i.d., 250 mm length). These columns contain polymerically 
bonded, endcapped n-octadecyl bond on silica. The pore size on both of these columns 
is 30 nm, which is required for work with large molecules such as proteins. Additional 
columns would have been purchased to expand the study, but the emphasis shifted to 
separation using MS, as detailed in 3.2.4. 
Variable Range Tested
column length 150, 250 mm
column internal diameter 2.1, 4.6 mm
column particle size 5  m only
column stationary phase C18 only
mobile phase solvents water with acetonitrile or methanol
initial concentration of 1, 5, 10%
gradient to 100% organic from 10 to 60 min
trifluoroacetic acid, formic acid, acetic acid
buffer concentrations of 0.1 to 2%
flow rate 0.8 to 5.0 mL.min
-1
temperature (column) not controlled, 25 and 35°C
injection volume 1.0 to 25.0  L
detector 205 to 300 nm, plus full UV spectrum
mobile phase % organic
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  Results obtained using HPLC showed a poor separation of the compounds in 
FCM. An example chromatogram is included to illustrate the problems encountered 
(Figure  3.5).  The  majority  of  the  compounds  were  un-retained  and  eluted  at  the 
beginning of the run, with very little material being effectively separated.  
 
 
Figure 3.5:  Chromatogram  of  fibroblast-conditioned  medium  obtained  using 
HPLC.  Response  is  shown  in  milli-absorbance  units  (mAU)  as  a 
function  of  time.  Detection  wavelengths  (nm)  are  indicated  by 
different colours. 
 
Attempts  to  separate  the  components  of  FCM  using  HPLC  proved  to  be 
problematic and time-consuming, primarily due to the fact that there was a large number 
of individual components and because most of the compounds of interest are likely to be 
present in very low concentrations. A second option for separation involves using a 
mass spectrometer, such as an ion trap MS, to perform the separation based on mass Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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rather than properties such as hydrophobicity. This is becoming a more popular option 
as more complex systems are investigated (e.g. Lu et al., 2007). 
 
3.2.3 Neuregulin standard 
Publication  of  data  indicating  that  neuregulin-1β  (NRG1)  was  possibly  FPF 
(Dammann et al., 2003) provided a new approach for LC/MS analysis of FCM. A mass 
spectrum for NRG1 could be obtained and used to search FCM. Recombinant human 
neuregulin-1β (sold as heregulin-β1) (PeproTech, Rocky Hill, NJ, USA) is a 7.5 kDa 
form of NRG1 which comprises only the EGF-like domain (the bioactive domain). 
NRG1 was supplied as a lyophilized powder, was reconstituted in MilliQ-H2O to a 
concentration of 100  g.mL
-1
 and stored at -20°C until use. Further dilutions were also 
undertaken with MilliQ-H2O. 
 
3.2.4 Mass spectrometry 
  Ion  trap  mass  spectrometry  was  undertaken  utilizing an Agilent 1100 Series 
LC/MSD  Trap  (Agilent  Technologies  Ltd.,  Alpharetta,  GA,  USA),  operating  with 
Bruker-Daltonik  MSD  Trap  Control  software  (v  5.1)  (Bruker-Daltonik,  Bremen, 
Germany). The MS was calibrated with a 1:5 dilution of Agilent ES Tuning Mix.  
  Settings for the mass spectrometer were adapted from Mandel and Lopez (2000) 
and Zumwalt (2005) and then optimized for NRG1. The MS was run in standard mode 
and at normal scan resolution, scanning for positive ions. The ESI nebulizer was set at 
15 psi, with drying gas (N2) flow at 5 L.min
-1 and 325°C. Target mass was initially set 
to  1000  m/z  and  changed  to  1068  m/z  once  NRG1  had  been  detected.  Compound 
stability  was  35%  and  the  trap  drive  level  100%.  Scan  range  was  initially  50  to  
2200 m/z, although this was reduced to 500 to 1500 m/z when NRG1 was detected.  
Scan averaging was set at 5, with rolling averages off. Ion Charge Control (ICC) was on Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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and set to collect 3x10
4 ions, with a maximum accumulation time of 300 ms. In expert 
mode, Skim 1 voltage was changed to 15 V, Skim 2 to 6 V and Cap Exit Offset to 60 V. 
Collision-induced dissociation utilized helium as the collision gas. 
  Both  NRG1  and  pretreated  FCM  were  infused  directly  into  the  MS  at  
5  L.min
-1using a KD Scientific 100 syringe pump (KD Scientific Inc., Holliston, MA, 
USA) and a 500  L GasTight syringe (Hamilton Company, Reno, NV, USA). The ESI 
source  and  spray  shield  were  cleaned  after  every  sample  with  a  50:50  solution  of 
isopropanol and H2O. Every 24 hours, the source and trap were cleaned by infusing  
500   L  of  a  cleaning  solution  composed  of  50%  acetonitrile,  25%  isopropanol,  
15% cyclohexane and 10% dichloromethane, followed by 500  L of 50:50 isopropanol 
and water. 
 
3.2.5 Quantitation of neuregulin 
  An Agilent 1100 Series capillary HPLC (Agilent Technologies Ltd., Alpharetta, 
GA, USA), with two binary pumps configured to operate at a maximum flow rate of  
20   L.min
-1,  was  connected  to  the  ion  trap  MS.  This  LC  was  equipped  with  both 
column and autosampler thermostats and a diode array detector (DAD). This instrument 
was running Agilent Chemstation for LC 3D, Rev. A.09.01 software. The column used 
for all work on this instrument was an Agilent Zorbax 300SB-C18 capillary column  
(3.5  m particle size, 0.3 mm i.d., 100 mm length). 
  Mobile  phase  solvents  were  water  and  acetonitrile,  both  buffered  with  
0.1%  formic  acid.  Flow  rate  was  set  at  a  5   L.min
-1 with a  maximum pressure  of  
400 bar. A 35-minute gradient was used as indicated in Table 3.3, with a 10-minute 
post-time to ensure the column was completely flushed prior to the subsequent run. 
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Table 3.3:  Gradient  used  in  capillary  HPLC  runs,  indicating  percentage  of 
acetonitrile (ACN) at different times in the run. The transition from 
10 to 100% is linear over 15 minutes. 
 
 
 
 
A volume of 1  L of sample was injected at the start of each run, and the autosampler 
was kept at 4°C to prevent sample degradation. Column temperature was also kept at 
25°C to ensure it remained constant. The DAD was used to collect full spectra (190 to 
600 nm) as well as specifically monitoring 254 and 280 nm. 
  This HPLC method was used in conjunction with the MS method outlined in 
3.2.4 to quantify the amount of NRG1 present in FCM. Multiple reaction monitoring 
(MRM) was used, meaning that only ions at 1068, 1142 and 1246 m/z were monitored. 
This greatly improved the signal to noise ratio compared to the full scans of FCM. 
 
3.3 Results 
3.3.1 Direct infusion mass spectrometry 
  NRG1 solution (10 ng.mL
-1) was infused directly into the MS and showed a 
mass spectrum characteristic of a protein (Figure 3.6). The protein exists in multiple 
charge  states,  due  to the many potential binding sites  for protons on the molecule.  
The predominant ions were 1068, 1142 and 1246 m/z. Deconvolution of this spectrum 
suggested a molecular weight of 7.480 kDa, very close to the actual value of 7.478 kDa. 
MS
2  using  CID  was  attempted  for  1068  m/z  (Figure  3.7),  but  was  only  partially 
successful due to the large amount of energy required to fragment an intact protein.  
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Figure 3.6:  Mass spectrum for neuregulin-1β β β β (10 ng.mL
-1) obtained using direct 
infusion into a quadrupole ion trap mass spectrometer. Intensity is 
an arbitrary scale and indicates relative abundance of ions in the 
trap for a given scan. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.7:  Mass spectrum for collision-induced dissociation of the 1068 m/z ion 
of  neuregulin-1β β β β  obtained  using direct infusion into a quadrupole 
ion trap mass spectrometer. This spectrum represents MS
2. Intensity 
is an arbitrary scale and indicates relative abundance of ions in the 
trap for a given scan. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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The primary fragment ion was 1047.3 m/z, indicating a neutral loss of 20.7 m/z from the 
original molecule. Other fragment ions included 958.3, 1010.0 and 1028.7 m/z. 
  FCM  of  both  control  and  dexamethasone  (test)  treatments  was  also  infused 
directly into the MS. Mass spectra for both types of FCM were complex, with many 
compounds present, and many of those in multiple charge states (Figures 3.8, 3.9). A 
key difference is that 1068 m/z is clearly visible in the test FCM, but not in the control 
FCM. MS
2 indicated that ions of 1068, 1142 and 1246 m/z were all present in both types 
of FCM, but these results indicated that the concentration of these ions was likely to be 
greater in the test FCM. MS
2 using CID was attempted for 1068 m/z, and the response 
was identical  for both  FCM types, indicating  that this ion corresponds to the same 
compound. The resultant fragmentation spectrum (Figure 3.10) displayed ions of 958.3, 
1016.5,  1028.7  and  1047.2  m/z.  Several  of  these  ions  are  in  common  with  those 
generated from NRG1 standard (Figure 3.7), providing strong evidence that the ion at 
1068 m/z in FCM is NRG1. 
 
3.3.2 Capillary HPLC 
  Quantitation of NRG1 in FCM required the use of an HPLC system to deliver 
the entire sample into the MS simultaneously. A method was developed for NRG1 and 
subsequently used for the FCM samples (see 3.2.5). The 280 nm chromatogram for  
10  ng.mL
-1 NRG1 (Figure 3.11) showed that NRG1 was largely un-retained by the 
column and eluted with a retention time of approximately 2.5 minutes. Control FCM 
was  also  run  with  this  method  to  ensure  that  it  was  suitable,  and  the  280  nm 
chromatogram  for  this  sample  was  overlaid  with  that  for  NRG1  (Figure  3.12).  
This comparison showed that if NRG1 was present in FCM, then it was likely to be co-
eluting with a large number of other compounds that absorbed strongly at 280 nm. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.8:  Mass  spectrum  for  fibroblast-conditioned  medium  from  control 
cultures obtained using direct infusion into a quadrupole ion trap 
mass  spectrometer.  Intensity  is  an  arbitrary  scale  and  indicates 
relative abundance of ions in the trap for a given scan. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.9:  Mass  spectrum  for  fibroblast-conditioned  medium  from 
dexamethasone-treated cultures obtained using direct infusion into a 
quadrupole  ion  trap  mass  spectrometer.  Intensity  is  an  arbitrary 
scale  and  indicates  relative  abundance  of  ions  in  the  trap  for  a  
given scan. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.10:  Mass spectrum for collision-induced dissociation of the 1068 m/z ion 
of fibroblast-conditioned medium obtained using direct infusion into 
a quadrupole ion trap mass spectrometer. This spectrum represents 
MS
2. Intensity is an arbitrary scale and indicates relative abundance 
of ions in the trap for a given scan. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.11:  Chromatogram  of  neuregulin-1β β β β  (10  ng.mL
-1)  obtained  using 
capillary  HPLC.  Response  is  shown  in  milli-Absorbance  units 
(mAU) as a function of time. Detection wavelength was 280 nm. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.12:  Chromatogram of neuregulin-1β β β β (blue) overlaid on chromatogram 
of  fibroblast-conditioned  medium  (red)  obtained  using  capillary 
HPLC.  Response  is  shown  in  milli-Absorbance  units  (mAU)  as  a 
function  of  time.  Detection  wavelength  was  280  nm  for  
both analyses. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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3.3.3 Quantitation of NRG1 
  Solutions of NRG1 at concentrations of 0.1, 0.5, 1, 5, 10, 50 and 100 ng.mL
-1 
were run using the capillary HPLC method described in 3.2.5 and the MS conditions 
outlined  in  3.2.4.  The  resultant  mass  spectrum  chromatograms  were  then  used  to 
generate a standard curve for NRG1 in the ion trap MS (Figure 3.13). The area under 
the peak was calculated using the mass spectrometry software, and this area plotted 
against  NRG1  concentration.  Samples  were  run  in  triplicate  and  this  generated  a 
standard curve with a very strong correlation (R = 0.9978).  
  Six pairs of control and dexamethasone (test) treatment FCM were analyzed 
using the same method, and chromatograms generated. To provide comparison, three 
pairs  of  FCM  from  experiments  which  had  shown  no  indirect  response  to 
dexamethasone, in spite of being below the cell density threshold, were also chosen and 
analyzed.  As  no  suitable  internal  standard  was  available,  all  samples  were  run  in 
triplicate  to  reduce  standard  error.  The  area  under  the  peak  for  each  sample  was 
calculated and the standard curve used to calculate NRG1 concentration. Results of this 
analysis  showed  that  mean  NRG1  concentration  in  the  control  treatment  FCM  was 
19.85 ng.mL
-1 (± 1.73 ng.mL
-1), while in the test treatment FCM it was 41.59 ng.mL
-1 
(± 1.44 ng.mL
-1) (Figure 3.14). For FCM which had shown no indirect response, control 
FCM  contained  20.85  ng.mL
-1  (±  3.03 ng.mL
-1)  NRG1,  while  test  FCM  had  a 
concentration of 22.84 ng.mL
-1 (± 1.67 ng.mL
-1). Single-factor ANOVA of these results 
indicated  a significant difference  between the  test  treatment FCM (positive indirect 
response) and the remaining three FCM samples (p = 7.51x10
-7). Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.13:  Standard curve for response of neuregulin-1β β β β in quadrupole ion trap 
mass spectrometer. Peak area is calculated by the mass spectrometer 
software and has no units. The line is a trend line with a correlation  
of 0.9978. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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Figure 3.14:   Concentration of neuregulin-1β β β β (ng.mL
-1), calculated using ion trap 
mass  spectrometry,  in  fibroblast-conditioned  media  (FCM) 
generated  in  the  absence  (control)  and  presence  of  100nM 
dexamethasone (dexamethasone). Red indicates FCM for which no 
indirect  response  to  dexamethasone  was  detected,  blue  represent 
FCM for which a positive response was observed. 
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3.4 Discussion 
  This study has provided further evidence of a significant role for neuregulin-1 
(NRG1)  in  the  fibroblast-pneumocyte  factor  response  observed  in  fetal  lung  cells.  
The  presence  of  this  growth  factor  in such a large number of  systems during  fetal 
development  shows  the  breadth  of  its  activity,  so  its  involvement  in  the  surfactant 
system  is  unsurprising.  It  is  also  known  to  be  involved  in  earlier  stages  of  lung 
development, including the stimulation of branching morphogenesis (Liu et al., 2004).  
In fact, given the number of systems in which NRG1 has been identified, it is surprising 
that a role in this system was not postulated prior to 2003. 
Neuregulins are related to epidermal growth factor, which has previously been 
shown to have a significant impact on surfactant synthesis (Sen and Cake, 1991), and 
the two factors share the same receptors, the ErbB family. Receptors for NRG1 have 
been shown to be present in the fetal lung at the same time that surfactant synthesis is 
initiated (Liu et al., 2004). Furthermore, these receptors have only been detected on 
epithelial cells (i.e. type II pneumocytes) (Patel et al., 2000), while NRG1 expression 
has  been  detected  in  mesenchymal  cells  (i.e.  fibroblasts)  (Citri  et  al.,  2003).  
This  localization  implies  that  NRG1  is  secreted  from  fibroblast  cells  and  acts  in  a 
paracrine  fashion  on  neighboring  type  II  pneumocytes,  exactly  as  FPF  has  been 
proposed to act (Smith and Post, 1989).  
  Further  study  of  ErbB  receptors  has  found  that  only  ErbB2  and  ErbB3  are 
expressed in the fetal lung (Liu et al., 2004). This implies that the action of NRG1 on  
type II pneumocytes would be via the ErbB2/ErbB3 heterodimer. Activation of PI3K 
(Liu  et  al.,  2004)  and  Jak-STAT  (Liu  and  Kern,  2002)  via  ErbB2/ErbB3  has  been 
demonstrated in fetal lung cells, but stimulation of surfactant synthesis by NRG1 is 
likely to occur via protein kinase C (PKC), as known activators of PKC such as EGF 
(Sawyer  and  Cohen,  1981)  and  PMA  (Sen,  1991)  have  been  shown  to  stimulate Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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surfactant  synthesis.  Activation  of  PKC  by  ErbB2/ErbB3  signaling  has  been  noted  
(Citri et al., 2003), although it is not one of the primary pathways for this receptor 
system. It is likely that ErbB2/ErbB3 increases the activity of phospholipase Cγ, which 
would  increase  hydrolysis  of  phosphatidylinositol-4,5-bisphosphate  to  diacylglycerol 
and inositol-1,4,5-trisphosphate. The latter compound elevates the intracellular level of 
calcium and this, together with diacylglycerol, regulates the activity of PKC (Spitaler 
and  Cantrell,  2004).  It  has  been  proposed  that  activity  of  choline  phosphate 
cytidylyltransferase  (CPCT),  the  rate-limiting  enzyme  of  surfactant  synthesis,  is 
regulated  by  enzyme  modulator  interactions  (e.g.  phosphorylation)  rather  than 
transcriptional regulation (Post et al., 1986). If NRG1 is acting via PLC and PKC, then 
it is possible that PKC then acts on CPCT and causes an increase in its activity. 
  One of the main pathways by which ErbB2/ErbB3 transduces signals involves 
mitogen-activated  protein  kinase.  The  MAPK  signaling  cascade  leads  to  increased 
mitogenesis and cellular proliferation (Seger and Krebs, 1995). If NRG1 action on type 
II cells leads to an increase in MAPK activity as well as PKC, it is likely that it causes 
type II cell numbers to increase. This mitogenic effect may contribute to the stimulation 
of surfactant synthesis prior to parturition in vivo, but is unlikely to have an effect in the 
culture system, as results are expressed as dpm.ng DNA
-1.  
  Elevation of protein kinase C activity (via diacylglycerol) has also been shown 
to increase secretion of surfactant (Sano et al., 1985; Asokananthan and Cake, 1996). 
Direct activation of protein kinase C via the ErbB2/ErbB3 heterodimer may lead to an 
increase in secretion from type II cells. FPF has always been postulated as a direct 
control on synthesis of surfactant, but not secretion. If FPF is NRG1, then the action of 
this protein could in fact regulate both synthesis and secretion, and could be considered 
a regulator for the entire pulmonary surfactant system. 
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A discrepancy between this  work  and that of Dammann et al. (2003) is the 
molecular weight observed for NRG1. Dammann et al. isolated NRG1 with a molecular 
weight of 44 kDa, while this study focused on the much smaller mass of 7.5 kDa.  
The  44  kDa  form  is  thought  to  be  a  proteolysed  soluble  form  of  the  75  kDa 
transmembrane isoform of NRG1. The 7.5 kDa form is known to comprise only the 
EGF-like  bioactive  domain,  the  only  domain  possessed  by  all  known  isoforms  of 
NRG1. Only this domain is required for the activity of the protein, and so this molecular 
weight likely represents a fully-processed form of NRG1. It is therefore possible that the 
quantitation of NRG1 obtained using ions of the 7.5 kDa isoform does not represent the 
total concentration of NRG1 present in FCM. Other, larger isoforms may be present and 
are likely to ionize very differently. Some isoforms may not ionize at all if electrospray 
ionization cannot impart sufficient energy. 
 
Expression  of  the  protein  NRG1  by  fetal  lung  fibroblasts  is  enhanced  by 
dexamethasone. The gene for NRG1, nrg1, therefore probably possesses at least one 
glucocorticoid response element. These are located upstream of the promoter for a given 
gene, providing a binding site for glucocorticoid receptors (Bentley, 1998). The gene 
nrg1 is known to possess multiple promoters that can generate different isoforms of 
NRG1 (Steinthorsdottir et al., 2004). Depending on the degree of separation of these 
promoters, it is possible that only particular promoters are preceded by a GRE, meaning 
that only certain isoforms are expressed when cells are exposed to glucocorticoids. This 
may mean that compounds other than glucocorticoids that stimulate surfactant synthesis 
indirectly may act via different promoters, leading to the production of different NRG1 
isoforms with different activity. Such convoluted regulation is probably unlikely, but 
due to the complexity of this system, all aspects of the system must be considered. Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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  Another  possibility  that  must  be  considered  is  that  in  addition  to  enhancing 
expression of growth factors, dexamethasone may also suppress expression of inhibitory 
factors. Torday and Kourembanas (1990) observed that fetal lung fibroblasts produced a 
growth factor homologous to transforming growth factor β (TGFβ) that blocked the 
maturation of type II pneumocytes. This has been supported by recent work (McDevitt 
et al., 2007) which used RT-PCR and microarrays to confirm the expression of TGFβ 
by fibroblasts. Any increase in synthesis with dexamethasone treatment may therefore 
be due to a combination of enhanced expression of FPF and inhibition of expression of 
TGFβ. The compelling evidence that exists for both regulatory pathways indicates that 
signaling in the developing lung is more complex than initially thought. 
The  main  evidence  to  indicate  that  the  ions  observed  in  FCM  were ions  of 
NRG1 is the partial fragmentation pattern obtained. The pattern matched that of the 
NRG1 standard for several ions. A more detailed fragmentation pattern, preferably over 
several  MS
n  steps  would  be  desired  for  a  definitive  identification,  but  insufficient 
energy was available through CID to allow for further fragmentation of an intact protein 
molecule such as NRG1. Thus, it is possible (although unlikely) that the ions observed 
in FCM were ions of an unrelated compound with an identical m/z. The best approach 
would  be  to  use  a  more  powerful  mass  spectrometry  technique  such  as  Fourier 
transform ion cyclotron resonance mass spectrometry (FT-ICR-MS). The use of high 
strength  magnetic  fields  means  that  this  instrument  can  provide  molecular  weights 
accurate to five decimal places, sufficient for definitive identification of a compound 
(Marshall et al., 1998). This type of high-resolution analysis, combined with proteomic 
techniques such as Multidimensional Protein Identification Technology (Washburn et 
al., 2001), would remove any doubt as to the identity of the ions in FCM. 
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  The  concentration  of  NRG1  in  FCM  from  experiments  which  exhibited  no 
indirect  response  to  glucocorticoids  showed  no  significant  difference  from  control 
FCM.  This  clearly  established  a  strong  correlation  between  NRG1  concentration in 
FCM and increased surfactant synthesis. The reason for the lack of response in some 
cultures is not clear, and is possibly related to the sensitivity of the tissue culture system 
that  was  highlighted  in  Chapter  2.  This  particular  observation  warrants  further 
investigation to determine if a particular aspect of the system can prevent the cells from 
responding to dexamethasone and secreting NRG1. 
 
  Attempts  to  separate  the  components  of  FCM  using  HPLC  were  largely 
unsuccessful. This can be attributed to the complexity of FCM, both in terms of the 
array of compounds secreted from the cultured lung fibroblasts into the medium, and the 
composition of MEM
+ itself. Compounds of interest, mostly secreted proteins, are also 
likely  to  be  present  in  much  lower  concentrations  than  other  components.  For  this 
reason,  further  research  into  NRG1  in  this  system  would  be  greatly  advantaged  by 
improved separation. This may require protein purification techniques to extract the 
proteins from solution, although important non-protein compounds may be overlooked. 
A technique such as solid phase extraction may be of use, as it allows compounds to be 
separated initially on the basis of solubility in different solvents. Other possibilities 
include HPLC using two columns of differing chemistry, or possibly a column of larger 
pore size (e.g. 100 nm); use of two-dimensional gel electrophoresis to separate proteins 
prior to  mass spectral analysis;  or the use of other forms of mass spectrometry, as 
detailed earlier. FT-ICR-MS would remove the need for adequate separation on HPLC 
and allow all of the components of FCM to be identified using mass spectrometry. 
Identification of all of the compounds present in FCM would be highly advantageous, as Chapter 3                                                                                                           Fibroblast-pneumocyte factor 
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it would provide a much clearer picture of exactly what is secreted from fetal lung 
fibroblasts. 
This study has provided further evidence that FPF, whose molecular identity has 
been  unknown,  is  most  likely  NRG1,  or  at  least  includes  NRG1  as  a  significant 
component. The concentration of a particular NRG1 isoform in fibroblast-conditioned 
medium was shown to increase significantly when fibroblast cultures derived from fetal 
rat lung were exposed to dexamethasone. Previous findings about the localization of 
NRG1 and its receptors, the ErbB family, show that the appropriate receptor-ligand 
system  exists  for  NRG1  to  have  the  effects  previously  observed  for  FPF  in  the 
surfactant system. Transduction of the signal by ErbB2/ErbB3 can occur via a number 
of  pathways,  and  it  is  likely  that  phospholipase  Cγ/protein  kinase  C  provides  the 
signaling pathway in type II pneumocytes. The complexity of regulation of the NRG1 
system, from transcription of the nrg1 gene through to receptor interactions, has made it 
difficult  to  generate  a  complete  picture  of  this  system  from  a  single  study.  More 
research is required into NRG1 isoforms and receptors to fully understand the role of 
NRG1 in the surfactant system. In spite of the remaining ambiguity, it does seem likely 
that neuregulin-1 is a major component of the activity of the compound identified as 
‘fibroblast-pneumocyte factor’. Chapter 4. Effect of insulin-like growth factor II on 
surfactant synthesis and secretion 
 
4.1 Introduction 
4.1.1 Insulin-like growth factors 
Insulin-like  growth  factors  (IGFs)  are  a  group  of  growth  factors  that  share 
similarities in function with the neuregulins (Zorzano et al., 2003). IGFs are involved in 
many biochemical processes, including cell differentiation, proliferation and apoptosis 
(Jones  and  Clemmons,  1995).  Two  IGFs  have  been  identified  to  date:  insulin-like 
growth factor I (IGF-I) and insulin-like growth factor II (IGF-II). Specific IGF receptors 
(IGFRs) and binding proteins (IGFBPs) have also been identified (Yu and Rohan, 2000) 
(Figure 4.1). Other components of the system include an acid labile subunit (ALS) and 
several low-affinity IGFBP-related proteins (IGFBP-rPs) (Frystyk, 2004).  
  Insulin-like growth factor I is a 70-amino acid polypeptide that has been found 
to be important in growth and injury repair in a variety of organs, including the lung.  
It shares 49% homology with insulin (Ullrich et al., 1986). Insulin-like growth factor II 
is a 67-amino acid polypeptide with 47% homology with insulin and 61% with IGF-I 
(Rinderknecht and Humbel, 1978). The concentration of IGF-II in adult human serum is 
660 ± 124 ng.mL
-1, while in adult rat serum it is 11.4 ± 0.7 ng.mL
-1 (Bowsher et al., 
1991). Expression and regulation of IGFs is not well understood. IGF concentration is 
regulated by a number of hormones, including estrogen, follicle-stimulating hormone 
and luteinising hormone (Yu and Rohan, 2000), but there are likely to be many other 
mechanisms of regulation that have not yet been identified. 
Considerable  evidence  exists  to  indicate  that  IGF-II  plays  a  key  role  in 
mammalian development, and is more important in early life than IGF-I (Brissenden et 
al., 1984). It has been suggested that the main functions of IGF-II occur during fetalChapter 4                                                                                                             Insulin-like growth factor II 
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Figure 4.1:   Schematic representation of the IGF axis (Bayes-Genis et al., 
2000). 
 
The IGFs are present in circulation as binary complexes with IGFBPs. IGFBPs 
modulate cell response to IGFs (A); and specific proteases act on IGFBPs to 
release IGFs (B). IGF can then interact with transmembrane receptors (C). 
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development and that these roles are taken over by IGF-I post-parturition (Stewart and 
Rotwein, 1996). The IGF-II gene is expressed during fetal life (Brown et al., 1986; 
Graham et al., 1986), and IGF-II mRNA has been detected in a number of fetal tissues 
(Beck et al., 1987). Expression of the IGF-II gene in rat liver is highest during fetal 
development,  begins  to  decrease  post-parturition  and  is  undetectable  after  weaning 
(Carr et al., 1995; Langford et al., 1998). 
 
4.1.2 Insulin-like growth factor receptors 
  Two distinct transmembrane insulin-like growth factor receptors (IGFRs) have 
been identified: type 1 and type 2. 
  The type 1 IGF receptor (IGFR-1) is a glycoprotein with a molecular weight of 
approximately 325 kDa, composed of four subunits (Sara and Hall, 1990). IGFR-1 has 
60% structural and functional homology with the insulin receptor (Ullrich et al., 1986), 
and transduces its effect intracellularly via tyrosine kinase (Humbel, 1990). Both IGFs 
can  bind  to  IGFR-1,  but  IGF-I  shows  a  greater  affinity  than  IGF-II  (Rechler  and 
Nissley,  1985).  IGFR-1  has  been  detected  in  a  number  of  systems  during  fetal 
development (Humbel, 1990; Baker et al., 1993) and its role is likely to be an essential 
one, as null mutations in IGFR-1 are lethal (Liu et al., 1993). Levels of IGFR-1 decline 
post-parturition, but it is still detectable (Baker et al., 1993). 
  The type 2 IGF receptor (IGFR-2) is a single-chain polypeptide with a molecular 
weight of approximately 250 kDa, composed of three domains (Sara and Hall, 1990).  
It is structurally unrelated to either the insulin receptor or IGFR-1, but appears to be 
identical  to  the  mannose-6-phosphate  cation-independent  receptor  (Kornfeld,  1992).  
As a result, it is able to bind mannose-6-phosphate-containing proteins such as renin, 
proliferin and thyroglobulin (Jones and Clemmons, 1995). IGFR-2 has a high affinity 
for IGF-II and is unable to bind insulin (Massague and Czech, 1982). IGFR-2 acts via a Chapter 4                                                                                                             Insulin-like growth factor II 
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G-protein  secondary  messenger  system  (Nishimoto  et  al.,  1989),  but  there  is  much 
evidence to suggest that IGFR-2 is not involved in any signal transduction pathways 
(Sakano et al., 1991; Kornfeld, 1992). Instead, IGFR-2 is likely to be involved primarily 
in regulation of IGF-II levels (Filson et al., 1993). 
  Insulin and the IGFs are able to bind to each other’s receptors, although with a 
greatly reduced affinity (Frattali and Pessin, 1993). A hybrid of the insulin receptor and 
IGFR-1  has  also  been  identified,  but  its  expression  is  inconsistent  (Jones  and 
Clemmons, 1995). This hybrid receptor has a higher affinity for IGF-I than for insulin, 
but its biological function is not known. 
 
4.1.3 Insulin-like growth factor binding proteins 
  Circulating IGFs are almost exclusively bound to one of the insulin-like growth 
factor  binding  proteins  (IGFBPs).  Six  IGFBPs  (IGFBP-1  to  IGFBP-6)  have  been 
purified and they have a high affinity for both IGFs (Wallen et al., 1997). The amino 
acid  sequences  of  the  IGFBPs  show  47%  to  60%  homology  (Murphy,  1998).  
Most circulating IGF-I is bound to IGFBP-3, forming a 150 kDa complex that regulates 
transport of IGF-I (Bayes-Genis et al., 2000). The four main functions of IGFBPs are 
(Jones and Clemmons, 1995): 
 
a)  transport and storage 
b)  clearance and recycling 
c)  tissue-specific and cell-specific localization 
d)  modulation of the interaction of IGFs with IGFRs 
 
The affinity of IGFBPs for IGFs is modulated by IGFBP proteases (Blat et al., 
1994).  Consequently,  these  proteases  are  very  important  in  determining  the 
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proteases have been identified as being able to cleave IGFBPs, and there are likely to be 
many others that have not been identified. An example is cathepsin D, a lysosomal 
protease, which can act on all six known IGFBPs (Claussen et al., 1997). 
 
4.1.4 The role of insulin-like growth factors in lung development 
  Considerable evidence exists to indicate that IGFs play an important regulatory 
role in the development of the fetal lung. mRNA and peptides for both IGF-I and IGF-II 
have been detected in lung tissue (Retsch-Bogart et al., 1996), and abundance of these 
varies with developmental stages (Klempt et al., 1992). Fetal lung cells in culture have 
been shown to produce both IGFs and IGFBPs (Maitre et al., 1995), and IGFs have 
been demonstrated to be involved in mitogenesis in similar cultures (Mouhieddine et 
al., 1994).  
IGF-II mRNA is most abundant during early fetal lung development in rats (up 
to days 16-18), and declines until four weeks post-partum (Klempt et al., 1992; Wallen 
and Han, 1994). Peptide fragments of IGF-II are also found in the lung, although their 
abundance  varies  greatly  in  different  parts  of  the  lung  and  different  developmental 
stages. The highest levels of these peptides are observed in the time immediately after 
birth (Kauffman et al., 1974). Elevated cortisol levels decrease the IGF-II concentration 
in the lung (Li et al., 1993), so it is possible that the rise in cortisol observed in fetal 
plasma prior to birth may be the cause of the gradual decline in IGF-II levels. 
  Receptors for IGFs are present in the fetal lung, but the pattern of expression is 
difficult to interpret. IGFR-1 is detectable in day 14 rat epithelial cells, but not day 18 
cells (Maitre et al., 1995), and its expression is almost negligible in human fetal lung 
cells  (Chetty  et  al.,  2004).  IGFR-1  is  largely  expressed  post-parturition,  when  
IGF-II is not detected, indicating that IGF-I is likely to be more important to postnatal 
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rat lung during the early stages of gestation, but it cannot be detected at day 18 or later. 
It  can  be  found  in  mesenchymal  tissues  at  this  time,  but  IGF-II  is  present  only  in 
epithelial  tissues  at  this  stage  of  development  (Maitre  et  al.,  1995).  This  evidence 
indicates that if IGF-II has a role in the surfactant system at birth, it is likely to be 
through a receptor other than the IGFRs. 
  Human  insulin  receptor  (IR)  is  expressed  in  two  distinct  forms,  IR-A  and  
IR-B. IR-B is the dominant form, and is thought to be essential for the metabolic effects 
of  insulin  (Mosthaf  et  al.,  1990).  IR-A  binds  to  both  insulin  and  IGF-II  with  high 
affinity and is expressed primarily in tumours and fetal tissues (Frasca et al., 1999). It is 
therefore possible that IR-A is the main receptor for the IGF system in fetal rat lung.  
In  hepatoma  cells,  dexamethasone  causes  expression  to  switch  from  IR-A  to  IR-B 
(Kosaki  and  Webster,  1993),  so  the  increase  in  glucocorticoid  expression  in  late 
gestation may cause the tissues to change to the adult expression of IR-B.  
IGFBPs have also been identified in the developing lung, particularly in the later 
stages  of  development  (Delhanty  and  Han,  1993).  Genes  for  IGFBP-2  to  
IGFBP-6 are expressed in fetal rat lung (Wallen et al., 1997) and mRNA for IGFBP-2 
to IGFBP-5 has been detected in lung cultures, although the expression appears to be at 
a different rate to that observed in vivo (van de Wetering et al., 1997). This indicates 
that regulation of IGFBPs in the developing lung may be controlled by factors extrinsic 
to the tissue. The most abundant IGFBP in the fetal rat lung is IGFBP-2, which is 
expressed most during late gestation (Klempt et al., 1992). It is possible that increased 
production of IGFBPs occurs to bind IGFs and prevent them from interacting with their 
receptors  (Mouhieddine  et  al.,  1994).  A  potentially  important  observation  made  by 
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increased  in  growth  arrested  type  II  pneumocytes.  This  may  be  important  for 
experiments using cultured type II pneumocytes, such as in this study. 
  The  presence  of  IGFs,  IGFRs  and  IGFBPs  in  the  developing  lung,  and  the 
changes in distribution and abundance observed indicate that the IGFs are likely to be 
involved in many different processes during lung growth and maturation. It is therefore 
possible that they are also involved in regulation of the surfactant system. This potential 
role for IGFs has not been previously investigated, and given that IGFs are functionally 
similar to neuregulins, a study was undertaken to determine if IGFs have an effect on 
synthesis or secretion of pulmonary surfactant. 
 
4.2 Methods 
4.2.1 IGF-II preparation 
Insulin-like  growth  factor-II  (IGF-II)  (Novozymes  GroPep,  Thebarton,  SA, 
Australia) was supplied as a lyophilized powder and dissolved in 10 mM hydrochloric 
acid  (HCl) to  a concentration  of 100   M IGF-II. This stock solution was stored at  
-80°C  until  use.  This  solution  was  further diluted with  10 mM HCl to provide the 
required  working  concentration  for  each  experiment.  Control  plates  in  these 
experiments included 10 mM HCl. 
 
4.2.2 Surfactant synthesis experiments 
Tissue  culture  and  surfactant  synthesis  experiments  were  carried  out  as 
described in the revised method of 2.8. The circulating concentration of IGF-II in fetal 
rats  prior  to  parturition  has  been  determined  to  be  in  the  range  of  0.4  to  0.7   M 
(Daughaday  et  al.,  1982),  so  experiments  focused  on  the  following  concentrations:  
0.4, 0.6 and 0.8  M.  
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4.2.3 Surfactant secretion experiments 
  In addition to studying the effect of IGF-II on surfactant synthesis, the effect on 
secretion of surfactant from type II pneumocytes was also examined. Insulin is known 
to stimulate the rate of surfactant secretion (Snyder and Mendelson, 1987), so it is 
possible  that  related  compounds  like  IGF-II  may  exert  a  similar  effect.  As  with 
synthesis, IGF-II was studied at 0.4, 0.6 and 0.8  M, as well as 0.1, 0.2 and 1.6  M as 
part of a concentration curve. 
  After 72 hours in culture, type II cells were taken from the incubator, media was 
removed and plates washed twice with 2.0 mL of BSS. A solution of MEM
+ containing 
2  Ci.mL
-1 [methyl-
3H]-choline chloride was prepared and placed in a 37°C shaking 
water bath for 10 minutes. 2.0 mL of this solution was added to each type II plate and 
plates were returned to the incubator for 24 hours. 
  Following incubation, plates were washed with BSS to remove unincorporated 
choline. 1.7 mL of MEM
+ was added to all plates and plates were equilibrated in the 
incubator for a further 60 minutes. Two plates were then removed from the incubator to 
determine  the  amount  of  phospholipid  in  media  and  cells  at  ‘time  zero’.  To  the 
remaining plates 17  L of IGF-II + vehicle (test) or vehicle only (control) were added. 
Plates were returned to the incubator for a further three hours. 
  Plates were removed from the incubator after three hours and briefly stored on 
ice. Media was transferred to a centrifuge tube and plates washed three times with  
0.83 mL of BSS. Wash buffer was also transferred to the same centrifuge tube and 
plates were placed back on ice. Tubes were centrifuged at 1000 g for two minutes and a 
3.5 mL aliquot of the supernatant was added to a screw-capped tube. To this tube,  
50   L  of  L-3-phosphatidylcholine-1,2-di[1-
14C]  palmitoyl  was  added  as  a  recovery 
standard  and  20   L  of  2.5  mg.mL
-1  phosphatidylcholine  was  added  as  a  carrier. 
Following this, 13.125 mL of 1:2 chlorform:methanol was added, tubes vortexed and Chapter 4                                                                                                             Insulin-like growth factor II 
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the mixture left to stand at room temperature. After 10 minutes, 4.375 mL of chloroform 
was  added,  tubes  vortexed  and  the  contents  left  to  stand  for  a  further  10  minutes. 
Finally,  4.375  mL  of  MilliQ-H2O  was  added,  tubes  vortexed  and  placed  in  a  
4°C refrigerator for at least 48 hours. Cells were also harvested for both lipid and DNA 
assays using the revised method described above for synthesis experiments in 2.8. 
  Lipid  assays  for  media  and  cells  were  completed  as  described  above,  with  
400  L samples being taken into scintillation vials, dried, vials filled with scintillant, 
vortexed and left in the dark for 24 hours before being counted for both 
3H and 
14C. 
DNA  assays  were  completed  as  in  2.8.  Calculations  to  determine  mean  
dpm.ng DNA
-1,  cell density and percentage recovery were also undertaken as described 
previously. The calculation for percentage secretion was: 
 
% secretion =          dpm in media phospholipids                     ,x 100 
           (dpm in media phospholipids) + (dpm in cellular phospholipids) 
 
  Results were tabulated and graphed using Microsoft Excel 2003 (v11.8117) and 
statistics calculated using SPSS for Windows 14.0.1. 
 
4.3 Results 
4.3.1 Surfactant synthesis 
  A  total  of  31  pairs  of  control  and  test  FCM  were  tested,  ten  at  0.4   M  
IGF-II, seven at 0.6  M and fourteen at 0.8  M (Table 4.1). Response to IGF-II was 
small, with direct treatment showing a mean increase in synthesis of 3.34%, and indirect 
treatment  a  mean  increase  of  3.60%.  Single-factor  ANOVA  showed  no  significant 
difference between direct and indirect treatments at any of the concentrations tested  
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Table 4.1:  The direct and indirect effect of IGF-II on the augmentation of  
PC synthesis by type II pneumocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary  cultures  of  lung  fibroblasts  were  grown  to  near  confluence,  followed  by  
24 hours incubation in the presence or absence of either 0.4, 0.6 or 0.8  M in MEM
+. 
The fibroblast-conditioned media (FCM) were collected and stored at -80°C. Prior to 
use,  the  media  were  thawed  and  incubated  at  65°C  for  one  hour,  cooled  to  room 
temperature and filter-sterilized to remove detached cells and cellular debris. The media 
were then diluted 1:4 with MEM
+. The effect on PC synthesis by type II pneumocytes 
was investigated by exposing the cells either to the FCM (indirect) or to MEM
+, with 
and without IGF-II (direct). The data represent the mean ± SE. The number of replicates 
examined for each condition is indicated in parentheses, and each replicate comprised 
four cultures. Data were compared using single-factor ANOVA. 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference P-value
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
IGF-II 0.4        M
Direct (10)
Control 21.24 ± 3.26
IGF-II 22.01 ± 3.65 ↑  3.60% 25.54
Indirect (10) 0.86
Control 19.65 ± 3.54
IGF-II 20.17 ± 4.06 ↑  2.65% 26.75 8.30
IGF-II 0.6        M
Direct (7)
Control 25.51 ± 7.41
IGF-II 26.39 ± 6.66 ↑  3.44% 20.59
Indirect (7) 0.99
Control 18.44 ± 3.69
IGF-II 19.35 ± 4.47 ↑  4.94% 27.26 4.19
IGF-II 0.8        M
Direct (14)
Control 26.92 ± 4.81
IGF-II 27.73 ± 4.25 ↑  2.99% 23.18
Indirect (14) 0.98
Control 23.43 ± 3.63
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  116
(p = 0.86, 0.99 and 0.98 for 0.4, 0.6 and 0.8  M IGF-II, respectively). As with the 
results  for  dexamethasone  (2.9),  experiments  with  a  type  II  cell  density  above  the 
threshold  value  of  25   g.plate
-1  were  removed  from  the  data  set  and  the  results 
recalculated.  
In the revised data set, a total of 22 pairs of control and test FCM were tested, 
seven at 0.4  M IGF-II, six at 0.6  M and nine at 0.8  M (Table 4.2). Response at the 
three different concentrations was very similar, with direct treatment showing a mean 
increase  in  synthesis  of  4.65%,  and  indirect  treatment  a  mean  increase  of  6.35%.  
The lowest indirect response was at 0.4  M (6.00%) and the highest at 0.8  M (6.91%). 
Standard error values were high, with an error of 31.5% for direct controls at 0.6  M. 
PC synthesis values (expressed in dpm.ng DNA
-1) for these experiments were generally 
consistent with those observed previously (Sen and Cake, 1991). Single-factor ANOVA 
showed no significant difference between the direct and indirect treatments at any of the 
concentrations  tested  (p  =  0.90,  0.93  and  0.89  for  0.4,  0.6  and  0.8   M  IGF-II, 
respectively).  While  still  not  significant,  the  level  of  response  to  the  various 
concentrations of IGF-II for the revised data set was much more consistent, indicating 
that type II cell density was affecting the calculated results of synthesis experiments. 
 
4.3.2 Surfactant secretion 
  Initial secretion experiments tested a range of IGF-II concentrations from 0.1 to  
1.6  M to determine if there was any significant response (Figure 4.2). The control 
cultures had a mean secretion rate of 1.48% (± 0.07%), while the greatest response from 
IGF-II was observed at 0.4  M with a secretion rate of 1.69% (± 0.08%). A mean value 
of only 1.18% (± 0.15%) was seen at 1.6  M IGF-II. The secretion rate for the other 
three concentrations tested (0.1, 0.2 and 0.8  M) fell between these two values. Single-
factor ANOVA revealed no significant differences in secretory response between any of  Chapter 4                                                                                                             Insulin-like growth factor II 
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Table 4.2:  The effect of IGF-II on PC synthesis in type II pneumocytes for type 
II cultures with cell density below 25        g.plate
-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary  cultures  of  lung  fibroblasts  were  grown  to  near  confluence,  followed  by  
24 hours incubation in the presence or absence of either 0.4, 0.6 or 0.8  M in MEM
+. 
The fibroblast-conditioned media (FCM) were collected and stored at -80°C. Prior to 
use,  the  media  were  thawed  and  incubated  at  65°C  for  one  hour,  cooled  to  room 
temperature and filter-sterilized to remove detached cells and cellular debris. The media 
were then diluted 1:4 with MEM
+. The effect on PC synthesis by type II pneumocytes 
was investigated by exposing the cells either to the FCM (indirect) or to MEM
+, with 
and without IGF-II (direct). The data represent the mean ± SE. The number of replicates 
examined for each condition is indicated in parentheses, and each replicate comprised 
four cultures. Data were compared using single-factor ANOVA. 
Treatment
PC Synthesis 
(dpm/ng DNA)
Difference P-value
Mean type II 
pneumocyte DNA 
(       g/plate)
Mean fibroblast 
DNA level 
(       g/plate)
IGF-II 0.4        M
Direct (7)
Control 23.61 ± 3.99
IGF-II 24.76 ± 4.52 ↑  4.90% 13.40
Indirect (7) 0.12
Control 22.85 ± 4.35
IGF-II 24.22 ± 5.01 ↑  6.00% 14.68 4.86
IGF-II 0.6        M
Direct (6)
Control 29.30 ± 9.23
IGF-II 30.61 ± 8.31 ↑  4.47% 14.28
Indirect (6) 0.12
Control 28.11 ± 6.37
IGF-II 29.84 ± 7.24 ↑  6.15% 15.01 4.43
IGF-II 0.8        M
Direct (9)
Control 29.48 ± 6.37
IGF-II 30.83 ± 5.40 ↑  4.57% 13.77
Indirect (9) 0.12
Control 25.47 ± 5.20
IGF-II 27.23 ± 5.82 ↑  6.91% 13.67 3.23Chapter 4                                                                                                             Insulin-like growth factor II 
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Figure 4.2:  Effect of IGF-II on secretion of surfactant-associated phospholipids 
from cultured type II pneumocytes. 
 
Type  II  cells  were  isolated  from  lungs  of  19-day  fetal  rats  and,  after  reaching 
confluence, were incubated for a further 24 hours with [
3H]-choline chloride in order to 
label  cellular  phosphatidylcholine.  The  cells  were  then  washed  thoroughly  and 
equilibrated for one hour at 37°C in serum-free medium prior to the addition of the 
indicated  concentrations  of  IGF-II.  The  percentage  of  total  cellular  
[
3H]-phosphatidylcholine secreted into the media in the subsequent three hours was 
determined using the method outlined in 4.2.3. The data represent the mean ± SE. For 
comparison, the mean control response is also shown. 
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the  concentrations  tested  (p  =  0.12).  Standard  error  values  were  small,  indicating 
consistency between experiments. 
The  initial  experiments  showed  that  IGF-II  had  no  significant  effect  on 
surfactant secretion. However, some compounds have been shown to act synergistically 
or antagonistically with other secretagogues (Sullivan et al., 2003). To investigate this 
possibility, the effect of IGF-II was examined with two known stimulants of secretion, 
neuromedin  C  and  isoproterenol.  Both  compounds  have  been  shown  to  increase 
surfactant  secretion  from  type  II  pneumocytes  at  1.0  nM  (neuromedin  C) 
(Asokananthan,  1996)  and  1.0   M  (isoproterenol)  (Asokananthan  and  Cake,  1996).  
Neuromedin C is the biologically active C-terminal end of gastrin releasing peptide, a 
peptide with a wide range of signaling roles in mammalian systems ((Sunday et al., 
1988).  Isoproterenol  (also  known  as  isoprenaline)  is  a  β-adrenergic  agonist  that  is 
synthetically  derived  from  noradrenalin  (Gogarten  et  al.,  2001).  Both  of  these 
compounds have been previously shown in this laboratory to have no effect on cell 
viability, using media LDH as a reporter. 
  Neuromedin  C  at  1.0  nM  gave  rise  to  a  mean  secretion  rate  of  4.59%  
(Figure  4.3),  which  was  significantly  higher  than  the  mean  control  value of 1.55%  
(p = 4.76x10
-7). IGF-II at 0.4  M showed a mean secretion rate identical to the control 
value. The exposure of type II cells to the combined effects of 1.0 nM neuromedin C 
and  0.4   M  IGF-II  yielded  a  secretion  rate  (4.24%)  which  was  not  significantly 
different (p = 0.26) from the elevated level seen with 1.0 nM neuromedin C alone. 
Standard error values were small, indicating consistency between experiments.  
  Exposure to isoproterenol at 1.0  M resulted in a mean PC secretion rate of 
4.44%  (Figure  4.4),  which  was  significantly  higher  than  the  mean  control value  of 
1.56%  (p  =  7.63x10
-8).  The  effects  of  IGF-II  at  0.4   M  and  0.8   M  were  almost  
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Figure 4.3:  Effect of IGF-II on secretion of surfactant-associated phospholipids 
from cultured type II pneumocytes in response to neuromedin C. 
 
Type  II  cells  were  isolated  from  lungs  of  19-day  fetal  rats  and,  after  reaching 
confluence, were incubated for a further 24 hours with [
3H]-choline chloride in order to 
label  cellular  phosphatidylcholine.  The  cells  were  then  washed  thoroughly  and 
equilibrated for one hour at 37°C in serum-free medium prior to the addition of IGF-II 
(0.4   M)  and/or  neuromedin  C  (1.0  nM).  The  percentage  of  total  cellular  
[
3H]-phosphatidylcholine secreted into the media in the subsequent three hours was 
determined using the method outlined in 4.2.3. The data represent the mean ± SE.  
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Figure 4.4:  Effect of IGF-II on secretion of surfactant-associated phospholipids 
from  cultured  type  II  pneumocytes  in  response  to  isoproterenol.
   
Type  II  cells  were  isolated  from  lungs  of  19-day  fetal  rats  and,  after  reaching 
confluence, were incubated for a further 24 hours with [
3H]-choline chloride in order to 
label  cellular  phosphatidylcholine.  The  cells  were  then  washed  thoroughly  and 
equilibrated  for  one  hour  at  37°C  in  serum-free  medium  prior  to  the  addition  of 
isoproterenol (1.0  M) and/or the indicated concentration of IGF-II . The percentage of 
total cellular [
3H]-phosphatidylcholine secreted into the media in the subsequent three 
hours  was  determined  using  the  method  outlined  in  4.2.3.  The  data  represent  the  
mean ± SE. 
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identical  to  the  mean  control  value,  with  secretion  rates  of  1.55%  and  1.52%, 
respectively.  The  exposure  of  type  II  cells  to  the  combined  effects  of  1.0   M 
isoproterenol  and  0.4   M  IGF-II  yielded  a  secretion  rate  (4.53%)  which  was  not  
significantly different (p = 0.75) from the elevated level seen with 1.0  M isoproterenol 
alone. The combination of 1.0  M isoproterenol and 0.8  M IGF-II yielded a secretion 
rate  of  4.74%,  which  was  also  not  significantly  different  (p  =  0.42)  from  the  rate 
observed with 1.0  M isoproterenol. 
 
4.4 Discussion 
  The previously-described effects of insulin on surfactant synthesis and secretion, 
and the relationship between insulin and IGFs, suggested that IGF-II might have an 
impact  on  the  surfactant  system.  Insulin  delays  maturation  of  fetal  rat  lungs  and 
decreases the number of lamellar bodies present in type II cells (Gross et al., 1980).  
It also causes an increase in SP-B levels, at the expense of SP-A, which leads to an 
increase in secretion (Snyder and Mendelson, 1987). If insulin and IGF-II act through 
the same or similar mechanisms in the fetal lung, IGF-II would be expected to decrease 
synthesis and increase secretion of surfactant. 
The  results  of  this  study  indicate  that  IGF-II  had  no  significant  effect  on 
synthesis in either a direct or indirect manner, nor did it have any significant effect on 
secretion. The main receptor for the biological action of IGF-II in most systems is 
thought  to  be  IGFR-1,  and  it  is  likely  that  this  is  the  primary  receptor  in  type  II 
pneumocytes  immediately  post-parturition.  However,  IGFR-1  is  not  present  in 
detectable concentrations in type II pneumocytes derived from fetal rats at day 18 of 
gestation (Maitre et al., 1995), suggesting that it may not be present in the type II 
cultures used in this study. The absence of this receptor may account for the lack of a 
significant effect on synthesis or secretion of surfactant. It has been shown that, at this Chapter 4                                                                                                             Insulin-like growth factor II 
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stage of development, IGF-II may act through IR-A (Frasca et al., 1999). This receptor 
does have a high affinity for IGF-II, but its abundance in fetal lung tissue has not been 
characterized.  It  is  therefore  possible  that  IR-A  may  not  be  present  in  fetal  lung 
fibroblasts and type II pneumocytes, or may exist only at a very low level, meaning that 
IGF-II  is  unable  to  exert  a  significant  effect  on  the  surfactant  system  through  this 
receptor. 
Recent  research  (Siddle  and  Soos,  1999)  has  suggested  that  there  are  many 
atypical insulin and IGF receptors that are yet to be fully characterized. These receptors 
may arise from processes such as glycosylation, splicing or hybridization (Le Roith et 
al., 1995). Some atypical receptors are able to bind IGF-II with reasonable affinity, and 
so  may  be  important  in  IGF  signaling.  An  example  is  the  insulin-receptor-related 
receptor (IRR), which shares 55% homology with IR-B and IGFR-1 (Shier and Watt, 
1989).  The  possible  absence  of  the  primary  receptors  for  IGF-II  in  lung  cells  may 
indicate that receptors such as IRR are involved in the IGF system in fetal lung cells. 
The variable affinity and effect of these receptors (e.g. Zhang and Roth, 1992) may have 
contributed to the lack of response to IGF-II observed in this study. 
 
The important role of IGFBPs in modulating the action of IGF-II must also be 
considered. The expression of IGFBPs is different in culture than it is in vivo, implying 
that control of this system is exogenous to the tissue (van de Wetering et al., 1997).  
The IGFBPs may not have been present in the tissue cultures used in these experiments 
or may have been expressed at much higher levels than normal, possibly affecting the 
action of IGF-II. The potential absence/presence in excess of the other proteins of the 
IGF system must also be considered. The role of the IGFBP-related proteins is still not 
known and they may be involved in regulation of the effects of IGF-II. Further study is Chapter 4                                                                                                             Insulin-like growth factor II 
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needed to determine if any IGF-related proteins are present in either fibroblast or type II 
pneumocyte cultures and if so, which, and at what levels.  
Previous research (Mouhieddine et al., 1994) has shown that growth-arrested 
type  II  cells  show  an  increase  in  expression  of  IGFR-2  and  IGFBP-2.  
Confluent type II pneumocyte cultures may be considered to be non-proliferating, as 
they occupy the entire culture plate. The main role of IGFR-2 and IGFBP-2 appears to 
be to bind IGF-II and remove it from circulation, rather than being involved in any 
signaling pathways (Filson et al., 1993; Mouhieddine et al., 1994). As the regulation of 
some  components  of  the  IGF  axis  have  been  shown  to  be  exogenously  controlled, 
binding of IGF-II by receptors and binding proteins may not be solely concentration-
dependent.  If  the  type  II  cultures  used  in  this  study  up-regulated  IGFR-2  and/or  
IGFBP-2,  then  the  IGF-II  used  in  these  experiments  may  have  bound  to  either the 
IGFR-2 receptor or the binding protein and not been able to exert any significant effect 
on the synthesis or secretion of surfactant. The IGFBP proteases, required to free IGF-II 
from the IGFBPs, may not have been present in the system meaning that, once bound, 
the IGF-II could not be freed to interact with appropriate receptors. The lack of any 
significant  effect  of  IGF-II  observed  in  this  culture  system  may  therefore  not  be 
representative of that which occurs in vivo. 
 
The  primary  role  of  IGF-II  in  some  tissues  is  the  enhancement  of  cellular 
activities such as proliferation and differentiation (Jones and Clemmons, 1995), so it 
was thought that IGF-II might cause an increase in surfactant synthesis and secretion 
through  enhanced  proliferation  of  cultured  cells.  However,  research by Fraslon and 
Bourbon (1992) has shown that IGF-II does not lead to increased proliferation of type II 
cells.  Increased  cell  density  on  type  II  plates  would,  in  fact,  probably  have  had  a 
negative effect on synthesis, as detailed in 2.10.1. Fraslon and Bourbon (1992) did find Chapter 4                                                                                                             Insulin-like growth factor II 
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that  IGF-II  could  increase  lung  fibroblast  cell  numbers,  but  mean  cell  density  of 
fibroblast  cultures  for IGF-II  treatments was lower than for  experiments  with other 
compounds (as discussed in 2.10.2). The results obtained indicate that the mitogenic 
effects of IGF-II were unlikely to have been a significant factor in these experiments. 
Analysis  of  the  results  for  surfactant  synthesis  indicated  that  cell density of  
type II cultures was again likely to be affecting the results observed. While removal of 
cultures with a density above 25  g.DNA plate
-1 did not reveal significant differences 
between direct and indirect treatments, the calculated results were far more consistent.  
This consistency at three different concentrations provides further evidence that IGF-II 
had no effect on the surfactant system. The density of type II cultures clearly had an 
effect on the reliability of the results obtained, further reinforcing the need to develop a 
method of producing primary type II cultures with a consistent density. 
 
  Insulin-like growth factor II did not behave as expected in the surfactant system, 
with no significant effect on either synthesis or secretion. As has been discussed, the 
complexity of the IGF system means that there are many possible reasons for this lack 
of  effect. The most likely  reason is the absence  of  the  preferred receptor, IGFR-1.  
However,  the  receptors  that  IGF-II  acts  through  in  the  fetal  lung  have  not  been 
definitively identified, although there are several possible candidates. These receptors, 
such as IR-A, have differing abundance and affinity for IGF-II and these factors may 
have greatly reduced the response of this system to IGF-II. The potential up-regulation 
of IGFR-2 and IGFBPs may have removed IGF-II from the system and prevented it 
from  interacting  with  other  receptors.  IGF-II  is  clearly  involved  in many important 
developmental processes in the fetus, including lung development (Maitre et al., 1995), 
but the results of  this study indicate that it is unlikely to be a significant factor in 
modulating surfactant production. Chapter 5. General discussion 
 
  As it is studied further, the complexity of the pulmonary surfactant system is 
revealed,  both  in  terms  of  cellular  interaction  and  regulation.  One  of  the  most 
perplexing mysteries of this system has been the identity of the fibroblast-pneumocyte 
factor  (FPF),  the  fibroblast-expressed  protein  that  triggers  surfactant  synthesis  in  
type  II  pneumocytes.  This  study  has  provided  further  evidence  that  neuregulin-1 
(NRG1), a growth factor found in many stages of development, is at least one of the 
components, if not the major component, of FPF. It also provided more insight into the 
surfactant  system,  and  the  method  that  is  commonly  used  to  study  synthesis  and 
secretion of surfactant. 
 
  This  study  used  capillary  HPLC  coupled  with  quadrupole  ion  trap  mass 
spectrometry  to  analyze  fibroblast-conditioned  medium  (FCM)  for  FPF.  Previous 
research (Dammann et al., 2003) had indicated that NRG1 was possibly FPF, and that it 
possessed the same activity when exposed to type II pneumocyte cells, so analysis was 
focused on this protein. The concentration of NRG1 was significantly higher in FCM 
from fibroblast cultures treated with dexamethasone than control cultures. Importantly, 
FCM generated in the presence of dexamethasone, but which failed to stimulate PC 
synthesis in type II cells, was shown to contain a level of NRG1 comparable to controls.  
These findings strongly indicated that NRG1 is at the very least a major component of 
the response to FPF that has been observed in the past, if not FPF itself.  
  The  finding  that  NRG1  is  involved  in  this  stage  of  the  development  of  the 
surfactant system is not surprising, and indeed logical when neuregulin signaling is 
examined. Expression of NRG1 has been demonstrated in mesenchymal cells (Citri et Chapter 5                                                                                                                                        Discussion 
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al., 2003), such as the fibroblast cells that express FPF. Receptors for NRG1, the ErbB 
receptors,  have  been  observed  in  epithelial  cells  (Patel  et  al.,  2000),  such  as  the  
type  II  pneumocytes  in  which  FPF  is  known  to  stimulate  surfactant  synthesis.  
The  timing  of  this  stimulation  also  fits  well  with  previous  observations,  as  ErbB 
receptors have been shown to be present in the fetal lung at this time (Liu et al., 2004). 
The  findings  of  this  study  have  shown  that  dexamethasone  enhances  expression  of 
NRG1  by  fibroblasts.  Combination  of  all  of  this  information  allows  a  hypothetical 
picture of this system to be proposed.  
Dexamethasone  (and  likely  other  glucocorticoids)  acts  on  fibroblast  cells 
through its receptor, leading to increased expression of a number of glucocorticoid-
responsive  genes.  One  of  these  genes  is  nrg1,  which  is  expressed  as  NRG1,  in  a 
transmembrane isoform. This isoform is proteolysed to an unknown number of soluble 
forms,  including  at  least  a  44  kDa  form  (Dammann  et  al.,  2003)  and  the  
7.5 kDa form isolated in this study. These soluble isoforms are secreted by the cell, via 
some  form  of  exocytosis,  where  they  interact  with  adjacent  type  II  pneumocytes.  
These  type  II  cells  contain  both  ErbB2  and  ErbB3  receptors  (Liu  et  al.,  2004).  
NRG1  binds  to  ErbB3,  which  in  turn  binds  to  ErbB2  to  form  the  ErbB2/ErbB3 
heterodimer. This heterodimeric receptor then transduces its effects on the cell via a 
number of possible pathways. The most likely pathway for effect on surfactant synthesis 
(and  possibly  secretion)  is  activation  of  phospholipase  Cγ  (PLC).  PLC  increases 
hydrolysis of phosphatidylinositol-4,5-bisphosphate to diacylglycerol and inositol-1,4,5-
trisphosphates  which  in  turn  regulates  cellular  levels  of  calcium  (Ca
2+).  
These compounds regulate activity of protein kinase C (PKC) (Spitaler and Cantrell, 
2004), which phosphorylates choline phosphate cytidylyltransferase (CPCT), the rate-
limiting enzyme of surfactant synthesis. If this pathway, or something very similar, Chapter 5                                                                                                                                        Discussion 
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exists in the fetal lung, then it is essentially what would be expected of FPF. This makes 
the case even stronger for NRG1 being FPF. 
It is also possible that PKC acts on other enzymes, including those involved in 
surfactant  secretion.  This  indicates  a  possible  role  for  NRG1  in  regulation  of  both 
synthesis of surfactant and its subsequent secretion into the alveolar space. FPF was 
originally proposed as a direct regulator of synthesis, but any role in secretion was not 
studied. If NRG1 is acting via a pathway similar to that described above, it is distinctly 
possible  that  it  actually  represents  a  regulator  for  the  entire  surfactant  system.  
This would make it a very powerful compound and highlight its importance in the final 
stages of lung development around parturition. The fact that NRG1 is essential for lung 
maturation is certainly feasible given the vital roles for NRG1 in other developmental 
events, such as cardiac morphogenesis. 
The  proposed  role  for  NRG1 as  a ‘super-regulator’  of the surfactant system 
means that it could potentially be a very effective treatment for infants suffering from 
neonatal  respiratory  distress  syndrome  (NRDS).  If  NRG1  was  used  as  a  direct 
treatment,  it  would  avoid  the  problems  encountered  with  dihydrotestosterone,  and 
possibly  insulin,  and  the  side-effects  from  current  treatment  procedures  involving 
glucocorticoids. It would also provide a more rapid response, as it could act directly on 
the type II pneumocytes, as opposed to glucocorticoids which act on the fibroblasts to 
enhance expression of FPF. Treatment with NRG1 may also enhance secretion and 
possibly even have mitogenic effects on the lung tissues. Of course, care must be taken 
to establish if NRG1 is involved in other pathways at this specific stage of development, 
and if there exists the possibility for over-dose of NRG1 in these systems. The findings 
of this study provides a potential new option for treatment of NRDS, which warrant 
further exploration. There is currently no evidence as to whether NRG1 can cross the 
placenta, but it is known to be involved in signaling during implantation (Brown et al., Chapter 5                                                                                                                                        Discussion 
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2004). If it is able to cross the placenta, it may be able to administer NRG1 at the onset 
of premature labor, rather than post-partum, when NRDS may already have occurred. 
 
Insulin-like growth factors (IGFs) are related to neuregulins in terms of function, 
so the effect of IGF-II on surfactant synthesis and secretion was also investigated. It was 
expected to have a similar effect to insulin, in that it would decrease synthesis (Gross et 
al., 1980) and increase secretion (Snyder and Mendelson, 1987). These expectations 
were not met, with no significant effect being observed on either synthesis or secretion. 
The complexity of the IGF system means that there are a number of possible reasons for 
this lack of an effect. 
  The primary receptor for IGFs is IGFR-1, but this receptor is not found in fetal 
lung  cells  at  the  time  of  stimulation  of  surfactant  synthesis  (Maitre  et  al.,  1995).  
The secondary IGFR, IGFR-2, is thought to function primarily in binding IGF-II and 
removing it from circulation (Filson et al., 1993). The most likely receptor for action of 
IGF-II in the fetal lung in late gestation is an isoform of the insulin receptor, known as 
IR-A. This receptor has a lower affinity for IGF-II than for insulin, which may explain 
why  no  effect  was  observed.  It  has  also  been  found  that  growth-arrested  
type  II  pneumocyte  cells  increase  expression  of  IGFR-2  and  IGFBP-2,  one  of  the  
IGF  binding  proteins  (Mouhieddine  et  al.,  1994).  The  function  of  both  of  these 
molecules is to bind IGFs and remove them from circulation, implying that increased 
expression  of  these  may  have  prevented  IGF-II  from  having  any  significant  effect.  
It is therefore likely that the combination of a lack of an appropriate receptor and a 
regulatory system that is different in culture to in vivo meant that IGF-II showed no 
significant effect on either synthesis or secretion of surfactant.    
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    Analysis of FCM by mass spectrometry could not have been undertaken 
without a reliable method to generate FCM known to contain FPF. Early results from 
experiments  to  confirm  the  presence  of  FPF  were  very  inconsistent.  This  led  to  a 
thorough  examination  of  all  of  the  steps  of  tissue  culture  and  related  experimental 
methods  to  determine  which  could  be  contributing  to  the  unreliability  of  the 
experiments.  Several  parameters  were  identified,  mostly  related  to  the  density  of 
cultures or the addition of radioisotopes used in the experiments. This study led to the 
creation of a revised method, which was used for all subsequent experiments, including 
all those for which FCM was collected for analysis. This revised method can now be 
used for all future studies in this laboratory, and will reduce the variation that has been 
observed in the past. 
  The most significant effect on reliability was due to variations in the cell density 
of the type II pneumocyte cultures. This work, done in conjunction with an Honours 
student (Peh, 2006), found that cultures with a cell density above a threshold value of  
25  g.mL
-1 showed a mean decrease in phosphatidylcholine (PC) synthesis in response 
to dexamethasone-treated FCM, while those with density below the threshold showed a 
mean  increase.  When  the  results  of  experiments  involving  FCM  generated  in  the 
presence of dexamethasone were separated on this basis, the mean indirect response to 
dexamethasone was elevated from a 9.17% to a 17.56% increase. Results for the PC 
synthesis experiments using IGF-II were also subdivided according to cell density, and 
response to IGF-II was higher for cultures below the threshold. The reasons for these 
density-related effects are not clear, although they are likely to be due to the nature of 
type II cell cultures. Type II pneumocyte cultures are generated from clumps of cells 
(Tajbakhsh and Cake, unpublished observations), and if these do not spread evenly 
across the plate, it is possible that not all cells will be exposed to the agonist. These cells 
will not contribute to synthesis, but will contribute to the level of DNA, causing an Chapter 5                                                                                                                                        Discussion 
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apparent  decrease  in  response.  Fibroblast  cell  density  affected  results  of  some 
experiments, but much less so and not as consistently. 
  This section of the study also found that the application of the radioisotope-
labeled precursor was not as consistent as previously thought, and that it could have 
been  having  a  major  effect  on  the  variability  of  results.  The  erratic  results  of 
experiments  using  phorbol  12-myristate  13-acetate  were  due  in  part  to  inconsistent 
application of [
3H]-choline chloride. If insufficient precursor was available to cells, the 
response detected would have been reduced. In general, this part of the study served to 
highlight  the  sensitivity  of  the  method  used  to  even  slight  variations  in  some 
parameters, providing an understanding of why consistent results were initially difficult 
to obtain. 
 
  The findings of this study have provided more evidence that NRG1 is a major 
component of FPF. A study is currently in progress to examine the direct and indirect 
effect of recombinant NRG1 on synthesis and secretion of surfactant phospholipids. 
Fibroblast cells do not contain receptors for NRG1 at this stage of development (Patel et 
al., 2000), so it is unlikely that treatment of fibroblast cells with NRG1 will yield a 
significant indirect response. It is more likely that the direct effect of NRG1 on type II 
cells will be significant, as this should be equivalent to exposing the cells to FPF. It is 
also possible that NRG1 will enhance surfactant secretion from type II cells, acting 
through Ca
2+ and/or protein kinase C.  
  Further avenues for research also exist in studying NRG1 isoforms and the ErbB 
receptors. This study focused on only one of at least 16 different isoforms, and one 
other has already been observed in FCM (Dammann et al., 2003). Different isoforms 
are known to interact differently with receptors (Kita et al., 1995), so the presence of 
more than one form in FCM indicates the possibility of multiple roles for NRG1 in this Chapter 5                                                                                                                                        Discussion 
  132
intercellular  signaling  pathway.  The  identification  of  all  NRG1  isoforms  that  are 
involved in this system would be a major step, as would determining whether exposure 
of fibroblasts to different compounds (e.g. dexamethasone, EGF) leads to expression of 
different isoforms of NRG1.  Localization of specific ErbB receptors may also be an 
important aspect of this signaling system. While ErbB2 and ErbB3 have been identified 
as present in these tissues at this stage of development, the cultures used should be 
analyzed  to  ensure  that  this  expression  pattern  is  consistent.  It  is  possible  that  the 
conditions of cell culture led to modified receptor expression (as observed for IGF-II), 
and  if  ErbB4  is  involved  in  this  system,  it  could  mean  that  subsequent  signaling 
pathways  are  quite  different.  A  full  study  of  expression  of  both  NRG1  and  ErbB 
receptors  by  these  cultures  is  important  to  provide  a  clear  picture  of  the  total 
involvement of NRG1 in regulation of the surfactant system. 
  As detailed in 3.4, the use of a more powerful mass spectrometry technique, 
such as Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS), 
would  allow  some  of  the  limitations  of  ion  trap  MS  to  be  overcome.  Use  of  
FT-ICR-MS would allow the majority of compounds present in FCM to be separated 
with sufficient resolution for positive identification (Marshall et al., 1998). However, it 
must be considered that while a high-resolution technique such as FT-ICR-MS would 
certainly  provide  many  answers,  it  is  expensive.  For  this  reason,  further  work  on 
separation  of  the  components  of  FCM,  using  a  combination  of  HPLC  and  other 
separation/purification/fractionation  techniques  should  be  undertaken.  If  a  reliable 
method can be developed, future work on these important secretions would be greatly 
advantaged. 
  As  outlined  in  2.11,  more  work  is  also  required  on  the  tissue  culture 
methodology used in this study. Primarily, a procedure for obtaining primary type II 
pneumocyte cultures with cell  density  consistently below 25   g.plate
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ensure that results of experiments are not affected by density. Considerable time has 
been spent on this problem, but a dedicated study has not been undertaken. All of the 
conditions of culture, from setup to maintenance, should be examined to determine if 
such consistency is attainable. Primary cultures are definitely required for fibroblasts, 
but it may be possible to use cell line cultures for type II pneumocytes. Results obtained 
from  indirect  experiments  using  primary  and  cell  line  type  II  cultures  should  be 
compared to assess whether cell line cultures could be used in future.  
  The  role  of  FPF  has  been  known  for  three  decades,  but  its  existence  has 
remained a mystery. Confirmation of the identity of FPF represents a significant step in 
research into the surfactant system, and this study has contributed to that identification, 
making a strong case for NRG1. Research into the important role of FPF has dwindled 
in the last two decades, possibly because its unknown identity has meant that the work 
lacked  direction.  The  findings  of  this  study  have  provided a new direction for this 
research,  allowing  the  focus  to  be  shifted  to  NRG1  and  its  ErbB  receptors.  
The complexity of the neuregulin system means that there is a considerable scope for 
future work, and many questions to answer before a more complete picture can be 
uncovered.  
This study has provided a considerable amount of new information related to the 
surfactant  system.  It  has  examined  the  effects  of  insulin-like  growth  factor  II  and 
neuromedin C on surfactant synthesis and, in the case of IGF-II, surfactant secretion.  
A revised method has been developed for tissue culture and related experiments, which 
will  provide  future  research  with  more  reliable  results.  Most  significantly,  it  has 
achieved its primary goal of confirming the identity of the fibroblast-pneumocyte factor 
as neuregulin-1, and has also provided more information on the role of neuregulin-1 in 
the pulmonary surfactant system. References 
 
Abdel-Latif MM and Hollingsworth M (1980), "Effect of oxotremorine and epinephrine 
on lung surfactant secretion in neonatal rabbits", Pediatric Research, 14: 916-920. 
   
Adamson JYR and King GM (1984), "Sex-related differences in cellular composition 
and surfactant synthesis of developing fetal lungs", American Review of Respiratory 
Disease, 129: 130-134. 
   
Aebersold R and Goodlett DR (2001), "Mass spectrometry in proteomics", Chemical 
Reviews, 101(2): 269-295. 
   
Aebersold R and Mann M (2003), "Mass spectrometry-based proteomics", Nature, 422: 
198-207. 
   
Agilent (2003), Agilent 1100 Series LC/MSD Trap Techniques and Operation 
(H8966A), Alpharetta, USA: Agilent Technologies Ltd., 1. 
   
Ahmad M, Spitzer AR, Adeniyi-Jones S and Chander A (1996), "A comparative study 
of glucocorticoids and CAMP regulation of synexin, SP-A, and SP-B mRNA expression 
in fetal lung explants", FASEB Journal, 10(3). 
   
Asokananthan N (1996), Effect of bombesin and related peptides on surfactant 
secretion by cultured fetal lung cells, PhD thesis, Murdoch University, Perth, pp 135. 
   
Asokananthan N and Cake MH (1996), "Stimulation of surfactant lipid secretion from 
fetal type II pneumocytes by gastrin-releasing peptide", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 270(14): L331-L337. 
   
Avery ME and Mead J (1959), "Surface properties in relation to atelectasis and hyaline 
membrane disease", American Journal of Diseases of Children, 97: 517-523. 
   
Baker J, Liu JP, Robertson EJ and Efstratiadis A (1993), "Role of insulin-like growth 
factors in embryonic and postnatal growth", Cell, 75(1): 73-82. 
   
Ballard PL (1986), Hormones and Lung Maturation, Berlin: Springer-Verlag. 
   
Ballard PL, Ballard RA, Granberg JP, Sniderman S, Gluckman PD, Kaplan SL and 
Grumbach MM (1980), "Fetal sex and prenatal betamethasone therapy", Journal of 
Pediatrics, 97: 451-454. 
   
Ballard PL, Hovey ML and Gonzales LK (1984), "Thyroid hormone stimulation of 
phosphatidylcholine synthesis in cultured fetal rabbit lung", Journal of Clinical 
Investigation, 74: 898-905. 
   
Bangham AD and Horne RW (1964), "Negative staining of phospholipids and their 
structural modification by surface active agents as observed in the electron microscope", 
Journal of Molecular Biology, 8: 660-668. References 
  135
   
Baranska J and van Golde LMG (1977), "Role of lamellar bodies in the biosynthesis of 
phosphatidylcholine in mouse lung", Biochimica et Biophysica Acta, 488: 285-293. 
   
Bar-Sagi D and Hall A (2000), "Ras and Rho GTPases: A family reunion", Cell, 103: 
227-238. 
   
Batenburg JJ (1992), "Surfactant phospholipids: Synthesis and storage", American 
Journal of Physiology: Lung Cellular and Molecular Physiology, 262: L367-L385. 
   
Batenburg JJ and Whitsett JA (1989), "Levels of mRNAs coding for lipogenic enzymes 
in rat lung upon fasting and refeeding and during perinatal development", Biochimica et 
Biophysica Acta, 1006: 329-334. 
   
Bayes-Genis A, Conover CA and Schwartz RS (2000), "The insulin-like growth factor 
axis: A review of atherosclerosis and restenosis", Circulation Research, 86(2): 125-130. 
   
Beato M (1989), "Gene regulation by steroid hormones", Cell, 56: 335-344. 
   
Beck F, Samani NJ, Penschow JD, Thorley B, Tregear GW and Coghlan JP (1987), 
"Histochemical localization of IGF-I and IGF-II mRNA in the developing rat embryo", 
Development, 101(1): 175-184. 
   
Ben-Levy R, Paterson HF, Marshall CJ and Yarden Y (1994), "A single 
autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables 
coupling to the MAP kinase pathway", The EMBO Journal, 13: 3302-3311. 
   
Bentley PJ (1998), Comparative vertebrate endocrinology, Melbourne: Cambridge 
University Press. 
   
Beppu OS, Clements A and Goerke J (1983), "Phosphatidylglycerol-deficient lung 
surfactant has normal properties", Journal of Applied Physiology, 55: 496-502. 
   
Bergman B, Hedner T and Samsioe G (1982), "Terbutaline and pulmonary surfactant 
release in the rabbit fetus", Gynecologic and Obstetric Investigation, 13: 44-54. 
   
Berridge MJ (1987), "Inositol triphosphate and diacylglycerol: Two interacting second 
messengers", Annual Review of Biochemistry, 56: 159-193. 
   
Bier ME and Schwartz JC (1997), "Electrospray ionization quadrupole ion-trap mass 
spectrometry", Electrospray Ionization Mass Spectrometry: Fundamentals, 
Instrumentation & Applications, Cole R, Brisbane: John Wiley & Sons, Inc.: 235-290. 
   
Blat C, Villaudy J and Binoux M (1994), "In vivo proteolysis of serum insulin-like 
growth factor (IGF) binding protein-3 results in increased availability of IGF to target 
cells", Journal of Clinical Investigation, 93(5): 2286-2290. 
   
Bligh EG and Dyer WJ (1959), "A rapid method of total lipid extraction and 
purification", Candian Journal of Biochemistry and Physiology, 37: 911-917. 
   References 
  136
Bourbon JR (1991), "Secretion, Alveolar Processing, and Turnover of Pulmonary 
Surfactant", Pulmonary Surfactant: Biochemical, Functional, Regulatory and Clinical 
Concepts, Bourbon J, Boca Raton: CRC Press: 143-156. 
   
Bowsher RR, Lee W-H, Apathy JM, O'Brien PJ, Ferguson AL and Henry DP (1991), 
"Measurement of insulin-like growth factor-II in physiological fluids and tissues I: An 
improved extraction procedure and radioimmunoassay for human and rat fluids", 
Endocrinology, 128(2): 805-814. 
   
Brissenden JE, Ullrich A and Francke U (1984), "Human chromosomal mapping of 
genes for insulin-like growth factors I and II and epidermal growth factor", Nature, 310: 
781-784. 
   
Brockes JP, Lemke GE and Balzer DR, Jr. (1980), "Purification and preliminary 
characterization of a glial growth factor from the bovine pituitary", The Journal of 
Biological Chemistry, 255: 8374-8377. 
   
Brown AL, Graham DE, Nissley SP, Hill DJ, Strain AJ and Rechler MM (1986), 
"Developmental regulation of insulin-like growth factor II mRNA in different rat 
tissues", The Journal of Biological Chemistry, 261(28): 13144-13150. 
   
Brown LAS and Longmore WJ (1981), "Adrenergic and cholinergic regulation of lung 
surfactant secretion in the isolated perfused rat lung and in the alveolar type II cell in 
culture", The Journal of Biological Chemistry, 256: 66-72. 
   
Brown M, Rivier J and Vale W (1977), "Bombesin: Potent effects on thermoregulation 
in the rat", Science, 196: 998-1000. 
   
Brown N, Deb K, Paria BC, Das SK and Reese J (2004), "Embryo-uterine interactions 
via the neuregulin family of growth receptors during implantation in the mouse", 
Biology of Reproduction, 71: 2003-2011. 
   
Buckingham S, McNary WF, Sommers SC and Rothschild J (1968), "Is lung an analog 
of Moog's developing intestine?: I. Phosphatases and pulmonary alveolar differentiation 
in fetal rabbits", Federation Proceedings, 27: 328. 
   
Burgess TL, Ross SL, Qian YX, Brankow D and Hu S (1995), "Biosynthetic processing 
of neu differentiation factor: Glycosylation, trafficking, and regulated cleavage from the 
cell surface", The Journal of Biological Chemistry, 270: 19188-19196. 
   
Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma JY, Woolf EA, Comrack 
CA, Dussault BJ, Woolf J, Goodearl AD and Gearing DP (1997), "Characterization of a 
neuregulin-related gene, don-1, that is highly expressed in restricted regions of the 
cerebellum and hippocampus", Molecular and Cellular Biology, 17: 4007-4014. 
   
Caniggia I, Tseu I, Han RNN, Smith BT, Tanswell K and Post M (1991), "Spatial and 
temporal differences in fibroblast behavior in fetal rat lung", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 261(5): L424-L433. 
   References 
  137
Carlson KS, Smith BT and Post M (1984), "Insulin acts on the fibroblast to inhibit 
glucocorticoid stimulation of lung maturation", Journal of Applied Physiology: 
Respiratory, Environmental and Exercise Physiology, 57(5): 1577-1579. 
   
Carr JM, Owens JA, Grant PA, Walton PE, Owens PC and Wallace JC (1995), 
"Circulating insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and 
tissue mRNA levels of IGFBP-2 and IGFBP-4 in the ovine fetus", Journal of 
Endocrinology, 145(3): 545-557. 
   
Carraway KL III and Burden SJ (1995), "Neuregulins and their receptors", Current 
Biology, 5: 1-7. 
   
Carraway KL III and Cantley LC (1994), "A neu acquaintance for erbB3 and erbB4: A 
role for heterodimerization in growth signaling", Cell, 78: 5-8. 
   
Carraway KL III, Sliwkowksi MX, Akita RW, Platko JV, Guy PM, Nuijens A, 
Diamonti AJ, Vandlen RL, Cantley LC and Cerione RA (1994), "The erbB3 gene 
product is a receptor for heregulin", The Journal of Biological Chemistry, 269: 14303-
14306. 
   
Carraway KL III, Soltoff SP, Diamonti AJ and Cantley LC (1995), "Heregulin 
stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts 
transfected with erbB2/neu and erbB3", The Journal of Biological Chemistry, 270: 
7111-7116. 
   
Catterton WZ, Escobedo MB, Sexson WR, Gray ME, Sundell HW and Stahlman MT 
(1979), "Effect of epidermal growth factor on lung maturation in fetal rabbits", 
Pediatric Research, 13: 104-108. 
   
Chailley-Heu B, Chelly N, Lelievre-Pegorier M, Barlier-Mur AM, Merlet-Benichou C 
and Bourbon JR (1999), "Mild vitamin A deficiency delays fetal lung maturation in the 
rat", American Journal of Respiratory Cell and Molecular Biology, 21: 89-96. 
   
Chan SD, Antoniucci DM, Fok KS, Alajoki ML, Harkins RN, Thompson SA and Wada 
HG (1995), "Heregulin activation of extracellular acidification in mammary carcinoma 
cells is associated with expression of HER2 and HER3", The Journal of Biological 
Chemistry, 270: 22608-22613. 
   
Chander A (1989), "Regulation of lung surfactant secretion by intracellular pH", 
American Journal of Physiology, 245: C397-C404. 
   
Chander A, Claypool WD Jr., Strauss JF III and Fisher AB (1983), "Uptake of 
liposomal phosphatidylcholine by granular pneumocytes in primary cultures", American 
Journal of Physiology: Lung Cellular and Molecular Physiology, 258: L241-L253. 
   
Chander A, Sen N, Wu A-M and Spitzer AR (1995), "Protein kinase C in ATP 
regulation of lung surfactant secretion in type II cells", American Journal of Physiology: 
Lung Cellular and Molecular Physiology, 268(1): L108-L116. 
   References 
  138
Chander A, Wu A-I and Spitzer AR (1998), "Partial down regulation of protein kinase 
C-dependent surfactant secretion in ATP-treated alveolar type II cells", FASEB Journal, 
12(4). 
   
Chen MS, Bermingham-McDonogh O, Danehy FT, Jr., Nolan C, Scherer SS, Lucas J, 
Gwynne D and Marchionni MA (1994), "Expression of multiple neuregulin transcripts 
in postnatal rat brains", Journal of Comparative Neurology, 349: 389-400. 
   
Chetty A, Andersson S, Lassus O and Nielsen HC (2004), "Insulin-like growth factor-1 
(IGF-1) and IGF-1 receptor (IGF-1R) expression in human lungs in RDS and BPD", 
Pediatric Pulmonology, 37(2): 128-136. 
   
Chevalier G and Collett AJ (1972), "In vivo incorporation of choline-
3H, leucine-
3H and 
galactose-
3H in alveolar type II pneumocytes in relation to surfactant synthesis: A 
quantitative radioautographic study in mouse by electron microscopy", The Anatomical 
Record, 174: 289-310. 
   
Citri A, Skaria KB and Yarden Y (2003), "The deaf and the dumb: The biology of 
ErbB-2 and ErbB-3", Experimental Cell Research, 284: 54-65. 
   
Citri A and Yarden Y (2006), "EGF-ErbB signalling: Towards the systems level", 
Nature Reviews Molecular Cell Biology, 7: 505-516. 
   
Claussen M, Kubler B, Wendland M, Neifer K, Schmidt B, Zapf J and Braulke T 
(1997), "Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by 
cathepsin D", Endocrinology, 138(9): 3797-3803. 
   
Clements JA (1957), "Surface tension of lung extracts", Proceedings of the Society for 
Experimental Biology and Medicine, 95: 170-172. 
   
Clements JA and King RJ (1976), "Composition of surface-active material", The 
Biochemical Basis of Pulmonary Function, Crystal R, New York City: Marcel Dekker 
Inc., 2: 363-387. 
   
Cockshutt A, Weitz JI and Possmayer F (1990), "Pulmonary surfactant-associated 
protein A enhances the surface activity of lipid extract surfactant and reverses inhibition 
by blood proteins in vivo", Biochemistry, 29: 8424-8429. 
   
Cole RB, Ed. (1997), Electrospray ionization mass spectrometry: Fundamentals, 
instrumentation & applications, Brisbane: John Wiley & Sons. 
   
Comroe JH Jr. (1977), "Premature science and immature lungs, Part I: Some premature 
discoveries", American Review of Respiratory Disease, 116: 127-135. 
   
Cooney AJ and Tsai SY (1994), "Nuclear receptor-DNA interactions", Mechanism of 
steroid hormone regulation of gene transcription, Tsai M-J and O'Malley B, Austin: RG 
Landes Co: 31-33. 
   
Corbet AJS, Flax P and Rudolph AJ (1976), "Reduced surface tension in lungs of fetal 
rabbits injected with pilocarpine", Journal of Applied Physiology, 41: 7-14. 
   References 
  139
Cott GR, Walker SR and Mason RJ (1987), "The effect of substratum and serum on 
lipid synthesis and morphology of alveolar type II cells in vitro", Experimental Lung 
Research, 13: 427-447. 
   
Crouch E and Wright JR (2001), "Surfactant proteins A and D and pulmonary host 
defence", Annual Review of Physiology, 63: 521-554. 
   
Crovello CW, Lai C, Cantley LC and Carraway KL III (1998), "Differential signaling 
by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2", The 
Journal of Biological Chemistry, 273(41): 26954-26961. 
   
Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, 
Hajnoczky G and Iozzo RV (2000), "Sustained down-regulation of the epidermal 
growth factor receptor by decorin: A mechanism for controlling tumor growth in vivo", 
The Journal of Biological Chemistry, 42: 32879-32887. 
   
Cunningham MD, Desai NS, Thompson SA and Greene JM (1978), "Amniotic fluid 
phosphatidylglycerol in diabetic pregnancies", American Journal of Obstetrics and 
Gynecology, 131: 719-724. 
   
Dammann CEL, Nassimi N, Liu W and Nielsen HC (2006), "ErbB receptor regulation 
by dexamethasone in mouse type II epithelial cells", European Respiratory Journal, 28: 
1117-1123. 
   
Dammann CEL and Nielsen HC (1998), "Regulation of the epidermal growth factor 
receptor in fetal rat lung fibroblasts during late gestation", Endocrinology, 139(4): 1671-
1677. 
   
Dammann CEL, Nielsen HC and Carraway KL III (2003), "Role of neuregulin-1β in the 
developing lung", American Journal of Respiratory and Critical Care Medicine, 167: 
1711-1716. 
   
Daughaday WH, Parker KA, Borwsky S, Trivedi B and Kapodia M (1982), 
"Measurement of somatomedin related peptides in fetal, neonatal and maternal rat 
serum by IGF-I RIA, IGF-II RIA and MSA RRA after ethanol extraction", 
Endocrinology, 110: 575-581. 
   
Delhanty PJ and Han VK (1993), "The expression of insulin-like growth factor (IGF)-
binding protein-2 and IGF-II genes in the tissues of the developing ovine fetus", 
Endocrinology, 132(1): 41-52. 
   
DeSa DJ (1969), "Pulmonary fluid content in infants with respiratory diseases", Journal 
of Pathology, 97: 469-480. 
   
Dhand R, Sharma VK, Teng AL, Krishnasamy S and Gross NJ (1998), "Protein-lipid 
interactions and enzyme requirements for light subtype generation on cycling 
reconstituted surfactant", Biochemical and Biophysical Research Communications, 244: 
712-719. 
   
Dietl P and Haller T (2005), "Exocytosis of lung surfactant: From the secretory vesicle 
to the air-liquid interface", Annual Review of Physiology, 67: 595-621. References 
  140
   
Dobbs LG, Gonzalez RF, Marinari LA, Mescher EJ and Hawgood S (1986), "The role 
of calcium in the secretion of surfactant by rat alveolar type II cells", Biochimica et 
Biophysica Acta, 877: 155-166. 
   
Dobbs LG, Mason RJ, Williams MC, Benson BJ and Sueishi K (1982), "Secretion of 
surfactant by primary cultures of alveolar type II cells isolated from rat", Biochimica et 
Biophysica Acta, 713: 118-127. 
   
Dobbs LG, Wright JR, Hawgood S, Gonzalez RF, Venstrom K and Nellenbogen J 
(1987), "Pulmonary surfactant and its components inhibit secretion of 
phosphatidylcholine from cultured rat alveolar type II cells", Proceedings of the 
National Academy of Sciences of the United States of America, 84: 1010-1014. 
   
Dow KE, Sabry K and Smith BT (1983), "Evidence for epithelial-mesenchymal 
interactions mediating glucocorticoid effects in developing chick liver: Fibroblast-
hepatocyte factor", Cell and Tissue Research, 231: 83-91. 
   
Dunne SJ, Cornell RB, Johnson JE, Glover NR and Tracey AS (1996), "Structure of the 
membrane binding domain of CTP-phosphocholine cytidylyltransferase", Biochemistry, 
35: 11975-11984. 
   
Egberts J, Beintema-Duddeldam A and de Boers A (1987), "Phosphatidylinositol and 
not phosphatidylglycerol is the important minor phospholipid in Rhesus monkey 
surfactant", Biochimica et Biophysica Acta, 919: 90-92. 
   
Egberts J and Noort WA (1986), "Gestational age-dependent changes in plasma inositol 
levels and surfactant composition in the fetal rat", Pediatric Research, 20: 24-27. 
   
Enhorning G and Holm BA (1993), "Disruption of pulmonary surfacatant's ability to 
maintain openness of a narrow tube", Journal of Applied Physiology, 74: 2922-2927. 
   
Epstein MF and Farrell PM (1975), "The choline incorporation pathway: Primary 
mechanism for de novo lecithin synthesis in fetal primate lung", Pediatric Research, 9: 
658-666. 
   
Esper RM, Pankonin MS and Loeb JA (2006), "Neuregulins: Versatile growth and 
differentiation factors in nervous system development and human disease", Brain 
Research Reviews, 51: 161-175. 
   
Falls DL (2003), "Neuregulins: Functions, forms, and signaling strategies", 
Experimental Cell Research, 284: 14-30. 
   
Falls DL, Harris DA, Johnson FA, Morgan MM, Corfas G and Fischbach GD (1990), 
"Mr 42,000 ARIA: A protein that may regulate the accumulation of acetylcholine 
receptors at developing chick neuromuscular junctions", CSH Symposium of 
Quantitative Biology, 55: 397-406. 
   
Fenn JB, Mann M, Meng CK, Wong SF and Whitehouse CM (1989), "Electrospray 
ionization for mass spectrometry of large biomolecules", Science, 246: 64-71. 
   References 
  141
Filson AJ, Louvi A, Efstratiadis A and Robertson EJ (1993), "Rescue of the T-
associated maternal effect in mice carrying null mutations in Igf-2 and Igf2r, two 
reciprocally imprinted genes", Development, 118(3): 731-736. 
   
Fischbach GD, Aratake H, Corfas G, Falls DL, Goodearl AD and Rosen KM (1994), 
"Trophic interactions at developing synapses", Progress in Clinical and Biological 
Research, 390: 173-190. 
   
Fisher AB, Dodia C and Chander A (1987), "Degradation and reutilization of alveolar 
phosphatidylcholine by rat lung", Journal of Applied Physiology, 62: 2295-2299. 
   
Fisher SK, van Rooijen LAA and Agranoff BW (1984), "Renewed interest in the 
phosphoinositides", Trends in Biochemical Sciences, 9: 53-56. 
   
Fleisher B, Kulovich MV, Hallman M and Gluck L (1985), "Lung profile: Sex 
differences in normal pregnancy", Obstetrics and Gynecology, 66: 327-330. 
   
Floros J, Nielsen HC and Torday JS (1987), "Dihydrotestosterone blocks fetal lung 
fibroblast-pneumonocyte factor at a pretranslational level", The Journal of Biological 
Chemistry, 262(28): 13592-13598. 
   
Floros J, Post M and Smith BT (1985), "Glucocorticoids affect the synthesis of 
pulmonary fibroblast-pneumonocyte factor at a pretranslational level", The Journal of 
Biological Chemistry, 260(4): 2265-2267. 
   
Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Constantino A, Goldfine ID, 
Belfiore A and Vigneri R (1999), "Insulin receptor isoform A: A newly recognized 
high-affinity insulin-like growth factor II receptor in fetal and cancer cells", Molecular 
and Cellular Biology, 19(5): 3278-3288. 
   
Fraslon C and Batenburg JJ (1993), "Pre-translational regulation of lipid synthesizing 
enzymes and surfactant proteins in fetal rat", FEBS Letters, 325: 285-290. 
   
Fraslon C and Bourbon JR (1992), "Comparison of effects of epidermal and insulin-like 
growth factors, gastrin releasing peptide and retinoic acid on fetal lung cell growth and 
maturation in vivo", Biochimica et Biophysica Acta, 1123(1): 65-75. 
   
Fraslon-Vanhulle C, Chailley-Heu B, Batenburg JJ, Elfring RH and Bourbon JR (1994), 
"Ontogeny of surfactant proteins and lipid-synthesizing enzymes in cultured fetal lung 
epithelial cells", American Journal of Physiology: Lung Cellular and Molecular 
Physiology, 267: L375-L383. 
   
Frattali AL and Pessin JE (1993), "Relationship between alpha subunit ligand 
occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor 
hybrid receptors", The Journal of Biological Chemistry, 268(10): 7393-7400. 
   
Freeman M (2000), "Feedback control of intercellular signalling in development", 
Nature, 408: 313-319. 
   References 
  142
Frystyk J (2004), "Free insulin-like growth factors: Measurements and relationships to 
growth hormone secretion and glucose homeostasis", Growth Hormone & IGF 
Research, 14: 337-375. 
   
Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, 
Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW and Ward CW 
(2002), "Crystal structure of a truncated epidermal growth factor receptor extracellular 
domain bound to transforming growth factor alpha", Cell, 110: 763-773. 
   
Gil JP, Casals C and Marsh D (1995), "Interactions of hydrophobic lung surfactant 
protein SP-B and SP-C with dipalmitoylphosphatidylcholine and 
dipalmitoylphosphatidylglycerol bilayers studied with electron spin resonance 
spectroscopy", Biochemistry, 34: 3964-3971. 
   
Gilfillan AM and Rooney SA (1986), "Leukotrienes stimulate phosphatidylcholine 
secretion in cultured type II pneumocytes", Biochimica et Biophysica Acta, 876: 22-27. 
   
Gilfillan AM and Rooney SA (1987), "Purinoceptor agonists stimulate 
phosphatidylcholine secretion in primary cultures of adult rat type II pneumocytes", 
Biochimica et Biophysica Acta, 917: 18-23. 
   
Glasser SW, Burhans MS, Korhagen TR, Na CL, Sly PD, Ross GF, Ikegami M and 
Whitsett JA (2001), "Altered stability of pulmonary surfactant in SP-C deficient mice", 
Proceedings of the National Academy of Sciences of the United States of America, 
98(11): 6366-6371. 
   
Gogarten W, Strumper D, Buerkle H, van Aken H and Marcus MAE (2001), "Testing 
an epidural catheter in obstetrics: Epinephrine or isoproterenol?" International Journal 
of Obstetric Anesthesia, 10: 40-45. 
   
Gonzales LK, Ballard PL, Ertsey R and Williams MC (1986), "Glucocorticoids and 
thyroid hormones stimulate biochemical and morphological differentiation of human 
fetal lung in organ culture", Journal of Clinical Endocrinology and Metabolism, 62: 
678-691. 
   
Graham DE, Rechler MM, Brown AL, Frunzio R, Romanus JA, Bruni CB, Whitfield 
HJ, Nissley SP, Seelig S and Berry S (1986), "Coordinate developmental regulation of 
high and low molecular weight mRNAs for rat insulin-like growth factor II", 
Proceedings of the National Academy of Sciences of the United States of America, 
83(12): 4519-4523. 
   
Griese M (1999), "Pulmonary surfactant in health and human lung disease", Respiratory 
Journal, 13: 1455-1476. 
   
Griese M, Gobran LL and Rooney SA (1991), "ATP-stimulated inositol phospholipid 
metabolism and surfactant secretion in rat type II pneumocytes", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 260: L586-L593. 
   
Griese M, Gobran LL and Rooney SA (1992), "Ontogeny of surfactant secretion in type 
II pneumocytes from fetal, newborn, and adult rats", American Journal of Physiology: 
Lung Cellular and Molecular Physiology, 262: L337-L343. References 
  143
   
Griese M and Westerburg B (1998), "Surfactant function in neonates with respiratory 
distress syndrome", Respiration, 65: 136-142. 
   
Griffiths WJ, Jonsson AP, Liu S, Rai DK and Wang Y (2001), "Electrospray and 
tandem mass spectrometry in biochemistry", Biochemical Journal, 355: 545-561. 
   
Gross I and Dynia DW (1984), "Do EGF and glucocorticoids act at the same metabolic 
sites in fetal rat lung?" Pediatric Research, 18: 392A. 
   
Gross I, Dynia DW, Rooney SA, Smart DA, Warshaw JB, Sissom JF and Hoath SB 
(1986), "Influence of epidermal growth factor on fetal rat lung development in vitro", 
Pediatric Research, 20: 473-477. 
   
Gross I, Smith GJ, Wilson CM, Maniscalco WM, Ingelson LD, Brehier A and Rooney 
SA (1980), "The influence of hormones on the biochemical development of fetal rat 
lung in organ culture: II. Insulin", Pediatric Research, 14(6): 834-838. 
   
Gross I and Wilson CM (1982), "Fetal lung in organ culture: IV. Supra-additive 
hormone interactions", Journal of Applied Physiology, 52: 1420-1425. 
   
Guy J, Dhanireddy R and Mukherjee AB (1992), "Surfactant-producing rabbit 
pulmonary alveolar type II cells synthesize and secrete an antiinflammatory protein, 
uteroglobin", Biochemical and Biophysical Research Communications, 189: 662-669. 
   
Guy PM, Platko JV, Cantley LC, Cerione RA and Carraway KL III (1994), "Insect cell-
expressed p180 erbB3 possesses an impaired tyrosine kinase activity", Proceedings of 
the National Academy of Sciences of the United States of America, 91: 8132-8136. 
   
Guyton AC, Moffatt DS and Adair TH (1984), "Role of alveolar surface tension in 
transepithelial movement of fluid", Pulmonary Surfactant, Robertson B, van Golde L 
and Batenburg J, Amsterdam: Elsevier Science Publishers: 171-185. 
   
Haagsman HP and van Golde LMG (1991), "Synthesis and assembly of lung 
surfactant", Annual Review of Physiology, 53: 441-464. 
   
Hallman M, Enhorning G and Possmayer F (1985), "Composition and surface activity 
of normal and phosphatidylglycerol-deficient lung surfactant", Pediatric Research, 19: 
286-292. 
   
Hallman M, Epstein BL and Gluck L (1981), "Analysis of labeling and clearance of 
lung surfactant phospholipids in rabbit", Journal of Clinical Investigation, 68: 742-751. 
   
Hallman M, Feldman BH, Kirkpatrick E and Gluck L (1977), "Absence of 
phosphatidylglycerol (PG) in respiratory distress syndrome in the newborn", Pediatric 
Research, 11: 714-720. 
   
Hallman M and Gluck L (1976), "Phosphatidylglycerol in lung surfactant: III. Possible 
modifier of surfactant function", Journal of Lipid Research, 17: 257-262. 
   References 
  144
Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC and Yarden Y 
(1999), "Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor 
tyrosine kinase", Oncogene, 18: 2681-2689. 
   
Harris DA, Falls DL, Dill-Devor RM and Fischbach GD (1988), "Acetylcholine 
receptor-inducing factor from chicken brain increases the level of mRNA encoding the 
receptor alpha subunit", Proceedings of the National Academy of Sciences of the United 
States of America, 85: 1983-1987. 
   
Hecker E (1968), "Cocarcinogenic principles from the seed oil of Croton tiglium and 
from other Euphorbiacae", Cancer Research, 28: 2338-2349. 
   
Henry M, Ikegami M, Ueda T and Jobe A (1996), "Surfactant protein B in newborn 
rabbits", Biochimica et Biophysica Acta, 1300: 97-102. 
   
Hildebran JN, Goerke J and Clements A (1979), "Pulmonary surface film stability and 
composition", Journal of Applied Physiology, 47: 604-611. 
   
Hinegardner RT (1971), "An improved fluorometric assay for DNA", Analytical 
Biochemistry, 39(1): 197-201. 
   
Holm BA, Wang Z, Egan EA and Notter RH (1996), "Content of 
dipalmitoylphosphatidylcholine in lung surfactant: Ramification for surface activity", 
Pediatric Research, 39: 805-811. 
   
Holmes WE, Sliwkowksi MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, 
Abadi N, Raab H, Lewis GD, Shepard HM, Kuang W-J, Wood WI, Goeddel DV and 
Vandlen RL (1992), "Identification of heregulin: A specific activator of p185
erbB2", 
Science, 256: 1205-1210. 
   
Horan T, Wen J, Arakawa T, Liu N, Brankow D, Hu S, Ratzkin B and Philo JS (1995), 
"Binding of neu differentiation factor with the extracellular domain of Her2 and Her3", 
The Journal of Biological Chemistry, 270: 24604-24608. 
   
Hudson L and Hay FC (1976), Practical Immunology, Oxford: Blackwell Scientific 
Publications. 
   
Humbel RE (1990), "Insulin-like growth factors I and II", European Journal of 
Biochemistry, 190(3): 445-462. 
   
Ikegami M, Jobe A, Jacobs H and Lam R (1984), "A protein from airways of premature 
lambs that inhibits surfactant function", Journal of Applied Physiology, 57: 1134-1142. 
   
Jacobs H, Ikegami M, Jobe A, Borry DD and Jones S (1985), "Reutilization of 
surfactant phosphatidylcholine in adult rabbits", Biochimica et Biophysica Acta, 837: 
77-84. 
   
Jacobs H, Jobe A, Ikegami M and Conaway D (1983), "The significance of reutilization 
of surfactant phosphatidylcholine", The Journal of Biological Chemistry, 258: 4159-
4165. 
   References 
  145
Jarstrand C (1984), "Role of surfactant in the pulmonary defence system", Pulmonary 
Surfactant, Robertson B, van Golde L and Batenburg J, Amsterdam: Elsevier Science 
Publishers: 187-201. 
   
Jobe A, Ikegami M, Seidner SR, Pettenazzo A and Ruffini L (1989), "Surfactant 
phosphatidylcholine metabolism and surfactant function in preterm, ventilated lambs", 
American Review of Respiratory Disease, 139: 352-359. 
   
Johannson J and Curstedt T (1997), "Molecular structure and interactions of pulmonary 
surfactant components", European Journal of Biochemistry, 244: 675-693. 
   
Jones JI and Clemmons DR (1995), "Insulin-like growth factors and their binding 
proteins: Biological actions", Endocrine Reviews, 16(1): 3-34. 
   
Jones RB, Gordus A, Krall JA and Macbeath G (2006), "A quantitative protein 
interaction network for the ErbB receptors using protein microarrays", Nature, 439: 
168-174. 
   
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus Porta D, Ratzkin B, Seger R, 
Hynes NE and Yarden Y (1996), "ErbB-2 is a common auxiliary subunit of NDF and 
EGF receptors: Implications for breast cancer", The EMBO Journal, 15: 254-264. 
   
Katyal SL, Amenta JS, Singh G and Silverman JA (1984), "Deficient lung surfactant 
apoproteins in amniotic fluid with mature phospholipid profile from diabetic 
pregnancies", American Journal of Obstetrics and Gynecology, 148: 48-53. 
   
Kauffman SL, Burri PH and Weibel ER (1974), "The postnatal growth of the rat lung: 
II. Autoradiography", The Anatomical Record, 180(1): 63-76. 
   
Kebarle P (2000), "A brief overview of the present status of the mechanisms involved in 
electrospray mass spectrometry", Journal of Mass Spectrometry, 35(7): 804-817. 
   
Kebarle P and Ho Y (1997), "On the mechanism of electrospray mass spectrometry", 
Electrospray Ionization Mass Spectrometry: Fundamentals, Instrumentation & 
Applications, Cole R, Brisbane: John Wiley & Sons, Inc.: 3-64. 
   
Kennedy EP (1986), "The biosynthesis of phospholipids", Lipids and Membranes: Past, 
Present and Future, Op den Kamp J, Roelofsen B and Wirtz K, Amsterdam: Elsevier 
Science Publishers: 171-206. 
   
King RJ (1982), "Pulmonary surfactant", Journal of Applied Physiology, 53: 1-8. 
   
King RJ, Carmichael C and Horowitz PM (1983), "Reassembly of lipid-protein 
complexes of pulmonary surfactant", The Journal of Biological Chemistry, 258: 10672-
10680. 
   
King RJ, Klass DJ and Clements JA (1973), "Isolation of apoproteins from canine 
surfactant active material", American Journal of Physiology, 224: 789-795. 
   
King RJ and Martin H (1980), "Intracellular metabolism of the apoproteins of 
pulmonary surfactant in rat lung", Journal of Applied Physiology, 48: 812-820. References 
  146
   
Kirwin SM, Bhandari V, Dimatteo D, Barone C, Johnson L, Paul S, Spitzer AR, 
Chander A, Hassink SG and Funanage VL (2006), "Leptin enhances lung maturity in 
the fetal rat", Pediatric Research, 60(2): 200-204. 
   
Kita Y, Mayer J, Zamborelli T, Hara S, Rhode M, Watson E, Koski R, Ratzkin B and 
Nicolson M (1995), "Bioactive synthetic peptide of NDF/heregulin", Biochemical and 
Biophysical Research Communications, 210: 441-451. 
   
Klass DJ (1979), "Dibutyryl cyclic GMP and hyperventilation promote rat lung 
phospholipid release", Journal of Applied Physiology, 47: 285-289. 
   
Klempt M, Hutchins AM, Gluckman PD and Skinner SJ (1992), "IGF binding protein-2 
gene expression and the location of IGF-I and IGF-II in fetal rat lung", Development, 
115(3): 765-772. 
   
Kliewer M, Fram EK, Brody AM and Young SL (1985), "Secretion of surfactant by rat 
alveolar type II cells: Morphometric analysis and three-dimensional reconstruction", 
Experimental Lung Research, 9: 351-361. 
   
Kornfeld S (1992), "Structure and function of the mannose-6-phosphate/insulin-like 
growth factor II receptors", Annual Review of Biochemistry, 61: 307-330. 
   
Kosaki A and Webster NJ (1993), "Effect of dexamethasone on the alternative splicing 
of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells", The 
Journal of Biological Chemistry, 268(29): 21990-21996. 
   
Kotas RV and Avery ME (1980), "The influence of sex on fetal rabbit lung maturation 
and on the response to glucocorticoid", American Review of Respiratory Disease, 121: 
377-380. 
   
Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA (1989), "Isolation and 
characterization of ERBB3, a third member of the ERBB/epidermal growth factor 
receptor family: Evidence for overexpression in a subset of human mammary tumors", 
Proceedings of the National Academy of Sciences of the United States of America, 86: 
9193-9197. 
   
Langford K, Nicolaides K and Miell JP (1998), "Maternal and fetal insulin-like growth 
factors and their binding proteins in the second and third trimesters of human 
pregnancy", Human Reproduction, 13(5): 1389-1393. 
   
Langmuir I (1917), "The constitution and fundamental properties of solids and liquids: 
II. Liquids", Journal of the American Chemical Society, 39: 1848-1906. 
   
Le Roith D, Werner H, Beitner-Johnson D and Roberts CT, Jr. (1995), "Molecular and 
cellular aspects of the insulin-like growth factor I receptor", Endocrine Reviews, 16: 
143-163. 
   
Lemke G (1996), "Neuregulins in development", Molecular and Cellular Neuroscience, 
7: 247-262. 
   References 
  147
Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM and 
Schlessinger J (1997), "Two EGF molecules contribute additively to stabilization of the 
EGFR dimer", The EMBO Journal, 16: 281-294. 
   
Levine SZ and Gordon HH (1942), "Physiologic handicaps of the premature infant: I. 
Their pathogenesis, II. Clinical applications", American Journal of Diseases of 
Children, 64: 274-312. 
   
Li J, Saunders JC, Gilmour RS, Silver M and Fowden AL (1993), "Insulin-like growth 
factor-II messenger ribonucleic acid expression in fetal tissues of the sheep during late 
gestation: Effects of cortisol", Endocrinology, 132(5): 2083-2089. 
   
Liggins GC (1969), "Premature delivery of foetal lambs infused with glucocorticoids", 
Journal of Endocrinology, 45(4): 515-523. 
   
Liu J, Baker J, Perkins AS, Robertson EJ and Efstratiadis A (1993), "Mice carrying null 
mutations of the genes encoding insulin-like growth factor I (Igf-I) and type 1 IGF 
receptor (Igf1r)", Cell, 75(1): 59-72. 
   
Liu J and Kern JA (2002), "Neuregulin-1 activates the JAK-STAT pathway and 
regulates lung epithelial cell proliferation", American Journal of Respiratory Cell and 
Molecular Biology, 27: 306-313. 
   
Liu J, Nethery D and Kern JA (2004), "Neuregulin-1 induces branching morphogenesis 
in the developing lung through a PI3K signal pathway", Experimental Lung Research, 
30(6): 465-478. 
   
Liu M, Wang L, Holm BA and Enhorning G (1997), "Dysfunction of guinea pig 
pulmonary surfactant and type II pneumocytes after repetitive challenge with 
aerosolized ovalbumin", Clinical and Experimental Allergy, 27: 802-807. 
   
Lu C-Y, Wu C-Y and Lin C-H (2007), "Protein identification by syringe pump-drive 
reversed-phase LC-MS/MS", Analytical Biochemistry, 368(2): 123-129. 
   
Lupu R, Cardillo M, Harris L, Hijazi M and Rosenberg K (1995), "Interaction between 
erbB-receptors and heregulin in breast cancer tumor progression and drug resistance", 
Seminars in Cancer Biology, 6: 135-145. 
   
Macklin CC (1954), "The pulmonary alveolar mucoid film and the pneumonocytes", 
Lancet, 1: 1099-1104. 
   
Magoon MW, Wright JR, Baritussio A, Williams MC, Goerke J, Benson BJ, Hamilton 
RL and Clements JA (1983), "Subfractionation of lung surfactant: Implications for 
metabolism and surface activity", Biochimica et Biophysica Acta, 750: 18-31. 
   
Maitre B, Clement A, Williams MC and Brody JS (1995), "Expression of insulin-like 
growth factor receptors 1 and 2 in the developing lung and their relation to epithelial 
cell differentiation", American Journal of Respiratory Cell and Molecular Biology, 
13(3): 262-270. 
   References 
  148
Mandel F and Lopez LL (2000), Rapid protein characterization using microflow 
LC/MS/MS techniques: Agilent Technologies: 7. 
   
March RE (2000), "Quadrupole ion trap mass spectrometry: A view at the turn of the 
century", International Journal of Mass Spectrometry, 200: 285-312. 
   
Marchionni MA, Goodearl AD, Chen MS, Bermingham-McDonogh O, Kirk C, 
Hendricks M, Danehy FT, Jr., Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, 
Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBurney RN, 
Waterfield MD, Stroobant P and Gwynne D (1993), "Glial growth factors are 
alternatively spliced erbB2 ligands expressed in the nervous system", Nature, 362: 312-
318. 
   
Marino PA and Rooney SA (1980), "Surfactant secretion in a newborn rabbit lung slice 
model", Biochimica et Biophysica Acta, 620(3): 509-519. 
   
Markgraf LR, Paciga JE and Balis JU (1990), "Surfactant associated glycoproteins 
accumulate in alveolar cells and secretions during reparative stage of hyaline membrane 
disease", Human Pathology, 21: 392-396. 
   
Marshall AG, Hendrickson CL and Jackson GS (1998), "Fourier transform ion 
cyclotron resonance mass spectrometry: A primer", Mass Spectrometry Reviews, 17(1): 
1-35. 
   
Mason JR (1987), "Surfactant synthesis, secretion and function in alveoli and small 
airways", Respiration, Supplement 1: 3-9. 
   
Massague J and Czech MP (1982), "The subunit structures of two distinct receptors for 
insulin-like growth factors I and II and their relationship to the insulin receptor", The 
Journal of Biological Chemistry, 257(9): 5038-5045. 
   
McDevitt TM, Gonzales LW, Savani RC and Ballard PL (2007), "Role of endogenous 
TGF-b in glucocorticoid-induced lung type II cell differentiation", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 292: L249-L257. 
   
McEwen CN and Larsen BS (1997), "Electrospray ionization on quadrupole and 
magnetic-sector mass spectrometers", Electrospray Ionization Mass Spectrometry: 
Fundamentals, Instrumentation & Applications, Cole R, Brisbane: John Wiley & Sons, 
Inc.: 177-202. 
   
Mendelson CR, Johnston JM, MacDonald PC and Snyder JM (1981), "Multihormonal 
regulation of the surfactant synthesis by human fetal lung in vitro", Journal of Clinical 
Endocrinology and Metabolism, 53: 307-317. 
   
Mescher EJ, Dobbs LG and Mason RJ (1983), "Cholera toxin stimulates secretion of 
saturated phosphatidylcholine and increases cellular cyclic AMP in isolated rat alveolar 
type II cells", Experimental Lung Research, 5: 173-182. 
   
Meyer D and Birchmeier C (1995), "Multiple essential functions of neuregulin in 
development", Nature, 378: 386-390. 
   References 
  149
Meyer VR (2004), Practical high-performance liquid chromatography, Brisbane: John 
Wiley & Sons. 
   
Michael DJ, Cai H, Xiong W, Ouyang J and Chow RH (2006), "Mechanisms of peptide 
hormone secretion", Trends in Endocrinology and Metabolism, 17(10): 408-415. 
   
Miller HC and Futrakul P (1968), "Birth weight, gestational age, and sex as determining 
factors in the incidence of respiratory distress syndrome of prematurely born infants", 
Journal of Pediatrics, 72: 628-635. 
   
Mitulovic G and Mechtler K (2006), "HPLC techniques for proteomics analysis: A short 
overview of the latest developments", Briefings in Functional Genomics and 
Proteomics, 5(4): 249-260. 
   
Moriki T, Maruyama H and Maruyama IN (2001), "Activation of preformed EGF 
receptor dimers by ligand-induced rotation of the transmembrane domain", Journal of 
Molecular Biology, 311: 1011-1026. 
   
Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A and McClain DA (1990), 
"Functionally distinct insulin receptors generated by tissue-specific alternative 
splicing", The EMBO Journal, 9(8): 2409-2413. 
   
Mouhieddine OB, Cazals V, Maitre B, Le Bouc Y, Chadelat K and Clement A (1994), 
"Insulin-like growth factor-II (IGF-II), type 2 IGF receptor, and IGF-binding protein-2 
gene expression in rat lung alveolar epithelial cells: Relation to proliferation", 
Endocrinology, 135(1): 83-91. 
   
Murphy LJ (1998), "Insulin-like growth factor-binding proteins: Functional diversity or 
redundancy?" Journal of Molecular Endocrinology, 21(2): 97-107. 
   
Nielsen HC, Zinman HM and Torday JS (1982), "Dihydrotestosterone inhibits fetal 
rabbit pulmonary surfactant production", Journal of Clinical Investigation, 69: 611-616. 
   
Nishimoto I, Murayama Y, Katada T, Ui M and Ogata E (1989), "Possible direct 
linkage of insulin-like growth factor-II receptor with guanine nucleotide-binding 
proteins", The Journal of Biological Chemistry, 264(24): 14029-14038. 
   
Nishizuka Y (1984), "The role of protein kinase C in cell surface signal transduction 
and tumor promotion", Nature, 308: 693-698. 
   
Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, de Mello DE and Colten HR 
(1994), "A mutation in the surfactant protein B gene responsible for fetal neonatal 
respiratory disease in multiple kindreds", Journal of Clinical Investigation, 93: 1860-
1863. 
   
Obenshain SS, Adam PAJ, King KC, Teramo K, Raivio KO, Raiha N and Schwartz R 
(1970), "Human fetal insulin response to sustained maternal hyperglycemia", New 
England Journal of Medicine, 283: 566-570. 
   
Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R, Wen D, Rechavi G, Lonai P and Yarden 
Y (1993), "Neural expression and chromosomal mapping of neu differentiation factor to References 
  150
8p21-p21", Proceedings of the National Academy of Sciences of the United States of 
America, 90: 1867-1871. 
   
Oyarzun MJ and Clements JA (1978), "Control of lung surfactant by ventilation, 
adrenergic mediators and prostaglandins in the rabbit", American Review of Respiratory 
Disease, 117: 879-891. 
   
Paciga JE, Shelley SA and Balis JU (1980), "Secretory IgA is a component of rabbit 
lung surfactant", Biochimica et Biophysica Acta, 631: 487-494. 
   
Page-Robberts BA (1972), "Preparation and partial characterization of lamellar body 
fraction from rat lung", Biochimica et Biophysica Acta, 260: 334-338. 
   
Patel NV, Acarregiu MJ, Snyder JM, Klein JM, Sliwkowksi MX and Kern JA (2000), 
"Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in 
human lung development in vitro", American Journal of Respiratory Cell and 
Molecular Biology, 22: 432-440. 
   
Pattle RE (1955), "Properties, function and origin of the alveolar lining layer", Nature, 
175: 1125-1126. 
   
Peh SQ (2006), Effects of insulin-like growth factor II and dexamethasone on surfactant 
synthesis in fetal type II pneumocytes, Honours thesis, Murdoch University, Perth, pp 
91. 
   
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB and Yarden Y 
(1992), "Isolation of the neu/HER-2 stimulatory ligand: A 44 kDa glycoprotein that 
induces differentiation of mammary tumour cells", Cell, 69: 205-216. 
   
Peles E, Lamprecht R, Ben-Levy R, Tzahar E and Yarden Y (1991), "Regulated 
coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by 
oncogenic activation", The Journal of Biological Chemistry, 267: 12266-12274. 
   
Pinkas-Kramarski R, Lenferik AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, 
Tzahar E, Sela M, van Zoelen EJ and Yarden Y (1998), "The oncogenic ErbB-2/ErbB-3 
heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin", 
Oncogene, 16: 1249-1258. 
   
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper LN, Lavi 
S, Seger R, Ratzkin B, Sela M and Yarden Y (1996), "Diversification of Neu 
differentiation factor and epidermal growth factor signaling by combinatorial receptor 
interactions", The EMBO Journal, 15: 2452-2467. 
   
Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ and 
Shoyab M (1990), "Molecular cloning and expression of an additional epidermal growth 
factor receptor-related gene", Proceedings of the National Academy of Sciences of the 
United States of America, 87: 4905-4909. 
   
Possmayer F (1982), "The perinatal lung", Biochemical Development of the Fetus and 
Neonate, Jones C, Amsterdam: Elsevier Biomedical Press: 337-391. 
   References 
  151
Post M, Barsoumian A and Smith BT (1986), "The cellular mechanism of 
glucocorticoid acceleration of fetal lung maturation: Fibroblast-pneumonocyte factor 
stimulates choline-phosphate cytidylyltransferase activity", The Journal of Biological 
Chemistry, 261(5): 2179-2184. 
   
Post M, Floros J and Smith BT (1984), "Inhibition of lung maturation by monoclonal 
antibodies against fibroblast-pneumonocyte factor", Nature, 308: 284-286. 
   
Post M, Schuurmans EA, Batenburg JJ and van Golde LMG (1983), "Mechanisms 
involved in the synthesis of disaturated phosphatidylcholine by alveolar type II cells 
isolated from adult rat lung", Biochimica et Biophysica Acta, 750(1): 68-77. 
   
Post M and Smith BT (1984a), "Effect of fibroblast-pneumonocyte factor on the 
synthesis of surfactant phospholipids in type II cells from fetal rat lung", Biochimica et 
Biophysica Acta, 793: 297-299. 
   
Post M and Smith BT (1984b), "Fibroblast-pneumonocyte factor purified with the aid of 
monoclonal antibodies stimulates cholinephosphate cytidylyltransferase activity in fetal 
type II cells", Pediatric Research, 18: 401A. 
   
Pramanik BN, Ganguly AK and Gross ML, Eds. (2002), Applied electrospray mass 
spectrometry, Practical Spectroscopy Series, New York: Marcel Dekker, Inc. 
   
Prigent SA and Gullick WJ (1994), "Identification of c-erbB-3 binding sites for 
phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera", The 
EMBO Journal, 13: 2831-2841. 
   
Prigent SA and Lemoine NR (1992), "The type I (EGFR-related) family of growth 
factor receptors and their ligands", Progress in Growth Factor Research, 4: 1-24. 
   
Radford EP (1954), "Method for estimating respiratory surface area of mammalian 
lungs from their physical characteristics", Proceedings of the Society for Experimental 
Biology and Medicine, 87: 58-61. 
   
Rajah R, Katz L, Nunn S, Solberg P, Beers T and Cohen P (1995), "Insulin-like growth 
factor binding protein (IGFBP) proteases: Functional regulators of cell growth", 
Progress in Growth Factor Research, 6(2-4): 273-284. 
   
Rechler MM and Nissley SP (1985), "The nature and regulation of the receptors for 
insulin-like growth factors", Annual Review of Physiology, 47: 425-442. 
   
Redding RA, Douglas WHJ and Stein M (1972), "Thyroid hormone influence upon lung 
surfactant metabolism", Science, 175: 994-996. 
   
Retsch-Bogart GZ, Moats-Staats BM, Howard K, D'Ercole AJ and Stiles AD (1996), 
"Cellular localization of messenger RNAs for insulin-like growth factors (IGFs), their 
receptors and binding proteins during fetal rat lung development", American Journal of 
Respiratory Cell and Molecular Biology, 14(1): 61-69. 
   
Rice WR and Singleton FM (1986a), "Regulation of surfactant secretion from isolated 
type II pneumocytes by substance P", Biochimica et Biophysica Acta, 889: 123-127. References 
  152
   
Rice WR and Singleton FM (1986b), "P2 purinoceptors regulate surfactant secretion 
from rat isolated alveolar type II cells", British Journal of Pharmacology, 89: 485-491. 
   
Rice WR and Singleton FM (1987), "P2γ-purinoceptor regulation of surfactant secretion 
from rat isolated alveolar type II cells is associated with mobilization of intracellular 
calcium", British Journal of Pharmacology, 91: 833-838. 
   
Rice WR and Whitsett JA (1984), "Inhibition of surfactant release from isolated type II 
cells by compound 40/80", Biochimica et Biophysica Acta, 805: 261-267. 
   
Rinderknecht R and Humbel RE (1978), "Primary structure of human insulin-like 
growth factor II", FEBS Letters, 89(2): 283-286. 
   
Rio C, Buxbaum JD, Peschon JJ and Corfas G (2000), "Tumor necrosis factor-α-
converting enzyme is required for cleavage of erbB4/HER4", The Journal of Biological 
Chemistry, 275: 10379-10387. 
   
Robert KB (1994), "Linked-scan techniques for MS/MS using tandem-in-space 
instruments", Mass Spectrometry Reviews, 13(5-6): 359-410. 
   
Robert MF, Neff RK, Hubbell JP, Taeusch HW and Avery ME (1976), "Association 
between maternal diabetes and the respiratory distress syndrome in the newborn", New 
England Journal of Medicine, 294: 357-360. 
   
Robertson B (1984), "Pathology and pathophysiology of neonatal surfactant deficiency 
("Respiratory Distress Syndrome", "Hyaline Membrane Disease")", Pulmonary 
Surfactant, Robertson B, van Golde L and Batenburg J, Amsterdam: Elsevier Science 
Publishers: 383-418. 
   
Rooney SA (2001), "Regulation of surfactant secretion", Comparative Biochemistry and 
Physiology: Part A, 129: 233-243. 
   
Sakano K, Enjoh T, Numata F, Fujiwara H, Marumoto Y, Higashihashi N, Sato Y, 
Perdue JF and Fujita-Yamaguchi Y (1991), "The design, expression, and 
characterization of human insulin-like growth factor II (IGF-II) mutants specific for 
either the IGF-II/cation-independent mannose-6-phosphate receptor or IGF-I receptor", 
The Journal of Biological Chemistry, 266(31): 20626-20635. 
   
Sano K, Voelker DR and Mason RJ (1985), "Involvement of protein kinase C in 
pulmonary surfactant secretion from alveolar type II cells", The Journal of Biological 
Chemistry, 260: 12725-12729. 
   
Sara VR and Hall K (1990), "Insulin-like growth factors and their binding proteins", 
Physiological Reviews, 70(3): 591-614. 
   
Sawyer ST and Cohen S (1981), "Enhancement of calcium uptake and 
phosphatidylinositol turnover by epidermal growth factor in A431 cells", Biochemistry, 
20: 6280-6287. 
   References 
  153
Scheidereit C and Beato M (1984), "Contacts between hormone receptor and DNA 
double helix within a glucocorticoid regulatory element of mouse mammary tumor 
virus", Proceedings of the National Academy of Sciences of the United States of 
America, 81: 3029-3033. 
   
Schellenburg J-C, Liggins GC, Manzai M, Kitterman A and Lee CCH (1988), 
"Synergistic hormonal effects on lung maturation in fetal sheep", Journal of Applied 
Physiology, 65: 94-100. 
   
Schulze A, Lehmann K, Jefferies HB, McMahon M and Downward J (2001), "Analysis 
of the transcriptional program induced by Raf in epithelial cells", Genes and 
Development, 15: 981-994. 
   
Schurch S, Qanbar R, Bachofen H and Possmayer F (1995), "The surface associated 
surfactant reservoir in the alveolar lining", Biology of the Neonate, 67: 61-76. 
   
Scott JE and Das RM (1993), "Production of fibroblast-pneumocyte-like factor by fetal 
rabbit lung fibroblasts: Isolation and effects of it and related factors on fetal type II cells 
in vitro", Life Sciences, 53(10): 765-774. 
   
Seeger W, Stohr G, Wolf HRD and Neuhof H (1985), "Alteration of surfactant function 
due to protein leakage: Special interaction with fibrin monomer", Journal of Applied 
Physiology, 58: 326-338. 
   
Seger R and Krebs EG (1995), "The MAPK signaling cascade", FASEB Journal, 9(9): 
726-735. 
   
Seidner SR, Smith ME and Mendelson CR (1996), "Development and hormonal 
regulation of SP-A gene expression in baboon fetal lung", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 271(4): L609-L616. 
   
Sen N (1991), Hormonal regulation of surfactant production in cultured fetal lung cells, 
PhD thesis, Murdoch University, Perth, pp 170. 
   
Sen N and Cake MH (1991), "Enhancement of disaturated phosphatidylcholine 
synthesis by epidermal growth factor in cultured fetal lung cells involves a fibroblast-
epithelial cell interaction", American Journal of Respiratory Cell and Molecular 
Biology, 5: 337-343. 
   
Seybold WD and Smith BT (1980), "Human amniotic fluid contains fibroblast-
pneumonocyte factor", Early Human Development, 4(4): 337-345. 
   
Shelley SA, Paciga JE and Balis JU (1984), "Lung surfactant phospholipids in different 
animal species", Lipids, 19: 857-861. 
   
Shier P and Watt VM (1989), "Primary structure of a putative receptor for a ligand of 
the insulin family", The Journal of Biological Chemistry, 264: 14605-14608. 
   
Siddle K and Soos MA (1999), "Alternative IGF-related receptors", The IGF System: 
Molecular Biology, Physiology and Clinical Applications, Rosenfeld R and Roberts C, 
Jr., Totowa: Humana Press: 199-225. References 
  154
   
Sliwkowksi MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, 
Fendly BM, Cerione RA, Vandlen RL and Carraway KL III (1994), "Coexpression of 
erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin", The 
Journal of Biological Chemistry, 269: 14661-14665. 
   
Smith BT (1978), "Fibroblast-pneumonocyte factor: Intercellular mediator of 
glucocorticoid effect on fetal lung", Intensive Care in the Newborn, Stern L, Oh W and 
Friis-Hansen B, New York City: Masson, 2: 25-32. 
   
Smith BT (1979), "Lung maturation in the fetal rat: Acceleration by injection of 
fibroblast-pneumonocyte factor", Science, 204: 1094-1095. 
   
Smith BT (1981a), "Differentiation of the pneumonocyte: Optimization of production of 
fibroblast-pneumonocyte factor by rat fetal lung fibroblasts", The Biology of Normal 
Human Growth, Ritzen M, Aperia A and Hall K, New York: Raven Press: 157-162. 
   
Smith BT (1984), "Pulmonary surfactant during fetal development and neonatal 
adaptation: Hormonal control", Pulmonary surfactant, Robertson B, van Golde L and 
Batenburg J, Amsterdam: Elsevier Science Publishers: 357-381. 
   
Smith BT and Fletcher WA (1979), "Pulmonary epithelial-mesenchymal interactions: 
Beyond organogenesis", Human Pathology, 10(3): 248-250. 
   
Smith BT and Post M (1989), "Fibroblast-pneumonocyte factor", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 257(1): L174-L178. 
   
Smith BT and Post M (1991), "Fibroblast Pneumonocyte Factor", Pulmonary 
Surfactant: Biochemical, Functional, Regulatory and Clinical Concepts, Bourbon J, 
Boca Raton: CRC Press: 325-331. 
   
Smith BT and Post M (1993), "Fibroblast-Pneumonocyte Factor", Cytokines of the 
Lung, Kelley J, New York: Marcel Dekker Inc: 403-416. 
   
Smith BT and Sabry K (1983), "Glucocorticoid-thyroid synergism in lung maturation: 
A mechanism involving epithelial-mesenchymal interaction", Proceedings of the 
National Academy of Sciences of the United States of America, 80: 1951-1954. 
   
Snell RS (2007), Clinical Anatomy by Systems, Baltimore: Lippincott, Williams & 
Wilkins. 
   
Snyder JM and Mendelson CR (1987), "Insulin inhibits the accumulation of the major 
lung surfactant apoprotein in human fetal lung explants maintained in vitro", 
Endocrinology, 120(4): 1250-1257. 
   
Snyder LR, Kirkland JJ and Glajch JL (1997), Practical HPLC method development, 
Brisbane: John Wiley & Sons. 
   
Sorokin SP (1967), "A morphologic and cytochemical study on the great alveolar cell", 
Journal of Histochemistry and Cytochemistry, 14: 884-897. 
   References 
  155
Spitaler M and Cantrell DA (2004), "Protein kinase C and beyond", Nature 
Immunology, 5(8): 785-790. 
   
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh 
S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltson O, Birgisdottir B, 
Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, 
Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo 
A, Lemke G, Sainz J, Johanneson G, Andresson T, Gudbjartsson D, Manolescu A, 
Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H and Stefansson K (2002), 
"Neuregulin 1 and susceptibility to schizophrenia", American Journal of Human 
Genetics, 71: 877-892. 
   
Steinthorsdottir V, Stefansson H, Ghosh S, Birgisdottir B, Bjornsdottir S, Fasquel AC, 
Olafsson O, Stefansson K and Gulcher JR (2004), "Multiple novel transcription 
initiation sites for NRG1", Gene, 342: 97-105. 
   
Stewart CE and Rotwein P (1996), "Growth, differentiation, and survival: Multiple 
physiological functions for insulin-like growth factors", Physiological Reviews, 76(4): 
1005-1026. 
   
Sullivan LC, Orgeig S and Daniels CB (2003), "The role of extrinsic and intrinsic 
factors in the evolution of the control of pulmonary surfactant maturation during 
development in the amniotes", Physiological and Biochemical Zoology, 76(3): 281-295. 
   
Sunday ME, Kaplan LM, Motoyama E, Chin WW and Spindel ER (1988), "Biology of 
disease: Gastrin-releasing peptide (mammalian bombesin) gene expression in health and 
disease", Laboratory Investigation, 59: 5-24. 
   
Tarpey MM, O'Brodovich HM and Young SL (1983), "Role of lymphatics in removal 
of sheep lung surfactant lipid", Journal of Applied Physiology, 54: 984-988. 
   
Torday JS (1984), "The sex difference in type II cell surfactant synthesis originates in 
the fibroblast in vivo", Experimental Lung Research, 7: 187-194. 
   
Torday JS (1985), "Dihydrotestosterone inhibits fibroblast-pneumonocyte factor-
mediated synthesis of saturated phosphatidylcholine by fetal rat lung cells", Biochimica 
et Biophysica Acta, 835: 23-28. 
   
Torday JS and Kourembanas S (1990), "Fetal rat lung fibroblasts produce a TGFβ 
homolog that blocks alveolar type II cell maturation", Developmental Biology, 139(1): 
35-41. 
   
Torday JS and Nielsen HC (1987), "The sex difference in fetal lung surfactant 
production", Experimental Lung Research, 12: 1-19. 
   
Torday JS, Nielsen HC, Fencl MD and Avery ME (1981), "Sex differences in fetal lung 
maturation", American Review of Respiratory Disease, 123: 205-208. 
   
Torday JS and Rehan VK (2002), "Stretch-stimulated surfactant synthesis is coordinated 
by the paracrine actions of PTHrP and leptin", American Journal of Physiology: Lung 
Cellular and Molecular Physiology, 283: L130-L135. References 
  156
   
Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon 
A and Wen D (1994), "ErbB-3 and ErbB-4 function as the respective low and high 
affinity receptors of all neu differentiation factor/heregulin isoforms", The Journal of 
Biological Chemistry, 269: 25226-25233. 
   
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B and 
Yarden Y (1996), "A hierarchical network of interreceptor interactions determines 
signal transduction by Neu differentiation factor/neuregulin and epidermal growth 
factor", Molecular and Cellular Biology, 16: 5276-5287. 
   
Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le 
Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J and Fujita-
Yamaguchi Y (1986), "Insulin-like growth factor I receptor primary structure: 
Comparison with insulin receptor suggests structural determinants that define functional 
specificity", The EMBO Journal, 5(10): 2503-2512. 
   
van de Wetering JK, Elfring RH, Oosterlaken-Dijksterhuis MA, Mol JA, Haagsman HP 
and Batenburg JJ (1997), "Perinatal expression of IGFBPs in rat lung and its hormonal 
regulation in fetal lung explants", American Journal of Physiology: Lung Cellular and 
Molecular Physiology, 273: L1174-L1181. 
   
van der Greer P, Hunter T and Lindberg RA (1994), "Receptor protein-tyrosine kinases 
and their signal transduction pathways", Annual Review of Cell Biology, 10: 251-337. 
   
Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LMG and Geuze HJ 
(1992), "Immunocytochemical localization of surfactant protein D (SP-D) in type II 
cells, Clara cells, and alveolar macrophages of rat lung", Journal of Histochemistry and 
Cytochemistry, 40: 1589-1597. 
   
Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W and Ullrich A (1995), 
"Heregulin-dependent regulation of HER2/neu oncogenic signaling by 
heterodimerization with HER3", The EMBO Journal, 14: 4267-4275. 
   
Wallen LD and Han VK (1994), "Spatial and temporal distribution of insulin-like 
growth factors I and II during development of rat lung", American Journal of 
Physiology: Lung Cellular and Molecular Physiology, 267(5): L531-L542. 
   
Wallen LD, Myint W, Nygard K, Shimasaki S, Clemmons DR and Han VK (1997), 
"Cellular distribution of insulin-like growth factor binding protein mRNAs and peptides 
during rat lung development", Journal of Endocrinology, 155(2): 313-327. 
   
Wang EC and Notter RH (1998), "Additivity of protein and nonprotein inhibitors of 
lung surfactant activity", American Journal of Respiratory and Critical Care Medicine, 
158: 28-35. 
   
Washburn MP, Wolters D and Yates JR III (2001), "Large-scale analysis of the yeast 
proteome by multidimensional protein identification technology", Nature 
Biotechnology, 19(3): 242-247. 
   References 
  157
Weaver TE and Conkright JJ (2001), "Function of surfactant proteins B and C", Annual 
Review of Physiology, 63: 555-578. 
   
Whitsett JA, Hull W, Dion C and Lessard J (1985), "Cyclic AMP-dependent actin 
phosphorylation in developing rat lung and type II epithelial cells", Experimental Lung 
Research, 9: 191-209. 
   
Whitsett JA and Weaver TE (2002), "Hydrophobic surfactant proteins in lung function 
and disease", New England Journal of Medicine, 347(26): 2141-2148. 
   
Williams MC (1977), "Development of the alveolar structure of the fetal rat in late 
gestation", Federation Proceedings, 36(13): 2653-2659. 
   
Williams MC, Sueishi K and Benson BJ (1984), "Localization of a surfactant 
apoprotein in multivesicular bodies of type II cells", Progress in Respiratory Research, 
18: 101-105. 
   
Worthylake R, Opresko LK and Wiley HS (1999), "ErbB-2 amplification inhibits down-
regulation and induces constitutive activation of both ErbB-2 and epidermal growth 
factor receptors", The Journal of Biological Chemistry, 274: 8865-8874. 
   
Wright JR and Clements JA (1987), "Metabolism and turnover of lung surfactant", 
American Review of Respiratory Disease, 135: 426-444. 
   
Yost RW, Chander A and Fisher AB (1985), "Differential response of lung and liver of 
juvenile rats to choline deficiency", Journal of Applied Physiology, 59: 738-747. 
   
Young SL, Kremers SA, Apple JS, Carpo JD and Brumbley GW (1981), "Rat lung 
surfactant kinetics: Biochemical and morphological correlation", Journal of Applied 
Physiology, 51: 248-253. 
   
Yu H and Rohan T (2000), "Role of the insulin-like growth factor family in cancer 
development and progression", Journal of the National Cancer Institute, 92(18): 1472-
1489. 
   
Yu SH and Possmayer F (1988), "Comparative studies on the biophysical activities of 
low-molecular-weight hydrophobic proteins purified from bovine pulmonary 
surfactant", Biochimica et Biophysica Acta, 961(3): 337-350. 
   
Zhang B and Roth RA (1992), "The insulin receptor-related receptor: Tissue expression, 
ligand binding specificity and signaling capabilities", The Journal of Biological 
Chemistry, 267: 18320-18328. 
   
Zhang D, Sliwkowksi MX, Mark M, Frantz G, Akita RW, Sun Y, Hillan K, Crowley C, 
Brush J and Godowski PJ (1997), "Neuregulin-3 (NRG3): A novel neural tissue-
enriched protein that binds and activates ErbB4", Proceedings of the National Academy 
of Sciences of the United States of America, 94: 9562-9567. 
   
Zhang L, Ikegami M, Korfhagen TR, McCormack FX, Yoshida M, Senior RM, Shipley 
JM, Shapiro SD and Whitsett JA (2006), "Neither SP-A nor NH2-terminal domains of References 
  158
SP-A can substitute for SP-D in regulation of alveolar homeostasis", American Journal 
of Physiology: Lung Cellular and Molecular Physiology, 291: L181-L190. 
   
Zorzano A, Kaliman P, Guma A and Palacin M (2003), "Intracellular signals involved 
in the effects of insulin-like growth factors and neuregulins on myofibre formation", 
Cellular Signalling, 15: 141-149. 
   
Zumwalt M (2005), MS acquisition settings for protein/peptide samples, Alpharetti, 
USA: Agilent Technologies Ltd.: 1. 
   
 